0001833214 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-12-31 0001833214 2021-09-30 0001833214 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-07-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-01 2021-09-30 0001833214 srt:MaximumMember BCYP:SponsorMember 2020-11-12 2020-12-31 0001833214 srt:MaximumMember BCYP:LadenburgAndCertainEmployeesMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:IPOMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:OverAllotmentOptionMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:IPOMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:WarrantMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:MaximumMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:OverAllotmentOptionMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-01-01 2021-03-31 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-04-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:RestatementAdjustmentMember 2021-01-01 2021-06-30 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-01 2021-06-30 0001833214 us-gaap:IPOMember 2021-01-01 2021-09-30 0001833214 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember 2021-01-01 2021-09-30 0001833214 BCYP:ClosingIPOMember BCYP:SponsorMember 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2020-11-10 2020-11-13 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2020-11-13 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2020-12-06 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2020-12-06 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:FounderSharesMember 2021-01-03 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:FounderSharesMember 2021-01-02 2021-01-03 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:FounderSharesMember us-gaap:OverAllotmentOptionMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2021-12-06 2021-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2021-12-06 2021-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2021-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2021-01-02 2021-01-03 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:MaximumMember BCYP:SponsorMember 2020-11-19 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember 2020-11-18 2020-11-19 0001833214 BCYP:PromissoryNoteMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-10 2021-01-14 0001833214 BCYP:OfficerAndDirectorsMember BCYP:WorkingCapitalLoanMember 2021-01-01 2021-09-30 0001833214 BCYP:WorkingCapitalLoanMember 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:OfficerAndDirectorsMember BCYP:WorkingCapitalLoanMember 2021-09-30 0001833214 BCYP:SponsorMember 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:UnderwritersMember us-gaap:IPOMember 2021-01-13 2021-01-14 0001833214 us-gaap:OverAllotmentOptionMember BCYP:UnderwritingAgreementMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-01-01 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:WarrantsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:WarrantsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:PublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:WarrantsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember BCYP:BusinessCombinationAgreementMember 2021-10-22 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember BCYP:BusinessCombinationAgreementMember 2021-10-21 2021-10-22 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember BCYP:BusinessCombinationAgreementMember 2021-10-21 2021-10-22 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:MaximumMember BCYP:SponsorMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember srt:MaximumMember BCYP:LadenburgAndCertainEmployeesMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2020-11-11 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2020-11-11 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2020-11-11 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-11-11 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:CommonStockMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:RetainedEarningsMember 2020-11-12 2020-12-31 0001833214 us-gaap:IPOMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember 2020-11-17 2020-11-19 0001833214 BCYP:SponsorMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:OverAllotmentOptionMember BCYP:UnderwritingAgreementMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-11-18 2020-11-20 0001833214 BCYP:BigCypressAcquisitionCorpMember 2020-11-20 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember 2020-12-06 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2020-12-06 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember 2020-12-07 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:WarrantMember 2020-11-12 2020-12-31 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:FounderSharesMember us-gaap:SubsequentEventMember 2021-01-03 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:FounderSharesMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-03 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember BCYP:FounderSharesMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember BCYP:RepresentativeSharesMember us-gaap:SubsequentEventMember 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember us-gaap:SubsequentEventMember 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:SponsorMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:LadenburgAndCertainEmployeesMember us-gaap:SubsequentEventMember 2021-01-02 2021-01-04 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember us-gaap:SubsequentEventMember us-gaap:IPOMember 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember us-gaap:SubsequentEventMember 2021-01-13 2021-01-14 0001833214 BCYP:BigCypressAcquisitionCorpMember BCYP:ClosingIPOMember BCYP:SponsorMember us-gaap:SubsequentEventMember 2021-01-14 0001833214 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001833214 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember 2021-09-30 0001833214 BCYP:SeriesAOnePreferredStockMember 2020-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember 2021-09-30 0001833214 BCYP:SeriesATwoPreferredStockMember 2020-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember 2021-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember 2020-12-31 0001833214 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001833214 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001833214 2020-01-01 2020-09-30 0001833214 BCYP:GrantRevenueMember 2021-01-01 2021-09-30 0001833214 BCYP:GrantRevenueMember 2020-01-01 2020-09-30 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001833214 us-gaap:CommonStockMember 2020-12-31 0001833214 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001833214 us-gaap:RetainedEarningsMember 2020-12-31 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001833214 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001833214 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001833214 us-gaap:CommonStockMember 2021-09-30 0001833214 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001833214 us-gaap:RetainedEarningsMember 2021-09-30 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001833214 us-gaap:CommonStockMember 2019-12-31 0001833214 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001833214 us-gaap:RetainedEarningsMember 2019-12-31 0001833214 2019-12-31 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001833214 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001833214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001833214 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001833214 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001833214 us-gaap:CommonStockMember 2020-09-30 0001833214 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001833214 us-gaap:RetainedEarningsMember 2020-09-30 0001833214 2020-09-30 0001833214 2021-06-21 0001833214 us-gaap:CommonStockMember 2021-06-20 2021-06-21 0001833214 us-gaap:GovernmentMember 2021-01-01 2021-09-30 0001833214 us-gaap:GovernmentMember 2020-01-01 2020-09-30 0001833214 BCYP:NonGovernmentMember 2021-01-01 2021-09-30 0001833214 BCYP:NonGovernmentMember 2020-01-01 2020-09-30 0001833214 us-gaap:GovernmentMember 2021-01-01 2021-09-30 0001833214 us-gaap:GovernmentMember 2020-01-01 2020-09-30 0001833214 BCYP:NationalInstituteofHealthMember 2019-09-01 2021-08-31 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2021-01-01 2021-09-30 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2020-01-01 2020-09-30 0001833214 us-gaap:GovernmentMember 2019-04-01 2021-03-31 0001833214 BCYP:GenevaFoundationMember us-gaap:GovernmentMember 2017-08-01 2021-07-31 0001833214 BCYP:GenevaFoundationMember us-gaap:GovernmentMember 2021-01-01 2021-09-30 0001833214 BCYP:GenevaFoundationMember us-gaap:GovernmentMember 2020-01-01 2020-09-30 0001833214 BCYP:AdvancedTechnologyInternationalMember us-gaap:GovernmentMember 2021-01-01 2021-09-30 0001833214 us-gaap:GovernmentMember 2021-09-01 2021-09-30 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2021-09-01 2021-09-30 0001833214 BCYP:AdvancedTechnologyInternationalMember us-gaap:GovernmentMember 2020-01-01 2020-09-30 0001833214 BCYP:NonGovernmentMember 2021-01-01 2021-09-30 0001833214 BCYP:NonGovernmentMember 2020-01-01 2020-09-30 0001833214 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001833214 us-gaap:EquipmentMember 2021-09-30 0001833214 us-gaap:EquipmentMember 2020-12-31 0001833214 us-gaap:BreedingAndProductionAnimalsMember 2021-09-30 0001833214 us-gaap:BreedingAndProductionAnimalsMember 2020-12-31 0001833214 BCYP:AnimalFacilityEquipmentMember 2021-09-30 0001833214 BCYP:AnimalFacilityEquipmentMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember 2020-12-31 0001833214 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001833214 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001833214 us-gaap:VehiclesMember 2021-09-30 0001833214 us-gaap:VehiclesMember 2020-12-31 0001833214 us-gaap:OfficeEquipmentMember 2021-09-30 0001833214 us-gaap:OfficeEquipmentMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember 2021-01-01 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityEquipmentMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityEquipmentMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:FirstNewAnimalBarnMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:FirstNewAnimalBarnMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoNewAnimalBarnMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoNewAnimalBarnMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewOfficeSpaceMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewOfficeSpaceMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewLaboratorySpaceMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewLaboratorySpaceMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewLaboratorySpaceEquipmentMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewLaboratorySpaceEquipmentMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:SoftwareMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember BCYP:SoftwareMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember us-gaap:AllOtherSegmentsMember 2021-09-30 0001833214 us-gaap:ConstructionInProgressMember us-gaap:AllOtherSegmentsMember 2020-12-31 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2021-09-30 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2020-09-30 0001833214 BCYP:TractorLoanMember 2021-09-30 0001833214 BCYP:TractorLoanMember 2020-12-31 0001833214 BCYP:PaycheckProtectionProgramLoanMember 2021-09-30 0001833214 BCYP:PaycheckProtectionProgramLoanMember 2020-12-31 0001833214 BCYP:PaycheckProtectionProgramLoanMember 2021-01-01 2021-09-30 0001833214 BCYP:StockOptionGrantPlan2019Member 2014-08-05 0001833214 BCYP:StockOptionPlanMember 2021-09-30 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001833214 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001833214 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001833214 BCYP:ChristineHamiltonMember 2021-01-01 2021-09-30 0001833214 BCYP:ChristineHamiltonMember 2020-01-01 2020-09-30 0001833214 BCYP:NetworkPlusLLCMember 2020-09-30 0001833214 BCYP:DakotaAgPropertiesMember 2021-01-01 2021-09-30 0001833214 BCYP:DakotaAgPropertiesMember 2020-01-01 2020-09-30 0001833214 BCYP:SanfordHealthMember 2021-01-01 2021-09-30 0001833214 BCYP:SanfordHealthMember 2020-01-01 2020-09-30 0001833214 BCYP:ChristiansenLandandCattleLtdMember 2020-01-01 2020-09-30 0001833214 us-gaap:CommitmentsMember 2021-04-30 0001833214 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001833214 BCYP:SeriesATwoAPreferredStockMember 2019-12-31 0001833214 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember 2019-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember 2019-12-31 0001833214 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001833214 2020-01-01 2020-12-31 0001833214 2019-01-01 2019-12-31 0001833214 BCYP:GrantRevenueMember 2020-01-01 2020-12-31 0001833214 BCYP:GrantRevenueMember 2019-01-01 2019-12-31 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001833214 us-gaap:CommonStockMember 2018-12-31 0001833214 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001833214 us-gaap:RetainedEarningsMember 2018-12-31 0001833214 2018-12-31 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001833214 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001833214 BCYP:SeriesATwoARedeemablePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 BCYP:SeriesAOnePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 BCYP:SeriesATwoPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 BCYP:SeriesATwoAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001833214 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001833214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001833214 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001833214 us-gaap:GovernmentMember 2020-01-01 2020-12-31 0001833214 us-gaap:GovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:NonGovernmentMember 2020-01-01 2020-12-31 0001833214 BCYP:NonGovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:ContractResearchOrganizationsMember 2020-01-01 2020-12-31 0001833214 BCYP:HVIVIServicesMember 2020-01-01 2020-12-31 0001833214 BCYP:AnimalFacilityEquipmentMember 2020-01-01 2020-12-31 0001833214 us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001833214 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001833214 us-gaap:OfficeEquipmentMember 2020-01-01 2020-12-31 0001833214 us-gaap:VehiclesMember 2020-01-01 2020-12-31 0001833214 us-gaap:GovernmentMember 2020-01-01 2020-12-31 0001833214 us-gaap:GovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2019-09-01 2021-08-31 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2020-01-01 2020-12-31 0001833214 BCYP:NationalInstituteofHealthMember us-gaap:GovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:GenevaFoundationMember us-gaap:GovernmentMember 2020-01-01 2020-12-31 0001833214 BCYP:GenevaFoundationMember us-gaap:GovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:AdvancedTechnologyInternationalMember us-gaap:GovernmentMember 2020-01-01 2020-12-31 0001833214 BCYP:AdvancedTechnologyInternationalMember us-gaap:GovernmentMember 2019-01-01 2019-12-31 0001833214 us-gaap:GovernmentMember 2020-12-31 0001833214 BCYP:NonGovernmentMember 2020-01-01 2020-12-31 0001833214 BCYP:NonGovernmentMember 2019-01-01 2019-12-31 0001833214 BCYP:NonGovernmentMember BCYP:BattelleMemorialInstituteMember 2018-04-01 2019-01-31 0001833214 BCYP:NonGovernmentMember BCYP:BattelleMemorialInstituteMember 2019-01-01 2019-12-31 0001833214 BCYP:NonGovernmentMember BCYP:HenryJacksonFoundationMember 2018-09-01 2019-05-31 0001833214 BCYP:NonGovernmentMember BCYP:HenryJacksonFoundationMember 2019-01-01 2019-12-31 0001833214 BCYP:PreferredStocksMember 2020-01-01 2020-12-31 0001833214 BCYP:CommonStocksMember 2020-01-01 2020-12-31 0001833214 us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:EquipmentMember 2019-12-31 0001833214 us-gaap:BreedingAndProductionAnimalsMember 2019-12-31 0001833214 BCYP:AnimalFacilityEquipmentMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember 2019-12-31 0001833214 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001833214 us-gaap:VehiclesMember 2019-12-31 0001833214 us-gaap:OfficeEquipmentMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember 2020-01-01 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:TwoHunderdLCommercialFacilityEquipmentMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:AnimalBarnMember 2020-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:AnimalBarnMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember BCYP:NewOfficeSpaceMember 2019-12-31 0001833214 us-gaap:ConstructionInProgressMember us-gaap:AllOtherSegmentsMember 2019-12-31 0001833214 BCYP:LabSpaceMember 2020-01-01 2020-12-31 0001833214 BCYP:LabSpaceMember 2020-12-31 0001833214 srt:WarehouseMember 2020-12-31 0001833214 srt:WarehouseMember 2020-01-01 2020-12-31 0001833214 BCYP:BarnSpaceMember 2020-12-31 0001833214 BCYP:BarnSpaceMember 2019-01-01 2019-12-31 0001833214 BCYP:BarnSpaceMember 2020-01-01 2020-12-31 0001833214 2018-01-01 2018-12-31 0001833214 us-gaap:EquipmentMember 2018-12-31 0001833214 us-gaap:EquipmentMember 2018-12-01 2018-12-31 0001833214 2018-01-01 2018-07-31 0001833214 2019-03-31 0001833214 2019-03-01 2019-03-31 0001833214 BCYP:AnimalFaciltyMember 2020-01-01 2020-12-31 0001833214 us-gaap:LandMember 2020-01-01 2020-12-31 0001833214 us-gaap:RevolvingCreditFacilityMember BCYP:ChristiansenLandandCattleLtdMember 2016-02-24 0001833214 2016-12-31 0001833214 2017-12-31 0001833214 2018-08-31 0001833214 2017-11-15 0001833214 2017-11-14 2017-11-15 0001833214 BCYP:TractorMember 2017-01-01 2017-12-31 0001833214 BCYP:TractorMember 2017-12-31 0001833214 BCYP:TrailerTruckScaleAndChuteMember 2017-01-01 2017-12-31 0001833214 BCYP:TrailerTruckScaleAndChuteMember 2017-12-31 0001833214 2017-01-01 2017-12-31 0001833214 BCYP:TractorMember 2020-12-31 0001833214 BCYP:TractorMember 2019-12-31 0001833214 BCYP:PaycheckProtectionProgramMember 2020-03-26 2020-03-27 0001833214 BCYP:PaycheckProtectionProgramMember 2020-03-27 0001833214 us-gaap:LoansPayableMember 2020-12-31 0001833214 2019-08-31 0001833214 us-gaap:SeriesAPreferredStockMember 2019-08-31 0001833214 BCYP:SeriesAOnePreferredStockMember 2019-08-31 0001833214 BCYP:SeriesATwoPreferredStockMember 2019-08-31 0001833214 BCYP:SeriesATwoAPreferredStockMember 2019-08-31 0001833214 us-gaap:SeriesBPreferredStockMember 2019-08-31 0001833214 2019-09-30 0001833214 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-12-31 0001833214 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001833214 2014-08-05 0001833214 2019-01-01 2019-09-30 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001833214 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001833214 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001833214 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001833214 BCYP:SanfordHealthCorporationMember 2020-01-01 2020-12-31 0001833214 BCYP:SanfordHealthCorporationMember 2019-01-01 2019-12-31 0001833214 BCYP:SanfordHealthCorporationMember 2020-12-31 0001833214 BCYP:SanfordHealthCorporationMember 2019-12-31 0001833214 BCYP:UniversityOfSouthDakotaResearchParkIncMember 2019-06-30 0001833214 BCYP:UniversityOfSouthDakotaResearchParkIncMember 2019-06-01 2019-06-30 0001833214 srt:MaximumMember BCYP:UniversityOfSouthDakotaResearchParkIncMember 2019-06-01 2019-06-30 0001833214 BCYP:UniversityOfSouthDakotaResearchParkIncMember 2019-12-01 2019-12-31 0001833214 BCYP:UniversityOfSouthDakotaResearchParkIncMember 2019-01-01 2019-12-31 0001833214 BCYP:UniversityOfSouthDakotaResearchParkIncMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure utr:sqft BCYP:Integer 0001833214 false

S-1 SAB Biotherapeutics, Inc. DE 85-3899721 2100 East 54th Street North Sioux Falls SD 57104 605 679-6980 Non-accelerated Filer true true false

667873

84836

102742

2258

770615

87094

235111

116158244

116928859

322205

322376

156201

150000

322376

306201

-4220500

5529312

10072188

306201

11500000

10.10

116150000

0.0001

1000000

0.0001

50000000

3292200

2875000

11500000

330

288

24712

-9293659

-8996

-9293329

16004

116928859

322205

335552

704011

-335552

-704011

2929 8244 -359874

-1794

-1495871

4723

1144241

-330829

440230

14792200

14224714

-0.02

0.03

343125

31875

2875000

288

24712

-8996

16004

11500000 11500000 1150 1150 417200 417200 42 2771995 2772037 2105 2105

2973220

11500000

1150

-2798812 -9724893 -12523705

3292200

330

-6760669

-6760339

-2202161

3292200

330

-8962830

-8962500

-330829

3292200

330

-9293659

-9293329

440230

8244 -359874

-1495871

100484

251154

-553341

116150000

-116150000

113470500

4172000

-2105

150000

208227

117286378

583037

84836

667873

116150000

7025183 4220500 12523705

<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTmQSVNuAXI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 1 — Organization and Business Operations As of September 30, 2021, Big Cypress Acquisition Corp. (the “Company”), our predecessor, was a blank check company incorporated in Delaware on November 12, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). Prior to the Business Combination (described in Note 10), the Company had one subsidiary, Big Cypress Merger Sub Inc., a direct, wholly-owned subsidiary of the Company incorporated in Delaware on June 17, 2021 (“Merger Sub”). As of September 30, 2021, the Company had not commenced any operations. All activity through September 30, 2021 relates to the Company’s formation and the Initial Public Offering (“IPO”) which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 11, 2021 (the “Effective Date”). On January 14, 2021, the Company consummated the IPO of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zttaOoFZKg9f" title="Units issued during the period, shares">11,500,000 units (the “Units”) and, with respect to the shares of common stock included in the Units sold (the “Public Shares”), which included the full exercise by the underwriters of the over-allotment option to purchase an additional <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zor3UzOLxOff" title="Units issued during the period, shares">1,500,000 Units, at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEMwpLuUWyKa" title="Unit issued price">10.00 per Unit, generating gross proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6YSEEVIL0sc" title="Proceeds from IPO">115,000,000, which is discussed in Note 4. <span id="xdx_90B_eus-gaap--SaleOfStockDescriptionOfTransaction_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zaxk7GPAtZk6" title="Description of units">Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJTUJqEJRqs3" title="Unit issued price">11.50 per whole share. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210113__20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zATabjG02UE4" title="Sale of units">417,200 units (the “Placement Units”), at a price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zoUcEcRqiYrl" title="Unit issued price">10.00 per unit, in a private placement to Big Cypress Holdings LLC, a Delaware limited liability company which acted as the Company’s sponsor in connection with the IPO (the “Sponsor”), generating gross proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pip0_c20210113__20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ziWGjhDPKySh" title="Proceeds from sale of units">4,172,000, which is discussed in Note 5. Transaction costs of the IPO amounted to $<span id="xdx_906_ecustom--SaleOfStocksConsiderationReceivedPerTransaction_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zK4bFJ7OUFV7" title="Transaction costs">6,108,360 consisting of $<span id="xdx_907_ecustom--UnderwritingFee_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF117FDCpsT1" title="Underwriting fee">1,529,500 of underwriting fee, $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_pp0p0_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9ApYLvm13Ea" title="Deferred underwriting fee">4,220,500 of deferred underwriting fee, and $<span id="xdx_90C_ecustom--OtherDeferredCostNet_iI_pp0p0_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNWuUtvI3oOb" title="Other offering costs">358,360 of other offering costs, and of which $<span id="xdx_906_ecustom--WarrantLiabilityExpense_pp0p0_c20210113__20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3id6tqK8TGc" title="Warrant liability expense">359,874 were allocated to expense associated with the warrant liability. Following the closing of the IPO on January 14, 2021, $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3aG4xee1D07" title="Proceeds from sale of units">116,150,000 ($10.10 per Unit) from the net offering proceeds of the sale of the Units in the IPO and the sale of the Placement Units was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise and income tax obligations (less up to $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20210114__srt--RangeAxis__srt--MaximumMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zz9PHuuiT8E7" title="Interest to pay dissolution expenses">100,000 of interest to pay dissolution expenses), the proceeds from this IPO and the sale of the Placement Units will not be released from the trust account until the earliest of (a) the completion of the Company’s initial business combination, (b) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation, and (c) the redemption of the Company’s public shares if the Company is unable to complete the initial business combination within 15 months (or up to 21 months) from the closing of this IPO, subject to applicable law. The proceeds deposited in the trust account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial business combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial business combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). <span id="xdx_90C_ecustom--AgreementDescription_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEqqqUKcYctc" title="Agreement Description">The Company will have 15 months (or up to 21 months) from the closing of the IPO on January 14, 2021 to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and placement shares in connection with the completion of the initial business combination, (ii) waive their redemption rights with respect to their founder shares and placement shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and placement shares if the Company fails to complete the initial business combination within the Combination Period. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCYNb3pYt4Sh">10.10 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations. Risks and Uncertainties Management is continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that it could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

11500000

1500000

10.00

115000000

Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $11.50 per whole share.

11.50

417200

10.00

4172000

6108360 1529500

4220500

358360 359874

116150000

100000

10.10 The Company will have 15 months (or up to 21 months) from the closing of the IPO on January 14, 2021 to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.10 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations.

10.10

Note 2 — Restatement of Previously Issued Financial Statements In connection with the preparation of the Company’s financial statements as of September 30, 2021, management determined it should restate certain of its previously reported financial statements. The Company previously determined the common stock subject to possible redemption to be equal to the redemption value of $<span id="xdx_90D_ecustom--CommonStockRedemptionValuePerShare_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zoupv9WSnqka" title="Common stock redemption value per share">10.10 per common stock while also taking into consideration its charter’s requirement that a redemption cannot result in net tangible assets being less than $5,000,001. Upon review of certain of its financial statements for the period ended September 30, 2021, the Company reevaluated the classification of the common stock and determined that the common stock issued during the Initial Public Offering and pursuant to the exercise of the underwriters’ overallotment can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control under ASC 480-10-S99. Therefore, management concluded that the carrying value should include all common stock subject to possible redemption, resulting in the common stock subject to possible redemption being classified as temporary equity in its entirety. As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in a restatement to the initial carrying value of the common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), retained earnings (accumulated deficit) and common stock. In connection with the change in presentation for the common stock subject to possible redemption, the Company also restated its earnings per share calculation to allocate net income (loss) evenly to common stock subject to redemption and those that are not subject to redemption. This presentation contemplates a Business Combination as the most likely outcome, in which case, both classes of common stock share pro rata in the income (loss) of the Company. There has been no change in the Company’s total assets, liabilities or operating results. <p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJo1vAVyEhvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The impact of the restatement on the Company’s financial statements is reflected in the following table: Schedule of Financial Statements is Reflected <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Balance Sheet as of January 14, 2021 (as revised in footnote 2 per form 10-Q filed on May 21, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1Zj46Gshztj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">101,131,827</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDdSZTZPDZJ5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">15,018,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhZ2Y8x2xWWk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">116,150,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z8w53V2Ua331" title="Common stock, par value">0.0001 par value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvINqSS4gAm5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">479</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zI9O2TiUnxBd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">(149</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMJxD0cuw10h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional Paid in Capital</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJ12wOMK7973" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">5,359,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMrNA9MVl5O1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">(5,359,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzH0Rlrueu39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zd1L3dADorOa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(359,892</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4XNTLv9N3li" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(9,658,517</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zYKHa9yYmHlc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(10,018,499</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4UVq5ttgiFf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">5,000,004</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMr7TbZwQdrb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">(15,018,173</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFmSajDASbuh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">(10,018,169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4tx4VkQ1Lvi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">10,013,052</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zG6l8P55nT4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">1,486,948</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zq5wy14jWb43" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font-weight: bold">Balance Sheet as of March 31, 2021 (per form 10-Q filed on May 21, 2021)</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zILEfyRVxNkh" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">104,389,656</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1l32ECJMsa" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">11,760,344</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zk13nxtUDp9b" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">116,150,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zptTn3UzFQBk" title="Common stock, par value">0.0001 par value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwlBMnP4I7R5" style="text-align: right" title="Common stock, $0.0001 par value">445</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zg6f9Ot9uZe5" style="text-align: right" title="Common stock, $0.0001 par value">(115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5IHPKMM7LL" style="text-align: right" title="Common stock, $0.0001 par value">330</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additional Paid in Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zb7b0JKWPJG8" style="text-align: right" title="Additional Paid in Capital">2,035,336</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z2Ou8MfWlxJa" style="text-align: right" title="Additional Paid in Capital">(2,035,336</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zA6BprVMd8Nf" style="text-align: right" title="Additional Paid in Capital">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Retained Earnings (Accumulated Deficit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZnLnB7Ei0Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">2,964,224</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDpRPg93SID6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">(9,724,892</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTEKneaZZzQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">(6,760,669</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z35qxPXsUk12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">5,000,005</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zyK0YIkpuZ73" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">(11,760,344</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zIHHDBYDQXu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">(6,760,339</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQaRyV4SYMNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">10,335,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z48KLw0ry44c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">1,164,391</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbzOlsRl13r9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Unaudited Statement of Operations for the three months ended March 31, 2021 (per form 10-Q filed on May 21, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zspiADp9emEd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">3,532,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zI3LRK1Z2xxh" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">9,538,777</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKcdKKDdka78" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">13,070,827</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net income per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKhvu53WM2T2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zOtskGZeBxS8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">(0,61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgNLkOv1WqWj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">0.23</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Balance Sheet as of June 30, 2021 (per form 10-Q filed on August 9, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption ($)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlDQIIqSpaOj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">102,187,499</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPB0ytbjBg35" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">13,962,501</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ziNeDlqo1wz1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">116,150,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTdOtJ9Uw3I9" title="Common stock, par value">0.0001 par value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zIFgcT5pqwI" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHURVHMH95Oj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">(137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJyav27L4jC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional Paid in Capital</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6BS0AwMhVoc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">4,237,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zC1WZFfqCA06" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">(4,237,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJzwpSdG326h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Retained Earnings (Accumulated Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUHUZaiTQQwf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">762,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zY3iSZm3xLZa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(9,724,893</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zcyfisw5p8bk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(8,962,830</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znKCwJRAySm5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">5,000,002</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5fTOvgdoqF9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">(13,962,501</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znlv3EgP2aTj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">(8,962,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zGB5pOZHIPm5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">10,117,574</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPABeSTRtqej" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">1,382,426</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zjh4md7Rnqkj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Unaudited Statement of Operations For the three and six months ended June 30, 2021 (per form 10-Q filed on August 9, 2021)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Three months ended June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgA0Tei0JkBi" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">4,443,103</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDrMQIpu39qa" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">10,349,097</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvr0pCYpY3y1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">14,792,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net loss per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCmuORWMCYkf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNNBo9RN5Rua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9c5DaW6EQ0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Six months ended June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9hbXRfb6kn9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">4,162,957</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlnDNVWYXao9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">9,773,212</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFnNBVMUyHEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">13,936,269</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net loss per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zsja00BFAKsi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHuPLpFp1Veb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF61qoSBRoY3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.06</td><td style="text-align: left"> </td></tr> </table>

10.10

5000001

<p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJo1vAVyEhvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The impact of the restatement on the Company’s financial statements is reflected in the following table: Schedule of Financial Statements is Reflected <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Reported</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Adjustment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As Restated</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Balance Sheet as of January 14, 2021 (as revised in footnote 2 per form 10-Q filed on May 21, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1Zj46Gshztj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">101,131,827</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDdSZTZPDZJ5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">15,018,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhZ2Y8x2xWWk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common Stock subject to possible redemption">116,150,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z8w53V2Ua331" title="Common stock, par value">0.0001 par value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvINqSS4gAm5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">479</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zI9O2TiUnxBd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">(149</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMJxD0cuw10h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock, $0.0001 par value">330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional Paid in Capital</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJ12wOMK7973" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">5,359,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMrNA9MVl5O1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">(5,359,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzH0Rlrueu39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional Paid in Capital">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accumulated Deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zd1L3dADorOa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(359,892</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4XNTLv9N3li" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(9,658,517</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zYKHa9yYmHlc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Retained Earnings (Accumulated Deficit)">(10,018,499</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4UVq5ttgiFf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">5,000,004</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMr7TbZwQdrb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">(15,018,173</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockholdersEquity_iI_pp0p0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFmSajDASbuh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total Stockholders' Equity (Deficit)">(10,018,169</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4tx4VkQ1Lvi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">10,013,052</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zG6l8P55nT4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">1,486,948</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zq5wy14jWb43" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font-weight: bold">Balance Sheet as of March 31, 2021 (per form 10-Q filed on May 21, 2021)</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zILEfyRVxNkh" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">104,389,656</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1l32ECJMsa" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">11,760,344</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zk13nxtUDp9b" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Common Stock subject to possible redemption">116,150,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zptTn3UzFQBk" title="Common stock, par value">0.0001 par value</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwlBMnP4I7R5" style="text-align: right" title="Common stock, $0.0001 par value">445</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zg6f9Ot9uZe5" style="text-align: right" title="Common stock, $0.0001 par value">(115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CommonStockValue_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5IHPKMM7LL" style="text-align: right" title="Common stock, $0.0001 par value">330</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additional Paid in Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zb7b0JKWPJG8" style="text-align: right" title="Additional Paid in Capital">2,035,336</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z2Ou8MfWlxJa" style="text-align: right" title="Additional Paid in Capital">(2,035,336</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zA6BprVMd8Nf" style="text-align: right" title="Additional Paid in Capital">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Retained Earnings (Accumulated Deficit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZnLnB7Ei0Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">2,964,224</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDpRPg93SID6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">(9,724,892</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTEKneaZZzQ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Retained Earnings (Accumulated Deficit)">(6,760,669</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z35qxPXsUk12" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">5,000,005</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zyK0YIkpuZ73" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">(11,760,344</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--StockholdersEquity_iI_pp0p0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zIHHDBYDQXu8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Stockholders' Equity (Deficit)">(6,760,339</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQaRyV4SYMNj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">10,335,609</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z48KLw0ry44c" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">1,164,391</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbzOlsRl13r9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Unaudited Statement of Operations for the three months ended March 31, 2021 (per form 10-Q filed on May 21, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zspiADp9emEd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">3,532,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zI3LRK1Z2xxh" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">9,538,777</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKcdKKDdka78" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">13,070,827</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net income per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKhvu53WM2T2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zOtskGZeBxS8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">(0,61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210331__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgNLkOv1WqWj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net income per common share">0.23</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="12" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Balance Sheet as of June 30, 2021 (per form 10-Q filed on August 9, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1.5pt">Common Stock subject to possible redemption ($)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlDQIIqSpaOj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">102,187,499</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPB0ytbjBg35" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">13,962,501</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityRedemptionValue_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ziNeDlqo1wz1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Common stock subject to possible redemption">116,150,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Common stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlc3RhdGVtZW50IG9mIEJhbGFuY2UgU2hlZXQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTdOtJ9Uw3I9" title="Common stock, par value">0.0001 par value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zIFgcT5pqwI" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHURVHMH95Oj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">(137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockValue_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJyav27L4jC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Common stock - $0.0001 par value">330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional Paid in Capital</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6BS0AwMhVoc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">4,237,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zC1WZFfqCA06" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">(4,237,471</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AdditionalPaidInCapital_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJzwpSdG326h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additional paid-in-capital">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Retained Earnings (Accumulated Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUHUZaiTQQwf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">762,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zY3iSZm3xLZa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(9,724,893</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zcyfisw5p8bk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated deficit">(8,962,830</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Stockholders’ Equity (Deficit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znKCwJRAySm5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">5,000,002</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5fTOvgdoqF9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">(13,962,501</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--StockholdersEquity_iI_pp0p0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znlv3EgP2aTj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total stockholders' equity">(8,962,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Number of shares subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zGB5pOZHIPm5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">10,117,574</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPABeSTRtqej" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">1,382,426</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfSharesSubjectToRedemption_iI_pip0_c20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zjh4md7Rnqkj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares subject to redemption">11,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Unaudited Statement of Operations For the three and six months ended June 30, 2021 (per form 10-Q filed on August 9, 2021)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Three months ended June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgA0Tei0JkBi" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">4,443,103</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDrMQIpu39qa" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">10,349,097</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210401__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvr0pCYpY3y1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">14,792,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net loss per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCmuORWMCYkf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNNBo9RN5Rua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasicAndDiluted_c20210401__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9c5DaW6EQ0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif">Six months ended June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted weighted average shares outstanding, common stock subject to redemption</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9hbXRfb6kn9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">4,162,957</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlnDNVWYXao9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">9,773,212</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c20210101__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFnNBVMUyHEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted weighted average shares outstanding, common stock subject to redemption">13,936,269</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and diluted net loss per common share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zsja00BFAKsi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--RestatementAxis__srt--RestatementAdjustmentMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHuPLpFp1Veb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">(0.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_c20210101__20210630__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF61qoSBRoY3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Basic and diluted net loss per common share">0.06</td><td style="text-align: left"> </td></tr> </table>

101131827

15018173

116150000

0.0001

479

-149

330

5359507

-5359507

-359892

-9658517

-10018499

5000004

-15018173

-10018169

10013052 1486948 11500000

104389656

11760344

116150000

0.0001

445

-115

330

2035336

-2035336

2964224

-9724892

-6760669

5000005

-11760344

-6760339

10335609 1164391 11500000

3532050

9538777

13070827

0.84

-0.61

0.23

102187499

13962501

116150000

0.0001

467

-137

330

4237471

-4237471

762063

-9724893

-8962830

5000002

-13962501

-8962500

10117574 1382426 11500000

4443103

10349097

14792000

-0.50

0.35

-0.15

4162957

9773212

13936269

0.18

-0.12

0.06

<p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zrXKprZM1HKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 3 — Significant Accounting Policies Summary of Significant Accounting Policies <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z83Svvn5aMK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods. <p id="xdx_844_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zrtNiB6hTdOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <p id="xdx_84C_eus-gaap--UseOfEstimates_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zip0xldlqJbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwG0HYgDbcDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021 and December 31, 2020. <p id="xdx_84F_eus-gaap--MarketableSecuritiesPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfMuPGmzppdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable Securities Held in Trust Account At September 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest U.S. Treasury securities. <p id="xdx_844_ecustom--WarrantLiabilitiesPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zRSYENl2AWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant Liabilities The Company evaluated the Public Warrants and Private Placement Warrants (each as defined herein and collectively, “Warrants”, which are discussed in Note 2, Note 4, Note 5 and Note 9) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. <p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKcd4NX0usYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #211D1E">Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the common stock were charged to temporary equity upon the completion of the Initial Public Offering. Transaction costs amounted to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4uFWjsvmz82" title="Sale of Stock, Consideration Received Per Transaction">6,108,360, of which $359,874 were allocated to expense associated with the warrant liability. <p id="xdx_846_ecustom--CommonStockSubjectToPossibleRedemptionPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zSEbmJqFdlA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock Subject to Possible Redemption All of the <span id="xdx_901_ecustom--CommonStockSubjectToPossibleRedemptionShare_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQY36wTvThsl" title="Common stock sold subject to possible redemption shares">11,500,000 shares of common stock sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The common stock is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital and accumulated deficit. <p id="xdx_892_ecustom--CommonStockReflectedOnTheBalanceSheetTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwItNNTcwKY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of September 30, 2021, the common stock reflected on the balance sheet are reconciled in the following table: Schedule of Common Stock Reflected on the Balance Sheet <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Gross proceeds from IPO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPXx81VgDzte" style="width: 18%; text-align: right" title="Gross proceeds from IPO">116,150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Proceeds allocated to Public Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromIssuanceOfWarrants_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zpyDlTT3Xoy8" style="text-align: right" title="Proceeds allocated to Public Warrants">(6,775,220</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Common stock issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsOfStockIssuanceCosts_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zE5NVr2gO2V8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Common stock issuance costs">(5,748,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Accretion of carrying value to redemption value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgGXZpGrcgia" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of carrying value to redemption value">12,523,705</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--CommonStockSubjectToPossibleRedemption_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4042hCtEWnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock subject to possible redemption">116,150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVpWCkslU3q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimis as of September 30, 2021 and December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were <span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iI_pp0p0_do_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztj0VwwapSil" title="Unrecognized Tax Benefits, Income Tax Penalties Accrued"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iI_pp0p0_do_c20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z60jaCxnQXc8" title="Unrecognized Tax Benefits, Income Tax Penalties Accrued">no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimis for the period ended September 30, 2021. <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQSWGTFOOVyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Income (Loss) Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of any warrants sold in the Initial Public Offering and the private placement to purchase <span id="xdx_908_eus-gaap--StockIssued1_pp0p0_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zSq2YcKegEli">5,958,600 shares of common stock in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net loss per common share is the same as basic net loss per common share for the period presented. Accretion of the carrying value of common stock to redemption value is excluded from net income per ordinary share because the redemption value approximates fair value. <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNaOFchBDNU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20210701__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAf6BKCapNk2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the three months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhmzmcMs5tTe" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the nine months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net income (loss) per share:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zYChlJq33LT1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 56%; text-align: left">Allocation of net income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(330,829</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">440,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zj7iooHoJQg1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted-average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,792,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,224,714</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pid_ztlpokeXAap5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Basic and diluted net income (loss) per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEmHLcJU08Zh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMxdbpCSwiXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in; text-align: justify">Level 1 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 2 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 3 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr> </table> See Note 9 for additional information on assets and liabilities measured at fair value. <p id="xdx_845_ecustom--RecentlyAdoptedAccountingStandardsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zGdBLVvwPDy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHVFBWJB29R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

<p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z83Svvn5aMK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

<p id="xdx_844_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zrtNiB6hTdOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

<p id="xdx_84C_eus-gaap--UseOfEstimates_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zip0xldlqJbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwG0HYgDbcDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2021 and December 31, 2020.

<p id="xdx_84F_eus-gaap--MarketableSecuritiesPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfMuPGmzppdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable Securities Held in Trust Account At September 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest U.S. Treasury securities.

<p id="xdx_844_ecustom--WarrantLiabilitiesPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zRSYENl2AWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant Liabilities The Company evaluated the Public Warrants and Private Placement Warrants (each as defined herein and collectively, “Warrants”, which are discussed in Note 2, Note 4, Note 5 and Note 9) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. <p id="xdx_84D_ecustom--OfferingCostsAssociatedWithInitialPublicOfferingPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKcd4NX0usYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #211D1E">Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the common stock were charged to temporary equity upon the completion of the Initial Public Offering. Transaction costs amounted to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4uFWjsvmz82" title="Sale of Stock, Consideration Received Per Transaction">6,108,360, of which $359,874 were allocated to expense associated with the warrant liability.

6108360

359874

<p id="xdx_846_ecustom--CommonStockSubjectToPossibleRedemptionPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zSEbmJqFdlA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock Subject to Possible Redemption All of the <span id="xdx_901_ecustom--CommonStockSubjectToPossibleRedemptionShare_c20210101__20210930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQY36wTvThsl" title="Common stock sold subject to possible redemption shares">11,500,000 shares of common stock sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The common stock is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital and accumulated deficit. <p id="xdx_892_ecustom--CommonStockReflectedOnTheBalanceSheetTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwItNNTcwKY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of September 30, 2021, the common stock reflected on the balance sheet are reconciled in the following table: Schedule of Common Stock Reflected on the Balance Sheet <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Gross proceeds from IPO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPXx81VgDzte" style="width: 18%; text-align: right" title="Gross proceeds from IPO">116,150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Proceeds allocated to Public Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromIssuanceOfWarrants_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zpyDlTT3Xoy8" style="text-align: right" title="Proceeds allocated to Public Warrants">(6,775,220</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Common stock issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsOfStockIssuanceCosts_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zE5NVr2gO2V8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Common stock issuance costs">(5,748,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Accretion of carrying value to redemption value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgGXZpGrcgia" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of carrying value to redemption value">12,523,705</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--CommonStockSubjectToPossibleRedemption_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4042hCtEWnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock subject to possible redemption">116,150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11500000 <p id="xdx_892_ecustom--CommonStockReflectedOnTheBalanceSheetTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwItNNTcwKY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of September 30, 2021, the common stock reflected on the balance sheet are reconciled in the following table: Schedule of Common Stock Reflected on the Balance Sheet <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Gross proceeds from IPO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPXx81VgDzte" style="width: 18%; text-align: right" title="Gross proceeds from IPO">116,150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Proceeds allocated to Public Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromIssuanceOfWarrants_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zpyDlTT3Xoy8" style="text-align: right" title="Proceeds allocated to Public Warrants">(6,775,220</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Common stock issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsOfStockIssuanceCosts_iN_di_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zE5NVr2gO2V8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Common stock issuance costs">(5,748,485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Accretion of carrying value to redemption value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgGXZpGrcgia" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accretion of carrying value to redemption value">12,523,705</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Common stock subject to possible redemption</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--CommonStockSubjectToPossibleRedemption_iI_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4042hCtEWnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Common stock subject to possible redemption">116,150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

116150000

6775220

5748485

12523705

116150000

<p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVpWCkslU3q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimis as of September 30, 2021 and December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were <span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iI_pp0p0_do_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztj0VwwapSil" title="Unrecognized Tax Benefits, Income Tax Penalties Accrued"><span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iI_pp0p0_do_c20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z60jaCxnQXc8" title="Unrecognized Tax Benefits, Income Tax Penalties Accrued">no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimis for the period ended September 30, 2021.

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQSWGTFOOVyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Income (Loss) Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of any warrants sold in the Initial Public Offering and the private placement to purchase <span id="xdx_908_eus-gaap--StockIssued1_pp0p0_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zSq2YcKegEli">5,958,600 shares of common stock in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net loss per common share is the same as basic net loss per common share for the period presented. Accretion of the carrying value of common stock to redemption value is excluded from net income per ordinary share because the redemption value approximates fair value. <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNaOFchBDNU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20210701__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAf6BKCapNk2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the three months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhmzmcMs5tTe" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the nine months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net income (loss) per share:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zYChlJq33LT1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 56%; text-align: left">Allocation of net income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(330,829</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">440,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zj7iooHoJQg1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted-average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,792,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,224,714</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pid_ztlpokeXAap5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Basic and diluted net income (loss) per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5958600

<p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNaOFchBDNU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20210701__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAf6BKCapNk2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the three months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhmzmcMs5tTe" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the nine months ended September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net income (loss) per share:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zYChlJq33LT1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 56%; text-align: left">Allocation of net income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(330,829</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">440,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zj7iooHoJQg1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted-average shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,792,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,224,714</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pid_ztlpokeXAap5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Basic and diluted net income (loss) per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-330829

440230

14792200

14224714

-0.02

0.03

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEmHLcJU08Zh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

250000

<p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMxdbpCSwiXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in; text-align: justify">Level 1 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 2 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 3 —</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr> </table> See Note 9 for additional information on assets and liabilities measured at fair value.

<p id="xdx_845_ecustom--RecentlyAdoptedAccountingStandardsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zGdBLVvwPDy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20">Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows.

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHVFBWJB29R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

<p id="xdx_80E_ecustom--InitialPublicOfferingTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlkbhztRTnhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 4 — Initial Public Offering Public Units On January 14, 2021, the Company initially sold <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvkzC75RCVog">11,500,000 Units, at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6Q27v1dKjsa">10.00 per Unit, which includes the full exercise by the underwriters of the over-allotment option to purchase an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9Cf9BzKyzf8">1,500,000 Units, at a purchase price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zliQbkjIVNrj">10.00 per Unit. Each Unit consists of one share of common stock, and one-half warrant to purchase one share of common stock (the “Public Warrants”). Public Warrants Each whole Warrant entitles the holder to purchase one share of the Company’s common stock at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZYa3LoHzjLe" title="Unit issued price">11.50 per share, subject to adjustment as discussed herein. The Warrants will become exercisable on the later of 12 months from the closing of this offering or 30 days after the completion of its initial business combination, and will expire five years after the completion of the Company’s initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of common stock underlying such unit. Once the warrants become exercisable, the Company may call the warrants for redemption: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">in whole and not in part;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">at a price of $0.01 per warrant;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">if, and only if, <span id="xdx_900_ecustom--DescriptionOfRedemptionOfWarrants_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCpJw6ql3Nk8" title="Redemption of warrants description">the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders.</td></tr> </table> If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

11500000

10.00

1500000

10.00

11.50

In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price

0.01

the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders. Note 5 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_uShares_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBg20IvGLMkj" title="Sale of units">417,200 Placement Units, at a price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember_zxrl0loYKLrj" title="Unit issued price">10.00 per Placement Unit, for an aggregate purchase price of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNaB2nVXnrR5" title="Proceeds from sale of units">4,172,000, in a private placement. A portion of the proceeds from the private placement was added to the proceeds from the IPO held in the Trust. Each Placement Unit was identical to the Units sold in the IPO, except for the placement warrants (“Placement Warrants”). The Placement Warrants and the common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. If the Company does not complete its initial business combination within 15 months (or up to 21 months) from the closing of this IPO, the proceeds from the sale of the Placement Units held in the trust account will be used to fund the redemption of its public shares (subject to the requirements of applicable law) and the Placement Warrants will expire worthless.

417200

10.00

4172000

<p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zelqlF7zy9Dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 6 — Related Party Transactions Founder Shares On November 12, 2020, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20201110__20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPGKv1pZVUK3" title="Stock issued during the period, shares">2,156,250 shares of common stock to the Sponsor for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201110__20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z7Y7xZCPr7f5" title="Stock issued during the period">25,000 in cash, or approximately $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZuBcNKlglz4" title="Shares issued price per share">0.012 per share, in connection with formation. On December 7, 2020, the Sponsor forfeited <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUt0voEPEPag" title="Shares forfeited during the period">161,719 founder shares to the Company and Ladenburg Thalmann & Co. Inc., the representative of the underwriters, and certain of its employees (“Ladenburg”) purchased from the Company an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuCiqTpyPRJf" title="Stock issued during the period, shares">161,719 representative shares at an average purchase price of approximately $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z43JfLeJS9ph" title="Shares issued price per share">0.012 per share, for an aggregate purchase price of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zm1oVFys6Ru5" title="Stock issued during the period">1,875. On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQVVPFkZr5Ki" title="Common stock, shares outstanding">2,875,000 founder shares outstanding (including up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztmHgCpfYk7" title="Shares forfeited during the period">375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part). As a result of the underwriters’ election to fully exercise of their over-allotment option on January 14, 2021, the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfDtmsVGXvrd" title="Shares exercised during the period">375,000 shares are no longer subject to forfeiture. On January 4, 2021, the Sponsor forfeited <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zT8qDBgbid19" title="Shares forfeited during the period">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zi86LfKyEY6h" title="Stock issued during the period">28,750 representative shares at an average purchase price of approximately $0.008 per share, for an aggregate purchase price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMmJj3nhr4z" title="Stock issued during the period">230. As a result, the Sponsor currently owns <span id="xdx_901_ecustom--SharesOwned_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z0RoUa1xvguj" title="Shares Owned">2,630,625 shares. <span id="xdx_90F_ecustom--AgreementDescription_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhfF9uxy30Gd" title="Agreement description">The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Representative Shares On December 7, 2020, the Sponsor forfeited <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAvyxGFf8Ks" title="Shares forfeited during the period">161,719 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zL2gdiUG2s38">161,719 representative shares at an average purchase price of approximately $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zeTzi000TdM1" title="Shares issued price per share">0.012 per share, for an aggregate purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbbcMciLRVak" title="Stock issued during the period">1,875. On January 4, 2021, the Sponsor forfeited <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zqS98aqU8J0b" title="Shares forfeited during the period">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zN9NnQYMVrr6" title="Stock option exercised">28,750 representative shares at an average purchase price of approximately $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAGC3G5aOeFk" title="Shares issued price per share">0.008 per share, for an aggregate purchase price of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTMVClZ6i0U3" title="Stock issued during the period">230. Following the 1/3 common stock dividend effected January 3, 2020 (as described herein), Ladenburg and certain of its employees now hold an aggregate of <span id="xdx_902_ecustom--SharesOwned_pid_uShares_c20210102__20210103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zWD3t9TCUnb" title="Shares owned">244,375 representative shares (of which up to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znD76SkNEm3f" title="Shares forfeited during the period">31,875 were subject to forfeiture). As a result of the underwriters’ election to fully exercise of their over-allotment option, the <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zrlwiD14oQef" title="Shares forfeited during the period">31,875 shares are no longer subject to forfeiture. Ladenburg and certain of its employees have entered into a subscription agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their representative shares, as applicable, and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their representative shares, as applicable, (iii) waive their rights to liquidating distributions from the trust account with respect to their representative shares if the Company fails to complete the initial business combination within the Combination Period. Promissory Note — Related Party On November 19, 2020, Company issued an unsecured promissory note to the Sponsor for an aggregate of up to $<span id="xdx_904_eus-gaap--UnsecuredDebt_iI_pp0p0_c20201119__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--RangeAxis__srt--MaximumMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHEZzIyUhxO2" title="Unsecured debt">250,000 to cover expenses related to the IPO. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20201118__20201119__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zoewaYJYEOI" title="Debt instrument description">This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. As of December 31, 2020, the Company had drawn down $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztNnVcN7sPpf" title="Proceeds from issuance of debt">150,000 under the promissory note. On January 14, 2021, the Company paid the $150,000 balance on the note from the proceeds of the IPO. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans.<span id="xdx_909_eus-gaap--DebtConversionDescription_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorsMember_zG0AdeMwz4Bg" title="Debt conversions"> Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210930__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorsMember__us-gaap--DebtInstrumentAxis__custom--WorkingCapitalLoanMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmZQTOisQePc" title="Debt instrument convertible conversion price per share">10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. The units would be identical to the Placement Units. At September 30, 2021, no Working Capital Loans were outstanding. Administrative Service Fee The Company has agreed to pay an affiliate of the Company’s Sponsor a monthly fee of an aggregate of $<span id="xdx_90D_eus-gaap--OtherGeneralAndAdministrativeExpense_pp0p0_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zBbDclGAEez2" title="Other general and administrative expenses">10,000 for office space, utilities and secretarial and administrative support. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three and nine months ended September 30, 2021, the Company has recorded $30,000 and $90,000 in service fee expense, respectively.

2156250

25000

0.012

161719

0.012

1875

2875000

375000

28750

0.008

230

2630625 The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.

161719

0.012

1875

28750

0.008

230

244375

31875

250000

This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. As of December 31, 2020, the Company had drawn down $150,000 under the promissory note. On January 14, 2021, the Company paid the $150,000 balance on the note from the proceeds of the IPO

150000

Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. The units would be identical to the Placement Units. At September 30, 2021, no Working Capital Loans were outstanding.

1500000

10.00

10000

30000 90000

<p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmdyiJUXgx9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 7 — Commitments and Contingencies Underwriting Agreement The underwriter had a 45-day option from the date of the IPO to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHB9oF2wvTdc" title="Units issued during the period, shares"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zyCQVcxQClvk" title="Units issued during the period, shares">1,500,000 additional Units at the public offering price less the underwriting commissions to cover over-allotments, if any. On January 14, 2021, the underwriter fully exercised its over-allotment option. Upon consummation of the IPO on January 14, 2021, the underwriters were paid a cash underwriting fee of <span id="xdx_901_ecustom--CashUnderwritingFeePercentage_pid_dp_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zRarocI0q599" title="Cash underwriting fee, percentage">1.33% of the gross proceeds of the IPO, or $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuajvVMhbpW3" title="Gross proceeds from IPO">1,529,500 in the aggregate. The underwriters are entitled to deferred underwriting fee of <span id="xdx_904_ecustom--DeferredUnderwritingFeePercentage_pid_dp_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zP0lHXAs2QN3" title="Underwriting fee percentage">3.67% of the gross proceeds of the IPO, or $<span id="xdx_90B_ecustom--ProceedsFromDeferredUnderwriting_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zAQ8jkqWWsj3" title="Proceeds from deferred underwriting">4,220,500 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Registration Rights The holders of the founder shares, representative shares, placement units, and units that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

1500000

0.0133

1529500

0.0367 4220500

<p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zxhH3ckrpS5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 8 — Stockholders’ Equity Preferred Stock — The Company is authorized to issue a total of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbTOPM9mPiW6" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgo4c6k2NJS7" title="Preferred stock, shares authorized">1,000,000 preferred shares at par value of $0.0001 each. At September 30, 2021 and December 31, 2020, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue a total of 50,000,000 share of common stock at par value of $0.0001 each. At September 30, 2021 and December 31, 2020, there were <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zw6RTn0USkq4" title="Common stock, shares outstanding">3,292,200 and <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPqh6bG8gk1c" title="Common stock, shares outstanding">2,875,000 shares issued and outstanding, excluding <span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_uShares_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zsauLUWkpodg" title="Common stock shares redemption">11,500,000 and no shares subject to possible redemption, respectively. The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zz7PiPGk9Xtb" title="Shares issued price per share">12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares.

1000000

0.0001

50000000

0.0001

3292200

2875000

11500000

The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares.

12.50

<p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zcyuINav3h6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 9 — Fair Value Measurements The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: <p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgGQFtHCEFZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted Prices In Active Markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant Other Observable Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">U.S. Money Market held in Trust Account</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCI6usaBtuQ2" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">116,158,244</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVgIYKc4oTu4" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">116,158,244</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuWTtkVVQlY4" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">—</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhOVzT2pkk17" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">—</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public Warrants Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZIId1u25dih" style="text-align: right" title="Public Warrants Liability">5,290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6BFPi83Y1lh" style="text-align: right" title="Public Warrants Liability">5,290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFa7ZGhfnWZa" style="text-align: right" title="Public Warrants Liability">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmA3kfbMA6j" style="text-align: right" title="Public Warrants Liability">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Private Placement Warrants Liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUpXVsunHm24" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">239,312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJ2hNSOgZ9F1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zdavGuybrsS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbzruElThqC4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">239,312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zM3J7Wylb383" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">5,529,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF1UYo7SgDY9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">5,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4uMHWAoNXk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUd0IOxoy6uh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Condensed Balance Sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Condensed Statement of Operations. The Company established the initial fair value of the Public Warrants and Private Warrants on January 14, 2021, the date of the Company’s Initial Public Offering, using a Monte Carlo simulation model. On September 30, 2021, the Company established the fair value of the Private Warrants using a Monto Carlo simulation model, and the fair value of the Public Warrants by reference to the quoted market price. The Public and Private Warrants were classified as Level 3 at the initial measurement date and the Private Warrants were classified as Level 3 at September 30, 2021 due to the use of unobservable inputs. As of September 30, 2021, the Public Warrant were transferred to Level 1 due to the use of the quote market price. <p id="xdx_891_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzCtxhsodOHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the changes in the fair value of the Level 3 liabilities: Schedule of Change in Fair Value Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private Placement Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Public Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrant Liabilities</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair Value as of December 31, 2020</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNi24IICq4qa" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJohzuvylUYf" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zg280m1V6p7g" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Initial measurement on January 14, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzHT607Mytgc" style="width: 14%; text-align: right" title="Initial Measurement">249,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvzLME2BYdgb" style="width: 14%; text-align: right" title="Initial Measurement">6,775,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3DsQaiiAjoh" style="width: 14%; text-align: right" title="Initial Measurement">7,025,183</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zpGIW16R1u9b" style="text-align: right" title="Change in valuation">(10,651</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMR4UGlCJ5g5" style="text-align: right" title="Change in valuation">(1,485,220</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUcrLk6G5krc" style="text-align: right" title="Change in valuation">(1,495,871</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Transferred to Level 1</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZWOBmnJXro2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztKvDSp6wKb4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">(5,290,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zH0gcnOSErsk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">(5,290,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zOeWLM9zIVfc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVjyaBcSdfG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwzmFrHcoR82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89E_ecustom--ScheduleOfKeyInputsIntoMonteCarloSimulationTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zODCPeFfYCYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs into the Monte Carlo simulation as of January 14, 2021 and September 30, 2021 were as follows: Schedule of Key Inputs into Monte Carlo Simulation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Initial Measurement)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 14, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zRt12sl50LS9" style="width: 18%; text-align: right" title="Risk-free interest rate">0.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuAHTcDfXIH1" style="width: 18%; text-align: right" title="Risk-free interest rate">1.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term remaining (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHLZq6E1KIFe" title="Expected term remaining (years)">5.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfw5ZSOk4IC8" title="Expected term remaining (years)">5.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4orhOp9Y2I7" title="Expected volatility">24.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfbM90WI0Sq9" title="Expected volatility">18.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znGoMiZfBQ4a" style="text-align: right" title="Stock price">9.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCdQzBfmSCva" style="text-align: right" title="Stock price">10.08</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zgGQFtHCEFZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Quoted Prices In Active Markets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant Other Observable Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">U.S. Money Market held in Trust Account</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCI6usaBtuQ2" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">116,158,244</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVgIYKc4oTu4" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">116,158,244</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuWTtkVVQlY4" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">—</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhOVzT2pkk17" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="U.S. Money Market held in Trust Account">—</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Public Warrants Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZIId1u25dih" style="text-align: right" title="Public Warrants Liability">5,290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6BFPi83Y1lh" style="text-align: right" title="Public Warrants Liability">5,290,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFa7ZGhfnWZa" style="text-align: right" title="Public Warrants Liability">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--PublicWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmA3kfbMA6j" style="text-align: right" title="Public Warrants Liability">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Private Placement Warrants Liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUpXVsunHm24" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">239,312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJ2hNSOgZ9F1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zdavGuybrsS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--PrivatePlacementWarrantsLiability_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbzruElThqC4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Private Placement Warrants Liability">239,312</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zM3J7Wylb383" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">5,529,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF1UYo7SgDY9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">5,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4uMHWAoNXk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pp0p0_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUd0IOxoy6uh" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

116158244

5290000 5290000 239312 239312

5529312

5290000

239312

<p id="xdx_891_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzCtxhsodOHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the changes in the fair value of the Level 3 liabilities: Schedule of Change in Fair Value Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private Placement Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Public Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrant Liabilities</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair Value as of December 31, 2020</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zNi24IICq4qa" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zJohzuvylUYf" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zg280m1V6p7g" style="text-align: right" title="Fair Value Beginning">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Initial measurement on January 14, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzHT607Mytgc" style="width: 14%; text-align: right" title="Initial Measurement">249,963</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvzLME2BYdgb" style="width: 14%; text-align: right" title="Initial Measurement">6,775,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3DsQaiiAjoh" style="width: 14%; text-align: right" title="Initial Measurement">7,025,183</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zpGIW16R1u9b" style="text-align: right" title="Change in valuation">(10,651</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zMR4UGlCJ5g5" style="text-align: right" title="Change in valuation">(1,485,220</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUcrLk6G5krc" style="text-align: right" title="Change in valuation">(1,495,871</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Transferred to Level 1</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZWOBmnJXro2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztKvDSp6wKb4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">(5,290,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--TransferredToLevel1_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zH0gcnOSErsk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transferred to Level 1">(5,290,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PrivatePlacementWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zOeWLM9zIVfc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--PublicWarrantsMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVjyaBcSdfG9" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeFairValueOfDerivativeNet_iE_pp0p0_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantsLiabilitiesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zwzmFrHcoR82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of liabilities">239,312</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

249963

6775220

7025183

-10651

-1485220

-1495871

-5290000 -5290000

239312

<p id="xdx_89E_ecustom--ScheduleOfKeyInputsIntoMonteCarloSimulationTableTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zODCPeFfYCYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs into the Monte Carlo simulation as of January 14, 2021 and September 30, 2021 were as follows: Schedule of Key Inputs into Monte Carlo Simulation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Initial Measurement)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">January 14, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zRt12sl50LS9" style="width: 18%; text-align: right" title="Risk-free interest rate">0.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuAHTcDfXIH1" style="width: 18%; text-align: right" title="Risk-free interest rate">1.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term remaining (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHLZq6E1KIFe" title="Expected term remaining (years)">5.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfw5ZSOk4IC8" title="Expected term remaining (years)">5.14</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210113__20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4orhOp9Y2I7" title="Expected volatility">24.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfbM90WI0Sq9" title="Expected volatility">18.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znGoMiZfBQ4a" style="text-align: right" title="Stock price">9.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210930__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCdQzBfmSCva" style="text-align: right" title="Stock price">10.08</td><td style="text-align: left"> </td></tr> </table>

0.0060

0.0100

P5Y8M1D

P5Y1M20D

0.242

0.187

9.41

10.08

Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. Business Combination Agreement Business Combination On October 22, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination”), pursuant to the terms of the agreement and plan of merger, dated as of June 21, 2021 (as may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Company, Big Cypress Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and SAB Biotherapeutics, Inc., a Delaware corporation (“OLD SAB”). Pursuant to the Business Combination Agreement, on the Closing Date, (i) Merger Sub merged with and into OLD SAB (the “Merger”), with OLD SAB as the surviving company in the Merger, and, after giving effect to such Merger, OLD SAB was renamed SAB Sciences, Inc. and became a wholly-owned subsidiary of the Company and (ii) the Company changed its name to “SAB Biotherapeutics, Inc.” In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), (i) each share of common stock and preferred stock of OLD SAB outstanding as of immediately prior to the Effective Time was exchanged for shares of common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211022__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zcyKz88qpaS3" title="Common stock, par value">0.0001 per share, of the Company (“Common Stock”) based on the agreed upon OLD SAB equity value of $<span id="xdx_905_eus-gaap--StockholdersEquity_iI_pn6n6_c20211022__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zLsLeY8N1Zsh" title="Equity value">300 million (the “Equity Value”) and a conversion rate of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211022__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBYKTp3XN9hi" title="Conversion price per share">10.10; (ii) each outstanding vested and unvested option to purchase shares of OLD SAB common stock was exchanged for a comparable option to purchase Common Stock, based on the Equity Value and a conversion rate of $10.10; and (iii) holders of vested options to purchase shares of OLD SAB common stock received, in the aggregate, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20211021__20211022__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zkvsfXkXj54a" title="Aggregate of restricted stock units, shares">1,507,124 restricted stock units (the “Earnout RSUs”) related to shares of Common Stock. Additionally, holders of OLD SAB common stock and preferred stock are entitled to receive their pro rata share of the shares of Common Stock that were issued into escrow at the Closing (the “Earnout Shares”) which will be released if certain conditions are met within the five-year period following the Closing (the “Earnout Period”). The total number of Earnout Shares and shares underlying the Earnout RSUs equaled <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20211021__20211022__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zkDQ76kULjA1" title="Aggregate of restricted stock units, shares">12,000,000 shares of Common Stock, in the aggregate. No fraction of a share of Common Stock was issued at the Closing, and each person who was otherwise entitled to a fraction of a share of Common Stock (after aggregating all fractional shares of Common Stock that otherwise would be received by such holder) received the number of shares of Common Stock rounded in the aggregate to the nearest whole share of Common Stock.

0.0001

300000000

10.10

1507124

12000000

84836

2258

87094

235111

322205

156201

150000

306201

0.0001

1000000

0.0001

50000000

2875000

288

24712

-8996

16004

322205

343125

31875

8996

-8996

2500000

-0.00

343125

31875

2875000

288

24712

25000

-8996

2875000

288

24712

-8996

16004

2875000

288

24712

-8996

16004

343125

31875

-8996

2558

1222

-10032

25000

150000

80132

94868

84836

154979

<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zhWtrzAAAGPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 1 — Organization and Business Operations Big Cypress Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated in Delaware on November 12, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). The Company has not selected any specific business combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to the Business Combination. As of December 31, 2020, the Company had not commenced any operations. All activity for the period from November 12, 2020 (inception) through December 31, 2020 relates to the Company’s formation and preparation for the Initial Public Offering (“IPO”) as described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering as described below. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Big Cypress Holdings LLC, a Delaware limited liability company (the “Sponsor”). Subsequent to December 31, 2020, the registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 11, 2021 (the “Effective Date”). On January 14, 2021, the Company consummated the IPO of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zjg6UgPcztD3" title="Units issued during the period, shares">11,500,000 units (the “Units”), which included the full exercise by the underwriters of the over-allotment option to purchase an additional <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3Q9NTErMBq6" title="Units issued during the period, shares">1,500,000 Units, at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zyyKHbLO7om8" title="Unit issued price">10.00 per Unit, generating gross proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zKL8ANFibWg4" title="Proceeds from IPO">115,000,000, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210113__20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBtCO6Bj7a46" title="Sale of units">417,200 units (the “Placement Units”), at a price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zR0BgBlYHK9b" title="Unit issued price">10.00 per unit, generating gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210113__20210114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zzf8q8USgXaa" title="Proceeds from sale of units">4,172,000, which is discussed in Note 4. <span id="xdx_901_eus-gaap--SaleOfStockDescriptionOfTransaction_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z0PvLSbI3UJg" title="Description of units">Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfUcAEdxv258" title="Unit issued price">11.50 per whole share. Transaction costs of the IPO amounted to $6,038,360 consisting of $<span id="xdx_90E_ecustom--UnderwritingFee_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zsUyVMWBa8Xd" title="Underwriting fee">1,529,500 of underwriting fee, $<span id="xdx_909_eus-gaap--DeferredOfferingCosts_iI_pp0p0_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zShF5jg89od3" title="Deferred underwriting fee">4,220,500 of deferred underwriting fee, and $<span id="xdx_907_eus-gaap--OtherDeferredCostsNet_iI_pp0p0_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZEOw4AUjWu4" title="Other offering costs">288,360 of other offering costs (see Note 8). Following the closing of the IPO on January 14, 2021, $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zriMji7ZDNXg" title="Proceeds from sale of units">116,150,000 ($10.10 per Unit) from the net offering proceeds of the sale of the Units in the IPO and the sale of the Placement Units was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise and income tax obligations (less up to $100,000 of interest to pay dissolution expenses), the proceeds from this IPO and the sale of the Placement Units will not be released from the trust account until the earliest of (a) the completion of the Company’s initial business combination, (b) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation, and (c) the redemption of the Company’s public shares if the Company is unable to complete the initial business combination within 15 months (or up to 21 months) from the closing of this IPO, subject to applicable law. The proceeds deposited in the trust account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial business combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial business combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The shares of common stock subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. <span id="xdx_90F_ecustom--AmendedAgreementDescription_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3RFSGIxaruh" title="Agreement description">The Company will have 15 months (or up to 21 months) from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and placement shares in connection with the completion of the initial business combination, (ii) waive their redemption rights with respect to their founder shares and placement shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and placement shares if the Company fails to complete the initial business combination within the Combination Period. The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations. Liquidity and Capital Resources As of December 31, 2020, the Company had $84,836 in cash and working capital deficit of $219,107 (excluding deferred offering costs). The Company’s liquidity needs up to December 31, 2020 had been satisfied through a capital contribution from the Sponsor of $<span id="xdx_90B_eus-gaap--ProceedsFromContributedCapital_pp0p0_c20201112__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEswDYx48RF1" title="Capital contribution">25,000 (see Note 5) for the founder shares and the loan under an unsecured promissory note from the Sponsor of $<span id="xdx_90A_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_c20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zYyTdgZYYWN8" title="Unsecured promissory note">150,000 (see Note 5). Subsequent to December 31, 2020, on January 14, 2021, simultaneous with the consummation of the IPO, the net proceeds from the consummation of the Private Placement not held in Trust were deposited into the Company’s operating bank account (see Note 8). As of January 14, 2021, the Company had approximately $1.2 million in its operating bank account, and working capital of approximately $<span id="xdx_901_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pn5n6_c20210114__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQcFcOnsCGZ" title="Unsecured promissory note">1.2 million. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5). To date, there were no amounts outstanding under any Working Capital Loans. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Risks and Uncertainties Management continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that it could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

11500000

1500000

10.00

115000000

417200

10.00

4172000

Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $11.50 per whole share.

11.50

6038360

1529500

4220500

288360

116150000

10.10 The Company will have 15 months (or up to 21 months) from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate.

84836

219107

25000

150000

1200000

<p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zA19JLQhT3vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 2 — Significant Accounting Policies Summary of Significant Accounting Policies <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztCUl98uKFg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). <p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zyYy51t99pLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <p id="xdx_842_eus-gaap--UseOfEstimates_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBe3LUkpF0Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFxAQ7m3q5b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020. <p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9SMivzwYRxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred Offering Costs Deferred offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO and that will be charged to stockholders’ equity upon the completion of the IPO. <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbRMkdi5ALUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. <p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zv31CPRwRz0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Loss Per Common Stock Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201112__20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQMq8LES6Hj7" title="Shares forfeited during the period">375,000 shares of common stock that are subject to forfeiture if the over-allotment option is not exercised by the underwriters (see Note 5 and Note 8). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionExercised_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDEsRAe1jdc3" title="Shares exercised during the period">375,000 Founder Shares are no longer subject to forfeiture (see Note 8). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted loss per common share is the same as basic loss per common share for the period presented. <p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zxd8Jq6sCHP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimus as of December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimus for the period from November 12, 2020 (inception) through December 31, 2020. <p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z96Qgo8CWFeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zG1WEziPIXH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

<p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztCUl98uKFg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).

<p id="xdx_846_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zyYy51t99pLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

<p id="xdx_842_eus-gaap--UseOfEstimates_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBe3LUkpF0Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zFxAQ7m3q5b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020.

<p id="xdx_848_eus-gaap--DeferredChargesPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9SMivzwYRxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred Offering Costs Deferred offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO and that will be charged to stockholders’ equity upon the completion of the IPO.

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbRMkdi5ALUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zv31CPRwRz0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Loss Per Common Stock Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201112__20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQMq8LES6Hj7" title="Shares forfeited during the period">375,000 shares of common stock that are subject to forfeiture if the over-allotment option is not exercised by the underwriters (see Note 5 and Note 8). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionExercised_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zDEsRAe1jdc3" title="Shares exercised during the period">375,000 Founder Shares are no longer subject to forfeiture (see Note 8). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted loss per common share is the same as basic loss per common share for the period presented.

375000

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zxd8Jq6sCHP3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimus as of December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimus for the period from November 12, 2020 (inception) through December 31, 2020.

<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z96Qgo8CWFeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

250000

<p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zG1WEziPIXH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

<p id="xdx_804_ecustom--InitialPublicOfferingTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znP2GkScZlA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 3 — Initial Public Offering On January 14, 2021, the Company sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zktIKkjcRB1j" title="Units issued during the period, shares">11,500,000 at a purchase price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBqljQYNI7Ih" title="Unit issued price">10.00 per Unit, which includes the full exercise by the underwriters of the over-allotment option to purchase an additional <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5fBLAP9Uspc" title="Units issued during the period, shares">1,500,000 Units (see Note 8). Each Unit consists of one share of common stock, and one-half warrant to purchase one share of common stock (“Public Warrant”). Each Public Warrant entitles the holder thereof to purchase one share of common stock at a price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zASK7Mz4n8Qa" title="Unit issued price">11.50 per share, subject to adjustment. Each warrant will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of this offering and will expire five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation. (see Note 7).

11500000

10.00

1500000

11.50

<p id="xdx_809_ecustom--PrivatePlacementTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zqpAQxsusPD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 4 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201112__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3Y64l2ydgk2" title="Sale of units">417,200 Placement Units, at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zYVK054kZIGk" title="Unit issued price">10.00 per Placement Unit, for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20201112__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zc9ZOqPGfvcl" title="Proceeds from sale of units">4,172,000, in a private placement. A portion of the proceeds from the private placement was added to the proceeds from the IPO held in the Trust Account (see Note 8). Each Placement Unit was identical to the Units sold in the IPO, except for the placement warrants (“Placement Warrants”) (see Note 7). If the Company does not complete its initial business combination within 15 months (or up to 21 months) from the closing of this IPO, the proceeds from the sale of the Placement Units held in the trust account will be used to fund the redemption of its public shares (subject to the requirements of applicable law) and the Placement Warrants will expire worthless.

417200

10.00

4172000

<p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zXuFAayisVhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 5 — Related Party Transactions Founder Shares On November 12, 2020, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201110__20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCESNXWmSGB2" title="Units issued during the period, shares">2,156,250 shares of common stock to the Sponsor for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201110__20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQcWzRgXQHC5" title="Stock issued during the period">25,000 in cash, or approximately $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20201113__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znyOK9hMbYi2" title="Shares issued price per share">0.012 per share, in connection with formation. On December 7, 2020, the Sponsor forfeited <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zGtmeKbFR7K5" title="Shares forfeited during the period">161,719 founder shares to the Company and Ladenburg Thalmann & Co. Inc., the representative of the underwriters, and certain of its employees (“Ladenburg”) purchased from the Company an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVJRKI8w4MZa" title="Units issued during the period, shares">161,719 representative shares at an average purchase price of approximately $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zUxFJxZ9XYnf" title="Shares issued price per share">0.012 per share, for an aggregate purchase price of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201206__20201207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zeFj82An2Ggk" title="Stock issued during the period">1,875. On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zL1jYypjFov6" title="Common stock, shares outstanding">2,875,000 founder shares outstanding (including up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zphSnwujxyQ8" title="Shares forfeited during the period">375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part). As a result of the underwriters’ election to fully exercise of their over-allotment option on January 14, 2021, the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z7oIS1lNHw2b" title="Shares exercised during the period">375,000 shares were no longer subject to forfeiture (see Note 7). On January 4, 2021, the Sponsor forfeited <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zHCVxkNK0w3g" title="Shares forfeited during the period">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zfuK2MlkCcO4" title="Units issued during the period, shares">28,750 representative shares at an average purchase price of approximately $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zPyzaKSQYVR7" title="Shares issued price per share">0.008 per share, for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z7Sz5mH02nCd" title="Stock issued during the period">230. As a result, the Sponsor currently own <span id="xdx_90F_ecustom--SharesOwned_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z75avv1v7aj6" title="Shares owned">2,630,625 shares (see Note 7). All shares of common stock and associated amounts have been retroactively restated as disclosed in Note 7. <span id="xdx_900_ecustom--AgreementDescription_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5cDcXncT0c3" title="Agreement description">The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Representative Shares On December 7, 2020, the Sponsor forfeited <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztSfqNJk6aC3">161,719 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z37Ievj3q956">161,719 representative shares at an average purchase price of approximately $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zbyiCVfRbzO5">0.012 per share, for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20211206__20211207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z3ZmE96Nlhji">1,875. On January 4, 2021, the Sponsor forfeited <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zTvSqJMyXM3k">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zlWaGynn05we">28,750 representative shares at an average purchase price of approximately $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znRmIPO3BxG">0.008 per share, for an aggregate purchase price of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z7iCv247UkZ9">230. Following the 1/3 common stock dividend effected January 3, 2020 (as described herein), Ladenburg and certain of its employees now hold an aggregate of <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zkR1IKTRSer2" title="Common stock, shares outstanding">244,375 representative shares (of which up to <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zsNpcEVhPXNc" title="Shares forfeited during the period">31,875 were subject to forfeiture). As a result of the underwriters’ election to fully exercise of their over-allotment option, the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210102__20210103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zb14M2NcUnRb" title="Shares exercised during the period">31,875 shares were no longer subject to forfeiture (see Note 8). All shares of common stock and associated amounts have been retroactively restated as disclosed in Note 8. Ladenburg and certain of its employees have entered into a subscription agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their representative shares, as applicable, and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their representative shares, as applicable, (iii) waive their rights to liquidating distributions from the trust account with respect to their representative shares if the Company fails to complete the initial business combination within the Combination Period. Promissory Note — Related Party On November 19, 2020, Company issued an unsecured promissory note to the Sponsor for an aggregate of up to $<span id="xdx_906_eus-gaap--UnsecuredDebt_iI_pp0p0_c20201119__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--RangeAxis__srt--MaximumMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zxbrASx93qMj" title="Unsecured promissory note">250,000 to cover expenses related to the IPO. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20201117__20201119__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zZ6XK7naewY1" title="Debt instrument maturity date">This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. As of December 31, 2020, the Company has drawn down $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20201112__20201231__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1Q39GNplyP3" title="Proceeds from issuance of promissory note to related party">150,000 under the promissory note. On January 14, 2021, the Company paid the balance on the note from the proceeds of the IPO (see Note 8). Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. The units would be identical to the Placement Units. At January 14, 2021, no Working Capital Loans were outstanding. Administrative Service Fee The Company has agreed to pay an affiliate of the Company’s Sponsor a monthly fee of an aggregate of $10,000 for office space, utilities and secretarial and administrative support. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. As of December 31, 2020, the Company has recorded $7,742 in service fee expense.

2156250

25000

0.012

161719

0.012

1875

2875000

375000

28750

0.008

230

161719

0.012

1875

28750

0.008

230

244375

31875

250000

This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO.

150000

10000

7742

<p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z0dPoLZRXurd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 6 — Commitments and Contingencies Underwriting Agreement The underwriter had a 45-day option from the date of the IPO to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9XFZyZZl3C1" title="Units issued during the period, shares">1,500,000 additional Units at the public offering price less the underwriting commissions to cover over-allotments, if any. On January 14, 2021, the underwriter fully exercised its over-allotment option (see Note 8). The underwriter was entitled to a cash underwriting fee of <span id="xdx_90F_ecustom--CashUnderwritingFeePercentage_pid_dp_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5hTkbat274a">1.33% of the gross proceeds of the IPO and, upon consummation of the IPO on January 14, 2021, was paid an aggregate of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuqZFWeRVTWf">1,529,500. The underwriters are entitled to deferred underwriting fee of <span id="xdx_90C_ecustom--DeferredUnderwritingFeePercentage_pid_dp_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmNaGtJ5g0H2">3.67% of the gross proceeds of the IPO, or $<span id="xdx_902_ecustom--ProceedsFromDeferredUnderwriting_pp0p0_c20210113__20210114__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_za3BEHRNL2Gd">4,220,500 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Registration Rights The holders of the founder shares, representative shares, placement units, and units that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

1500000

0.0133

1529500

0.0367 4220500

<p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z1qNg3NvVyda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 7 — Stockholders’ Equity Preferred Stock — The Company is authorized to issue a total of 1,000,000 preferred shares at par value of $0.0001 each. At December 31, 2021, there were no shares of preferred stock issued or outstanding. Common Stock — The Company is authorized to issue a total of 50,000,000 share of common stock at par value of $0.0001 each. At November 20, 2020, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201118__20201120__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuqsN0W5elHj" title="Units issued during the period, shares">2,156,250 common shares to its initial stockholders for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201118__20201120__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQIsl7IHZyp" title="Stock issued during the period">25,000, or approximately $0.012 per share. On December 7, 2020, the Sponsor forfeited <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201206__20201207__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z52PxwXwxRek" title="Shares forfeited during the period">161,719 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201206__20201207__srt--TitleOfIndividualAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z4mKI7SPYwKc" title="Units issued during the period, shares">161,719 representative shares at an average purchase price of approximately $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20201207__srt--TitleOfIndividualAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zdcpFJEdT4Tl" title="Shares issued price per share">0.012 per share, for an aggregate purchase price of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20201206__20201207__srt--TitleOfIndividualAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zxT2QTV72Dk7" title="Stock issued during the period">1,875. On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zCPrFiBL0QE" title="Common stock, shares outstanding">2,875,000 founder shares outstanding (including up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210103__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmwBG0UakmZc" title="Shares forfeited during the period">375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part). On January 4, 2021, the Sponsor forfeited <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z59g9FxWrnX3" title="Shares forfeited during the period">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQJEWcMxShDi" title="Units issued during the period, shares">28,750 representative shares at an average purchase price of approximately $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zVvglJRWUcdc" title="Shares issued price per share">0.008 per share, for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zetr9HKhexU1" title="Stock issued during the period">230. As a result, the Sponsor currently own <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvjLfF4Y8Gkf" title="Common stock, shares outstanding">2,630,625 shares and Ladenburg and certain of its employees currently own <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zYwIZNvHs7ug" title="Common stock, shares outstanding">244,375 representative shares (including up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z9FJ4goHHSWe" title="Shares forfeited during the period">343,125 and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zvgmE0PRUdpl" title="Shares forfeited during the period">31,875 shares, respectively, that were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part). As a result of the underwriters’ election to fully exercise of their over-allotment option on January 14, 2021, the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210102__20210104__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zmR1PjoqrG4a" title="Shares exercised during the period">375,000 shares were no longer subject to forfeiture (see Note 8). All shares of common stock and associated amounts have been retroactively restated. The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. Warrants — Each whole warrant entitles the holder to purchase one share of the Company’s common stock at a price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zncHNociUPi3" title="Shares issued price per share">11.50 per share, subject to adjustment as discussed herein. <span id="xdx_90B_ecustom--AgreementDescription_c20201112__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zrIp2OCF09H6" title="Agreement description">In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The warrants will become exercisable on the later of 12 months from the closing of this offering or 30 days after the completion of its initial business combination, and will expire five years after the completion of the Company’s initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of common stock underlying such unit. Once the warrants become exercisable, the Company may call the warrants for redemption: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">in whole and not in part;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">at a price of $0.01 per warrant;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders.</td></tr> </table> The Placement Warrants will be identical to the Public Warrants underlying the Units being sold in the IPO, except that the Placement Warrants and the common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants

1000000

0.0001

50000000

0.0001

2156250

25000

0.012

161719

0.012

1875

2875000

375000

28750

0.008

230

2630625

244375

343125

31875

375000

11.50

In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

0.01

<p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_hsrt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zWlbG7Payi18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note 8 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20210103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zA6qsDUehdg9" title="Common stock, shares outstanding">2,875,000 founder shares outstanding (including up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z0hjBT7lx003" title="Shares forfeited during the period">375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part). On January 4, 2021, the Sponsor forfeited <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__us-gaap--StatementEquityComponentsAxis__custom--FounderSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zShGuFDVYr6l" title="Shares forfeited during the period">28,750 founder shares to the Company and Ladenburg and certain of its employees purchased from the Company an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210102__20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_ztLV3x8gitd4" title="Units issued during the period, shares">28,750 representative shares at an average purchase price of approximately $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_znqaz3x4hPAb" title="Shares issued price per share">0.008 per share, for an aggregate purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210102__20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zqjC6Knhrx44" title="Stock issued during the period">230. As a result, the Sponsor currently own <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBfp5fyuS6W4" title="Common stock, shares outstanding">2,630,625 shares and Ladenburg and certain of its employees currently own <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeSharesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z2llEZIsXjkl" title="Common stock, shares outstanding">244,375 representative shares (including up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z5kvHODCfVre" title="Shares forfeited during the period">343,125 and <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210102__20210104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LadenburgAndCertainEmployeesMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zaL3y5ssXlIe" title="Shares forfeited during the period">31,875 shares, respectively, that were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part). As a result of the underwriters’ election to fully exercise of their over-allotment option on January 14, 2021, the <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zE9Hc3tQDDma" title="Shares exercised during the period">375,000 shares were no longer subject to forfeiture All shares of common stock and associated amounts have been retroactively restated. On January 14, 2021, the Company the Company consummated the IPO of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z0O7iuN8Fouk" title="Units issued during the period, shares">11,500,000 units (the “Units”), which included the full exercise by the underwriters of the over-allotment option to purchase an additional <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zEYg9KcdxGN7" title="Units issued during the period, shares">1,500,000 Units, at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z13cdd8kU2z7" title="Shares issued price per share">10.00 per Unit, generating gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zthp8rD68eG" title="Proceeds from IPO">115,000,000. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z8hIoO8hFzAc" title="Sale of units">417,200 units (the “Placement Units”), at a price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zWzTNm8SED5e" title="Shares issued price per share">10.00 per unit, for an aggregate purchase price of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--StatementScenarioAxis__custom--ClosingIPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zuBDCZMtup8a" title="Proceeds from sale of units">4,172,000, in a private placement. Transaction costs of the IPO amounted to $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pp0p0_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_z6PiDyA1aAc2" title="Transaction costs">6,038,360 consisting of $<span id="xdx_900_ecustom--UnderwritingFee_pp0p0_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zBk9IfIp8UT8" title="Underwriting fee">1,529,500 of underwriting fee, $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_pp0p0_c20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zF280Au21Oi3" title="Deferred underwriting fee">4,220,500 of deferred underwriting fee, and $<span id="xdx_900_eus-gaap--OtherDeferredCostsNet_iI_pp0p0_c20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zdrz6pY8XSVf" title="Other offering costs">288,360 of other offering costs. On January 14, 2021, the Company paid the $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20210113__20210114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--BigCypressAcquisitionCorpMember_zQjvZ25Wgype" title="Proceeds from issuance of promissory note to related party">150,000 balance on the promissory note from the proceeds of the IPO.

2875000

375000

28750

0.008

230

2630625

244375

343125

31875

375000

11500000

1500000

10.00

115000000

417200

10.00

4172000

6038360

1529500

4220500

288360

150000

10750762

12610383

10213217

20569497

943574

1275134

21907553

34455014

2590682

3053022

4064568

4184427

22568477

14845470

51131280

56537933

4122602

7382361

24143

538731

1035211

924265

180243

194717

16778

100000

5009099

1904878

10471298

11061730

1753527

2372777

3803432

3923554

25013

172037

16053270

17530098

0.0001

6615000 6615000

6615000

662

0.0001

2525800 2525800

2525800

4752040

253

0.0001

4039963 4039963

4039963

12119889

404

0.0001

3333333 3333333

3333333

9999999

333

0.0001

8571429 8571429

4090540

14316890

409

0.0001

110000000 110000000

35216000

3522

52649882

50986672

-17577455

-11984420

35078010

39007835

51131280

56537933

49817825

29482614

49817825

29482614

46535671

12601333

9331125

4907306

55866796

17508639

-6048971

11973975

669549

3630

228184

325789

14571

21283

-5593035

11673099

-0.16

0.22

-0.16

0.20

35216000

58496676

6615000

662

2525800

253

4039963

404

3333333

333

4090540

409

35216000

3522

50986672

-11984420

39007835

1663210

-5593035

6615000

662

2525800

253

4039963

404

3333333

333

4090540

409

35216000

3522

52649882

-17577455

35078010

3333333

9999999

6615000

662

2525800

253

4039963

404

1236786

124

35216000

3522

29791662

-32102193

-2305566

87949

2853754

285

9899920

9900205

1040776

-3333333

-9999999

3333333

333

9999666

9999999

11673099

6615000

662

2525800

253

4039963

404

3333333

333

4090540

409

35216000

3522

50732024

20429094

30308513

-5593035

11673099

661612

868630

223888

123777 123777

1663210

1040776

5488

2252

-10356280

8009864

-331559

-56414

45964 -171908

-2727

4914

-3273848

-193554

3104260 384272

6865042

5473378

8581735

7371717

-8581735

-7371717

9900205

661612

1373846

142928

129495

-142928

9058476

-1859621

7160137

12610383

6345969

10750762

13506106

228184

329369

260682

993622

(1) Nature of Business and Basis of Presentation Nature of Business SAB Biotherapeutics, Inc. (“SAB” or the “Corporation”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb™ platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB’s platform is the first to produce fully human antibodies in large animals. The COVID-19 pandemic continues to evolve, and the extent to which it may impact the Corporation’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States (“U.S.”) and other countries, business closures or business disruptions, and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The Corporation is following, and will continue to follow, recommendations from the U.S. Centers for Disease Control and Prevention, as well as federal, state, and local governments. To date, the Corporation has not experienced material business disruptions, but it cannot be certain of the future impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. Basis of Presentation The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The condensed consolidated balance sheet data as of December 31, 2020 was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the Corporation’s financial position as of September 30, 2021, and its results of operations, statement of changes in redeemable preferred stock and stockholders’ equity and cash flows for the nine months ended September 30, 2021 and 2020. The condensed consolidated financial statements for the nine months ended September 30, 2021 should be read in conjunction with the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021. The results of operations for any interim period are not necessarily indicative of results for the full year.

(2) Summary of Significant Accounting Policies The Corporation’s significant accounting policies are disclosed in the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021. Since the date of such audited consolidated financial statements, there have been no changes to the Corporation’s significant accounting policies, except as disclosed in Note 3, New Accounting Standards, below.

(3) New accounting standards Recently-adopted standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. The guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption was permitted. The Corporation adopted the guidance as of January 1, 2021. The adoption did not have a material impact on the Corporation’s condensed consolidated financial statements. Standards issued not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models required under current GAAP. The guidance removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for such exception and simplifies the diluted earnings per share calculation in certain areas. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted in annual reporting periods ending after December 15, 2020. The Corporation is currently evaluating its adoption of the guidance and the impact that the guidance may have on its consolidated financial statements. The Corporation believes that the adoption of the guidance will not have a material impact on its consolidated financial statements. (4) Merger On June 21, 2021, the Corporation entered into an Agreement and Plan of Merger, as amended August 12, 2021 (as it may be amended or restated from time to time, the “Business Combination Agreement”) with Big Cypress Acquisition Corp. (“BCYP”) and Big Cypress Merger Sub Inc. (“Merger Sub”), a wholly-owned subsidiary of BCYP providing for, among other things, and subject to the terms and conditions therein, a business combination between the Corporation and BCYP pursuant to the proposed merger of Merger Sub with and into the Corporation, with the Corporation continuing as the surviving entity (the “Merger”). The Merger and the other transactions contemplated by the Business Combination Agreement are referred to as the “Business Combination.” At the effective time of the Merger, and in accordance with the terms and subject to the conditions of the Business Combination Agreement: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each outstanding share of the Corporation’s Common Stock and the Corporation’s Preferred Stock will be automatically cancelled, extinguished and converted into a number of shares of New SAB Biotherapeutics Common Stock, based on the Corporation’s Equity Value and a conversion rate of $10.10;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The holders of shares of the Corporation’s Common Stock and Preferred Stock will be entitled to receive their pro rata share of New SAB Biotherapeutics Common Stock being issued into escrow (the “Earnout Escrow Account”) at the closing (the “Earnout Shares”), which will be released if certain conditions are met within a five-year period following the closing of the Business Combination (the “Earnout Period”), pursuant to the terms and subject to the conditions set forth in the Business Combination Agreement and the Earnout Escrow Agreement; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each outstanding vested and unvested option to purchase shares of the Corporation’s Common Stock will be canceled in exchange for a comparable option to purchase shares of New SAB Biotherapeutics Common Stock based on the equity value of SAB Biotherapeutics and based on a conversion rate of $10.10. In addition, the holders of such options shall also receive restricted stock units (the “Earnout RSUs”) which final number will be determined prior to closing based on the pro rata percentage that the Corporation’s options represent compared to the fully diluted share capital of SAB Biotherapeutics prior to closing. Each Earnout RSU will be settled in shares of New SAB Biotherapeutics Common Stock, subject to the same milestones applicable to the Earnout Shares.</td></tr> </table> The total maximum number of Earnout Shares and shares underlying the Earnout RSUs will be equal to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210620__20210621__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2GhqyF48KFg" title="Aggregate of restricted stock units, shares">12,000,000 additional shares of New SAB Biotherapeutics Common Stock in the aggregate. For purposes herein and the Business Combination Agreement, the Corporation’s equity value is deemed to be an agreed upon amount equal to $300 million. Please refer to Note 15, Subsequent Events, for additional information on the Merger.

10.10

12000000

300000000

(5) Revenue The Corporation received approximately <span id="xdx_903_ecustom--RevenuePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zawdJ5CM8Cx5" title="Revenue percentage">100% and 92% of its total revenue through grants from government organizations for the nine months ended September 30, 2021 and 2020, respectively, and approximately <span id="xdx_908_ecustom--RevenuePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_z8yFm9Is2puf">0% and <span id="xdx_90B_ecustom--RevenuePercentage_pid_dp_uPure_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_z1YZvoed4Ypf">8% of its total revenue through a grant from a non-government organization for the nine months ended September 30, 2021 and 2020, respectively. To date, no receivables have been written off. For the nine months ended September 30, 2021 and 2020, the Corporation worked on the following grants: Government grants The total revenue for government grants was approximately $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn5n6_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zGJySEhbSjti" title="Revenue">49.8 million and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn5n6_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zI6LMRDTktEa">27.1 million, respectively, for the nine months ended September 30, 2021 and 2020, respectively. National Institute of Health – National Institute of Allergy and Infectious Disease (“NIH-NIAID”) (Federal Award #1R44AI117976-01A1) – this grant was for $1.4 million and started in September 2019 through August 2021. For the nine months ended September 30, 2021 and 2020, there was approximately $<span id="xdx_901_eus-gaap--NonoperatingIncomeExpense_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zrHEtzRxGPg9" title="Grant income">457,000 and $<span id="xdx_902_eus-gaap--NonoperatingIncomeExpense_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zWuw469nyEH1">219,000, respectively, in grant income recognized from this grant. The Corporation applied for an extension on the grant funding, which is pending approval. If approved, there is approximately $<span id="xdx_90A_ecustom--RemainingGrantFunding_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zpvN7WwL1Imd" title="Remaining grant">243,000 in funding remaining for this grant. NIH-NIAID (Federal Award #1R41AI131823-02) – this grant was for approximately $1.5 million and started in April 2019 through March 2021. The grant was subsequently amended to extend the date through March 2022. For the nine months ended September 30, 2021 and 2020, approximately $41,000 and $86,000, respectively, in grant income was recognized from this grant. Approximately $853,000 in funding remains for this grant. NIH-NIAID through Geneva Foundation (Federal Award #1R01AI132313-01, Subaward #S-10511-01) – this grant was for approximately $<span id="xdx_90F_eus-gaap--CostOfRevenue_pn5n6_c20170801__20210731__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zXciTHO5sGNf">2.7 million and started in August 2017 through July 2021. For the nine months ended September 30, 2021 and 2020, there was approximately $<span id="xdx_904_eus-gaap--NonoperatingIncomeExpense_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_z0GQhNNIWcS3">72,000 and $<span id="xdx_906_eus-gaap--NonoperatingIncomeExpense_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zr3dEDnrOiB1">248,000, respectively, in grant income recognized from this grant. The Corporation applied for an extension on the grant funding, which is pending approval. If approved, there is approximately $<span id="xdx_90B_ecustom--RemainingGrantFunding_pn5n6_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zeC7A1Xryobf">1.5 million in funding remains for this grant. Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies (“JPEO”) through Advanced Technology International – this grant was for a potential of $<span id="xdx_904_eus-gaap--CostOfRevenue_pn6n6_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zcgLQA340NK">25 million, awarded in stages starting in August 2019 and with potential stages running through February 2023. Additional contract modifications were added to this contract in 2020 for work on a COVID therapeutic, bringing the contract total to $143 million. In September 2021, an additional modification for $<span id="xdx_902_eus-gaap--BusinessDevelopment_pn5n6_c20210901__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zDdYw0N9scOg" title="Additional development">60.5 million was added to this contract for advanced clinical development through licensure and commercial manufacturing, bringing the contract total to $<span id="xdx_90F_ecustom--Contract_pn6n6_c20210901__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zdws4ft0xD7" title="Contract">204 million. For the nine months ended September 30, 2021 and 2020, approximately $<span id="xdx_909_eus-gaap--NonoperatingIncomeExpense_pn5n6_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zLkxdJCW6izd">49.2 million and $<span id="xdx_902_eus-gaap--NonoperatingIncomeExpense_pn5n6_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zznniAsyhSS4">26.5 million, respectively, in grant income was recognized from this grant. Approximately $<span id="xdx_905_ecustom--RemainingGrantFunding_pn5n6_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_z6mnrtpk6kPc">100.1 million in funding remains for this grant. Other grants (non-government) The Corporation recorded <span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_do_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zFabST7riQv2">no revenue for other grants (non-government) for the nine months ended September 30, 2021. The total revenue for other grants (non-government) was $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn5n6_c20200101__20200930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zNCcORLrK58e">2.4 million for the nine months ended September 30, 2020. CSL Behring – <span id="xdx_90E_eus-gaap--DepositContractsDescriptionOfLiabilityContracts_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_ztzxpHeDK9ke" title="Contracts description">there were three contracts for a combined $2.4 million that were started and completed in 2020. <span id="xdx_902_edei--DocumentDescription_c20210101__20210930__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zFSFvh2GpR09" title="Description">These contracts were related to research and development for a COVID-19 therapeutic ($2 million) and two other targets ($400,000). For the nine months ended September 30, 2020, there was approximately $2.4 million in grant income recognized from this grant.

1 0.92 0 0.08

49800000

27100000

1400000

457000

219000

243000

1500000

41000

86000

853000

2700000

72000

248000

1500000

25000000

143000000

60500000

204000000

49200000

26500000

100100000

2400000

there were three contracts for a combined $2.4 million that were started and completed in 2020.

These contracts were related to research and development for a COVID-19 therapeutic ($2 million) and two other targets ($400,000)

2400000

(6) Earnings (loss) per share Since the Corporation reported a net loss for the nine months ended September 30, 2021, it was required by ASC 260 to use basic weighted-average common shares outstanding when calculating diluted net loss per share for the nine months ended September 30, 2021, as the potential common shares are antidilutive. In addition, since the Corporation reported a loss from operations for the nine months ended September 30, 2021, the shares of preferred stock were not deemed to be participating securities for the nine months ended September 30, 2021, pursuant to ASC 260. The Corporation’s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Corporation. Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20210101__20210930_zcHYN2qCT1yd" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_di_zRjh5XgEIvIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Net loss attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5,593,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zN2ogGTl8EO8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average common shares outstanding - basic and diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,216,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDiluted_ztmqCfW4yF0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss per common share - basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="text-align: left">)</td></tr> </table> Options to purchase 10,062,381 shares of common stock and 20,604,636 shares of preferred stock were outstanding for the nine months ended September 30, 2021 but were not included in the computation of diluted net loss per share because their impact was antidilutive. The following table sets forth the allocation of net income attributable to the Corporation’s shareholders for the nine months ended September 30, 2020 under the two-class method: Schedule of Earnings per Share Allocation of Net Income <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20200101__20200930_z7HKeDbR6Ga4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_z2iXLXIW8OEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,673,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToPreferredStock_zXAlxuPW0Ckc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net income attributable to the Corporation’s shareholders applicable to preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,080,661</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToCommonStock_zUJTHOhqQI2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,592,438</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table reconciles the weighted-average common shares outstanding used in the calculation of basic earnings per share (“EPS”) to the weighted-average common shares outstanding used in the calculation of diluted EPS for the nine months ended September 30, 2020: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td>Determination of shares:</td><td> </td> <td colspan="2" id="xdx_498_20200101__20200930_zi3fzP8Oo8H5" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z54MQb95Xmve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Weighted-average common shares outstanding – basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">35,216,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_zaXr5dyndhT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Assumed conversion of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,927,326</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributabletoDilutiveEffectofEquityAwards_zkSHa7kXnRf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of equity awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,353,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zkTb0IyjGhf7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">58,496,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents the calculation of basic and diluted EPS for the Corporation’s common stock for the nine months ended September 30, 2020: Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Calculation of basic EPS attributable to the Corporation’s shareholders</td><td> </td> <td colspan="2" id="xdx_496_20200101__20200930_zB0JhvnmCvI7" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToCommonStock_zt2TLsdTsJs5" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,592,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zqmMYKLPh6Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average common shares outstanding – basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,216,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_zdX9Am7Nmzfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic EPS</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Calculation of diluted EPS attributable to the Corporation’s shareholders</td><td> </td> <td colspan="2" id="xdx_490_20200101__20200930_znzUEWcn0Y6i" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zeVwQIpHWP4g" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,673,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zKagCMTOj75a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average common shares outstanding – diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,496,676</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_zvCCzOK7Z0x3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted EPS</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> </table>

Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20210101__20210930_zcHYN2qCT1yd" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_di_zRjh5XgEIvIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Net loss attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5,593,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zN2ogGTl8EO8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average common shares outstanding - basic and diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,216,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDiluted_ztmqCfW4yF0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loss per common share - basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="text-align: left">)</td></tr> </table>

-5593035

35216000

-0.16

10062381

20604636

The following table sets forth the allocation of net income attributable to the Corporation’s shareholders for the nine months ended September 30, 2020 under the two-class method: Schedule of Earnings per Share Allocation of Net Income <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20200101__20200930_z7HKeDbR6Ga4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_z2iXLXIW8OEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,673,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToPreferredStock_zXAlxuPW0Ckc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net income attributable to the Corporation’s shareholders applicable to preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,080,661</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToCommonStock_zUJTHOhqQI2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,592,438</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

11673099

4080661 7592438

The following table reconciles the weighted-average common shares outstanding used in the calculation of basic earnings per share (“EPS”) to the weighted-average common shares outstanding used in the calculation of diluted EPS for the nine months ended September 30, 2020: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td>Determination of shares:</td><td> </td> <td colspan="2" id="xdx_498_20200101__20200930_zi3fzP8Oo8H5" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z54MQb95Xmve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Weighted-average common shares outstanding – basic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">35,216,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_zaXr5dyndhT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Assumed conversion of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,927,326</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributabletoDilutiveEffectofEquityAwards_zkSHa7kXnRf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of equity awards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,353,350</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zkTb0IyjGhf7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average common shares outstanding – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">58,496,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

35216000

18927326

4353350

58496676

The following table presents the calculation of basic and diluted EPS for the Corporation’s common stock for the nine months ended September 30, 2020: Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Calculation of basic EPS attributable to the Corporation’s shareholders</td><td> </td> <td colspan="2" id="xdx_496_20200101__20200930_zB0JhvnmCvI7" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--NetIncomeAttributableToCorporationsShareholdersApplicableToCommonStock_zt2TLsdTsJs5" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,592,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zqmMYKLPh6Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average common shares outstanding – basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,216,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_zdX9Am7Nmzfb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic EPS</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Calculation of diluted EPS attributable to the Corporation’s shareholders</td><td> </td> <td colspan="2" id="xdx_490_20200101__20200930_znzUEWcn0Y6i" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zeVwQIpHWP4g" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,673,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zKagCMTOj75a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average common shares outstanding – diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,496,676</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_zvCCzOK7Z0x3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted EPS</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td></tr> </table> 7592438

35216000

0.22

11673099

58496676

0.20

(7) Equipment As of September 30, 2021 and December 31, 2020, equipment was as follows: Schedule of Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210930_zySCvo4YXvCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20201231_zITiNFaPt7Si" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zCqWnxYnTYpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,997,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,205,346</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zDpFDW1xxvm4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Animal facility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,267,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,371,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zRPkvVIBu8F1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Animal facility equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,197,366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,003,629</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zq9DyAsHDYb9" style="vertical-align: bottom; background-color: White"> <td>Construction-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,922,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,729,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTSgOBlJfNl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,605,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,971</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zfDt17BO6JJ6" style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,693</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcHVKnJ8Jhzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzE3M_zivwLOjYfiMa" style="vertical-align: bottom; background-color: White"> <td>Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,172,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,612,656</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzE3M_z1AdU1ujzS0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,767,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENzE3M_zrk9KU0pPiy2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Property, plant and equipment net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,568,477</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,845,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation and amortization expense for the nine months ended September 30, 2021 and 2020 was $868,630 and $223,888, respectively. <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zM5UOC3v34k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has several ongoing construction projects related to the expansion of its operating capacity. As of September 30, 2021 and December 31, 2020, the Corporation’s construction-in-progress was as follows: Schedule of Construction-in-Progress <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210930_zt7WzuJVJWx1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20201231_zgFJRgZJrB87" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zEIIwml9ZvM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">200L commercial facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,148,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zaWxKgQAisK7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">200L commercial facility, equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,658,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--FirstNewAnimalBarnMember_zVQUpvnE01Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New animal barn (#6)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,551,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoNewAnimalBarnMember_zfrS6yIUk4Wa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New animal barn (#7)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,093,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_zP8cF1dmzBbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New office space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">477,907</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewLaboratorySpaceMember_zBuHDkhTG6f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New laboratory space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewLaboratorySpaceEquipmentMember_zCqjbcBRCJd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New laboratory space, equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--SoftwareMember_zzBATZFdntP2" style="vertical-align: bottom; background-color: White"> <td>Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zSUiZyOmGXUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_z9fFCUTx9O49" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total construction-in-progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,922,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,729,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Construction on the 200L commercial facility was completed in September 2021. As of September 30, 2021, validation of the 200L commercial facility equipment was still in progress and expected delivery and installation of the equipment is expected to be complete by December 31, 2021. Construction of the first new animal barn (#6) was completed in July 2021, and the second new animal barn (#7) is expected to be complete by December 31, 2021. Construction of the new office space (at Headquarters) was completed in August 2021. The new laboratory space (at Headquarters) is expected to be complete by December 31, 2021. Expected delivery, installation, and validation of equipment for the new laboratory space (at Headquarters) is expected to be complete in the first quarter of 2022. The installation and programming of the new ERP software (SAP) is expected to be complete in the third quarter of 2022.

As of September 30, 2021 and December 31, 2020, equipment was as follows: Schedule of Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210930_zySCvo4YXvCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20201231_zITiNFaPt7Si" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zCqWnxYnTYpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,997,964</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,205,346</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zDpFDW1xxvm4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Animal facility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,267,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,371,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zRPkvVIBu8F1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Animal facility equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,197,366</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,003,629</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zq9DyAsHDYb9" style="vertical-align: bottom; background-color: White"> <td>Construction-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,922,079</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,729,673</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTSgOBlJfNl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,605,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,971</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zfDt17BO6JJ6" style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,593</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,693</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcHVKnJ8Jhzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzE3M_zivwLOjYfiMa" style="vertical-align: bottom; background-color: White"> <td>Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,172,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,612,656</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzE3M_z1AdU1ujzS0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,767,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENzE3M_zrk9KU0pPiy2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Property, plant and equipment net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,568,477</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,845,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6997964

5205346

6267498

3371125

1197366

1003629

4922079

6729673

5605847

185971

135593

96693

46202

20219

25172549

16612656

2604072

1767186

22568477

14845470

868630

223888

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zM5UOC3v34k8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has several ongoing construction projects related to the expansion of its operating capacity. As of September 30, 2021 and December 31, 2020, the Corporation’s construction-in-progress was as follows: Schedule of Construction-in-Progress <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210930_zt7WzuJVJWx1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20201231_zgFJRgZJrB87" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zEIIwml9ZvM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">200L commercial facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,148,113</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zaWxKgQAisK7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">200L commercial facility, equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,658,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">486,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--FirstNewAnimalBarnMember_zVQUpvnE01Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New animal barn (#6)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,551,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoNewAnimalBarnMember_zfrS6yIUk4Wa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New animal barn (#7)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,093,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_zP8cF1dmzBbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New office space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">477,907</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewLaboratorySpaceMember_zBuHDkhTG6f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New laboratory space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">922,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewLaboratorySpaceEquipmentMember_zCqjbcBRCJd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New laboratory space, equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--SoftwareMember_zzBATZFdntP2" style="vertical-align: bottom; background-color: White"> <td>Software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConstructionInProgressGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zSUiZyOmGXUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,291</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConstructionInProgressGross_iI_z9fFCUTx9O49" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total construction-in-progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,922,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,729,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4148113

1658189

486381

1551167

2093263

477907

922077

60448

137811

50291

66105

4922079

6729673

(8) Leases The Corporation’s leases are disclosed in the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021. The Corporation’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of September 30, 2021 were as follows: Schedule of Operating and Finance Leases Discount Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Finance</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.66 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16.98 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Weighted-average discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">4.74</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">7.70</td><td style="width: 1%; text-align: left">%</td></tr> </table> The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2021: Schedule of Undiscounted Future Minimum Lease Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">2021 (remaining three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20210930_zYtoEkJqoLaa" style="width: 14%; text-align: right" title="Operating Leases, 2021 (remaining three months)">285,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20210930_zPj6rUrB7PJc" style="width: 14%; text-align: right" title="Finance Leases, 2021 (remaining three months)">128,861</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210930_zmn9Pjgtuezb" style="text-align: right" title="Operating Leases, 2022">1,138,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210930_z6530jSSDBGa" style="text-align: right" title="Finance Leases, 2022">449,159</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210930_zIcPmf6II60e" style="text-align: right" title="Operating Leases, 2023">1,067,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20210930_z9QPdBs4lPTh" style="text-align: right" title="Finance Leases, 2023">406,339</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20210930_zKIGj8iA5vw1" style="text-align: right" title="Operating Leases, 2024">467,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20210930_zJuqqTTSuKOf" style="text-align: right" title="Finance Leases, 2024">401,496</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20210930_zZWhsUlroBC4" style="text-align: right" title="Operating Leases, 2025">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20210930_zIEms6SnGkb4" style="text-align: right" title="Finance Leases, 2025">401,496</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20210930_zPvY8yGFcKNa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Thereafter">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20210930_zhqjnfGpI4k4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Thereafter">5,185,990</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210930_zlG5hdAxS4aj" style="text-align: right" title="Operating Leases, Undiscounted future minimum lease payments">2,959,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210930_zfb1DjiOeFbg" style="text-align: right" title="Finance Leases, Undiscounted future minimum lease payments">6,973,341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Amount representing interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20210930_zVkNnb3dQRI3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Operating Leases, Amount representing interest Payments">(170,673</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20210930_zsPdEyM5tTV7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Finance Leases, Amount representing interest Payments">(2,989,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20210930_zfkNqczlu2N3" style="text-align: right" title="Operating Leases, Total lease liabilities">2,788,738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iI_c20210930_z1rFAxK8Hjck" style="text-align: right" title="Finance Leases,Total lease liabilities">3,983,675</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20210930_ztaie4WQ37X1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less current portion">(1,035,211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_c20210930_zo059pfSejJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less current portion">(180,243</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20210930_zNF8Xdv23cl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Noncurrent lease liabilities">1,753,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20210930_z15oEuVNqoO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Noncurrent lease liabilities">3,803,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Operating lease expense was approximately $789,000 and $491,000, respectively, for the nine months ended September 30, 2021 and 2020. Operating lease costs are included within research and development expenses on the condensed consolidated statements of operations. Finance lease costs for the nine months ended September 30, 2021 and 2020 included approximately $124,000, for each period, in right-of-use asset amortization and approximately $228,000 and $232,000, respectively, of interest expense. Finance lease costs are included within research and development expenses on the condensed consolidated statements of operations. Cash payments under operating and finance leases were approximately $836,000 and $372,000, respectively, for the nine months ended September 30, 2021. Cash payments under operating and finance leases were approximately $338,000 and $362,000, respectively, for the nine months ended September 30, 2020.

The Corporation’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of September 30, 2021 were as follows: Schedule of Operating and Finance Leases Discount Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Finance</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.66 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16.98 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Weighted-average discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">4.74</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">7.70</td><td style="width: 1%; text-align: left">%</td></tr> </table>

P2Y7M28D

P16Y11M23D

0.0474

0.0770

The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2021: Schedule of Undiscounted Future Minimum Lease Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">2021 (remaining three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20210930_zYtoEkJqoLaa" style="width: 14%; text-align: right" title="Operating Leases, 2021 (remaining three months)">285,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_c20210930_zPj6rUrB7PJc" style="width: 14%; text-align: right" title="Finance Leases, 2021 (remaining three months)">128,861</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210930_zmn9Pjgtuezb" style="text-align: right" title="Operating Leases, 2022">1,138,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20210930_z6530jSSDBGa" style="text-align: right" title="Finance Leases, 2022">449,159</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20210930_zIcPmf6II60e" style="text-align: right" title="Operating Leases, 2023">1,067,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20210930_z9QPdBs4lPTh" style="text-align: right" title="Finance Leases, 2023">406,339</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20210930_zKIGj8iA5vw1" style="text-align: right" title="Operating Leases, 2024">467,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20210930_zJuqqTTSuKOf" style="text-align: right" title="Finance Leases, 2024">401,496</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20210930_zZWhsUlroBC4" style="text-align: right" title="Operating Leases, 2025">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20210930_zIEms6SnGkb4" style="text-align: right" title="Finance Leases, 2025">401,496</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20210930_zPvY8yGFcKNa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Thereafter">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20210930_zhqjnfGpI4k4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Thereafter">5,185,990</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20210930_zlG5hdAxS4aj" style="text-align: right" title="Operating Leases, Undiscounted future minimum lease payments">2,959,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20210930_zfb1DjiOeFbg" style="text-align: right" title="Finance Leases, Undiscounted future minimum lease payments">6,973,341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Amount representing interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20210930_zVkNnb3dQRI3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Operating Leases, Amount representing interest Payments">(170,673</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20210930_zsPdEyM5tTV7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Finance Leases, Amount representing interest Payments">(2,989,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_c20210930_zfkNqczlu2N3" style="text-align: right" title="Operating Leases, Total lease liabilities">2,788,738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iI_c20210930_z1rFAxK8Hjck" style="text-align: right" title="Finance Leases,Total lease liabilities">3,983,675</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20210930_ztaie4WQ37X1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less current portion">(1,035,211</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_c20210930_zo059pfSejJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Less current portion">(180,243</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Noncurrent lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20210930_zNF8Xdv23cl6" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating Leases, Noncurrent lease liabilities">1,753,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20210930_z15oEuVNqoO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Finance Leases, Noncurrent lease liabilities">3,803,432</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

285481

128861

1138368

449159

1067594

406339

467968

401496

5185990

2959411

6973341

170673

2989666

2788738

3983675

1035211

180243

1753527

3803432

789000

491000

124000

228000

232000

836000

372000

338000

362000

(9) Accrued Expenses and Other Current Liabilities As of September 30, 2021 and December 31, 2020, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210930_zOnXfH0lyqUj" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zHKK3rMJfqXj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedVacationCurrent_iI_maAPAOAz1cH_zItDu4MAyHg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued vacation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">673,541</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">438,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1cH_zzOaLbqCUcvl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,451</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedConstructioninProgressCurrent_iI_maAPAOAz1cH_zyM33PAldrrc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued construction-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,926</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637,776</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedSuppliesCurrent_iI_maAPAOAz1cH_zxYs7VQbtI2i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,989</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedContractManufacturing_iI_maAPAOAz1cH_z19ZTQQMLoQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued contract manufacturing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,709,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpense_iI_maAPAOAz1cH_znO19DS6Ht9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued clinical trial expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">338,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedOutsideLabServices_iI_maAPAOAz1cH_z4bQbW1q0khl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued outside lab services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_maAPAOAz1cH_zM8XUiWV9bJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120,744</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedAnimalCareExpense_iI_maAPAOAz1cH_zISCoXMIuGr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued animal care expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAOAz1cH_zJpCs0UGcmQk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,797</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,982</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1cH_zNhJWf65Bd6d" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,009,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,904,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

As of September 30, 2021 and December 31, 2020, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210930_zOnXfH0lyqUj" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zHKK3rMJfqXj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedVacationCurrent_iI_maAPAOAz1cH_zItDu4MAyHg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued vacation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">673,541</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">438,936</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedPayrollTaxesCurrent_iI_maAPAOAz1cH_zzOaLbqCUcvl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,451</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedConstructioninProgressCurrent_iI_maAPAOAz1cH_zyM33PAldrrc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued construction-in-progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,926</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637,776</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedSuppliesCurrent_iI_maAPAOAz1cH_zxYs7VQbtI2i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,989</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedContractManufacturing_iI_maAPAOAz1cH_z19ZTQQMLoQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued contract manufacturing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,709,964</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpense_iI_maAPAOAz1cH_znO19DS6Ht9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued clinical trial expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">338,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedOutsideLabServices_iI_maAPAOAz1cH_z4bQbW1q0khl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued outside lab services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,764</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedProfessionalFeesCurrent_iI_maAPAOAz1cH_zM8XUiWV9bJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470,476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120,744</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedAnimalCareExpense_iI_maAPAOAz1cH_zISCoXMIuGr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued animal care expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maAPAOAz1cH_zJpCs0UGcmQk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,797</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,982</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_mtAPAOAz1cH_zNhJWf65Bd6d" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,009,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,904,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

673541

438936

208105

314451

87926 637776 1261696 301989 1709964 338802 85764

470476

120744

128028

44797

90982

5009099

1904878

(10) Debt As of September 30, 2021 and December 31, 2020, debt was as follows: Schedule of Debt <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210930_zPgfaA4sON91" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20201231_zj2MJII1eVGh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TractorLoanMember_z4C14PGGRJM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Tractor loan</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,156</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,156</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zYzxysxV9l2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PPP loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">661,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayable_iI_zwRIvlTQyn57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,156</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">710,768</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DebtCurrent_iI_z4mUfalSYLM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion of debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,143</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">538,731</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtNoncurrent_iI_ztWUveXGmiPb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,013</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172,037</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In March 2021, the U.S. Small Business Administration (“SBA”) approved the forgiveness of the Paycheck Protection Program (“PPP”) Loan, plus accrued interest. The Corporation recorded a gain on extinguishment of PPP Loan of $661,612 for the forgiveness of the PPP Loan within other income on the condensed consolidated statement of operations for the nine months ended September 30, 2021. Please refer to the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021 for additional information on the Corporation’s debt.

As of September 30, 2021 and December 31, 2020, debt was as follows: Schedule of Debt <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210930_zPgfaA4sON91" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20201231_zj2MJII1eVGh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TractorLoanMember_z4C14PGGRJM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Tractor loan</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,156</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,156</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zYzxysxV9l2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PPP loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">661,612</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayable_iI_zwRIvlTQyn57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,156</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">710,768</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DebtCurrent_iI_z4mUfalSYLM2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion of debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,143</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">538,731</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtNoncurrent_iI_ztWUveXGmiPb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,013</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172,037</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

49156

661612

49156

710768

24143

538731

25013

172037

661612

(11) Stock Option Plan On August 5, 2014, the Corporation approved a stock option grant plan (the “Plan”) for employees, directors, and non-employee consultants, which provides for the issuance of options to purchase common stock. The total shares authorized under the plan was originally 8,000,000; however, during 2019, the Plan was amended to increase the total shares authorized under the plan to 16,000,000. Vesting of the stock options is based upon years of service (employment). As of September 30, 2021 and December 31, 2020, 7,896,284 and 6,882,575 stock options, respectively, were vested and exercisable. None of the vested stock options were exercised as of September 30, 2021 and December 31, 2020. As of September 30, 2021, the aggregate intrinsic value of stock options outstanding was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zQJdsIjZ9Mph" title="Aggregate intrinsic value of stock options">41,291,069, of which $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_iI_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_ztQydmacOuM8" title="Unvested">7,209,646 was unvested and $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlanMember_zfy96QWaAvn2" title="Vested and exercisable">34,081,423 was vested and exercisable. The Corporation uses the Black Scholes model to estimate the fair value of the stock options granted. For stock options granted for the nine months ended September 30, 2021 and 2020, the Corporation utilized the following weighted-average assumptions: A risk free interest rate of 0.14% and 0.13%, respectively; expected term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930_zTK2VuIolLge" title="Risk free interest rate term">6.25 years (both years); expected dividend yield of 0% (both years); and a volatility factor of 99.7% and 106.1%, respectively. There were 651,527 in stock options forfeitures for the nine months ended September 30, 2021. There were no stock option expirations for the nine months ended September 30, 2021, and no stock option forfeitures or stock option expirations for the nine months ended September 30, 2020. The expected term of the stock options was estimated using the “simplified” method, as defined by the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Corporation does not have sufficient trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Corporation’s history and expectation of dividend payouts. The Corporation has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Therefore, the Corporation has assumed no dividend yield for purposes of estimating the fair value of the options. Stock option activity for employees and non-employees under the Plan for the nine months ended September 30, 2021 was as follows: Schedule of share option activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20201231_zpj7qz7YC9Rh" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">8,815,992</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20210930_zN7CJsIKzxid" style="width: 14%; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20201231_zzsnrEafINLh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.60</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_z2xBZ8pJDSs2" style="text-align: right" title="Number of Stock Options Outstanding, Granted">1,897,916</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210930_zOgaSDNfE2p4" style="text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z9bw9gbsQOM2" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930_z8aUWihLYuec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Forfeited">(651,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20210101__20210930_zcx3sbVAnFvd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Price Per Share, Forfeited">1.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z237nl8G12mf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited">1.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930_zNLxF1cVPzee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,062,381</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20210930_z2ECqsChwr48" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Ending of Period">0.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20210930_z49Z5f716qEc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">0.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210930_zxBxpHA9jPE2" style="text-align: right" title="Number of Non-vested Stock Options">2,166,097</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateUnvested_pid_c20210101__20210930_zLXuiShq1Nui" style="text-align: right" title="Weighted Average Fair value, Unvested">1.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageUnvested_pid_c20210101__20210930_zDJWYQmBtOp5" style="text-align: right" title="Weighted Average Exercise Price Per Share, Unvested">1.51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and exercisable at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20210930_z7qKrS3EI3Fc" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">7,896,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateVestedandExercisable_pid_c20210101__20210930_zjDldDJTZ4Ol" style="text-align: right" title="Weighted Average Fair value, Vested">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageVestedandExercisable_pid_c20210101__20210930_z3cNM4DGeGth" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">0.52</td><td style="text-align: left"> </td></tr> </table> Total unrecognized compensation cost related to non-vested stock options as of September 30, 2021 was approximately $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn5n6_c20210930_ze7Mo7tDTTp" title="Non-vested stock options">4.2 million and is expected to be recognized within future operating results over a weighted-average period of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zlzT9LsqFgYi" title="Future operating results over weighted average period">2.34 years. As of September 30, 2021, the weighted-average contractual term of the options outstanding was approximately <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zXYQ1gw5AXnl" title="Weighted-average contractual term options outstanding">5.68 years. As of September 30, 2021, the weighted-average contractual term of the vested options was approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zBeLwJ91gII6" title="Weighted-average contractual term vested options">4.74. For the nine months ended September 30, 2021 and 2020, 837,319 shares and 791,367 shares, respectively, vested. <p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zUyQVittqng1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation expense for the nine months ended September 30, 2021 and 2020 was as follows: Schedule of share based compensation expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znKoUc6dkUK2" style="width: 16%; text-align: right" title="Total share-based compensation expense">726,245</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUO3c9Du07c6" style="width: 16%; text-align: right" title="Total share-based compensation expense">491,092</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbv6QUIU6P55" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">936,965</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7MhLnZky4Pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">549,684</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930_zqlnHsyHZCu1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">1,663,210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930_zLvW4UiOBDM" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">1,040,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

8000000

16000000

7896284

6882575

41291069

7209646

34081423

0.0014

0.0013

P6Y3M

0.997

1.061

651527

Stock option activity for employees and non-employees under the Plan for the nine months ended September 30, 2021 was as follows: Schedule of share option activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20201231_zpj7qz7YC9Rh" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">8,815,992</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20210930_zN7CJsIKzxid" style="width: 14%; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20201231_zzsnrEafINLh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.60</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_z2xBZ8pJDSs2" style="text-align: right" title="Number of Stock Options Outstanding, Granted">1,897,916</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210930_zOgaSDNfE2p4" style="text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z9bw9gbsQOM2" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.78</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930_z8aUWihLYuec" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Forfeited">(651,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20210101__20210930_zcx3sbVAnFvd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Price Per Share, Forfeited">1.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z237nl8G12mf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Forfeited">1.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20210930_zNLxF1cVPzee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">10,062,381</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20210930_z2ECqsChwr48" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Ending of Period">0.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20210930_z49Z5f716qEc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">0.79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210930_zxBxpHA9jPE2" style="text-align: right" title="Number of Non-vested Stock Options">2,166,097</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateUnvested_pid_c20210101__20210930_zLXuiShq1Nui" style="text-align: right" title="Weighted Average Fair value, Unvested">1.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageUnvested_pid_c20210101__20210930_zDJWYQmBtOp5" style="text-align: right" title="Weighted Average Exercise Price Per Share, Unvested">1.51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Vested and exercisable at September 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20210930_z7qKrS3EI3Fc" style="text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">7,896,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateVestedandExercisable_pid_c20210101__20210930_zjDldDJTZ4Ol" style="text-align: right" title="Weighted Average Fair value, Vested">0.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageVestedandExercisable_pid_c20210101__20210930_z3cNM4DGeGth" style="text-align: right" title="Weighted Average Exercise Price Per Share, Vested">0.52</td><td style="text-align: left"> </td></tr> </table>

8815992

0.62

0.60

1897916

2.43

1.78

651527

1.09

1.04

10062381

0.93

0.79

2166097

1.94 1.51

7896284

0.54 0.52

4200000

P2Y4M2D

P5Y8M4D

P4Y8M26D

837319

791367

<p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zUyQVittqng1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation expense for the nine months ended September 30, 2021 and 2020 was as follows: Schedule of share based compensation expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znKoUc6dkUK2" style="width: 16%; text-align: right" title="Total share-based compensation expense">726,245</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zUO3c9Du07c6" style="width: 16%; text-align: right" title="Total share-based compensation expense">491,092</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbv6QUIU6P55" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">936,965</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7MhLnZky4Pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">549,684</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930_zqlnHsyHZCu1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">1,663,210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930_zLvW4UiOBDM" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total share-based compensation expense">1,040,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

726245

491092

936965

549684

1663210

1040776

(12) Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $0 for each of the nine months ended September 30, 2021 and 2020, and the effective tax rate for each of the nine months ended September 30, 2021 and 2020 was 0%. The Corporation continues to maintain a full valuation allowance on its net deferred tax assets. The Corporation has not recognized any reserves for uncertain tax positions. Please refer to the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021 for additional information on the Corporation’s income taxes.

(13) Related Party Transactions The Corporation’s related party transactions are disclosed in the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021. Since the date of such audited consolidated financial statements, there have been no significant changes to the Corporation’s related party transactions. For the nine months ended September 30, 2021 and 2020, the Corporation paid consulting fees to a board member, Christine Hamilton, who is also an owner, of $19,000 and $19,000, respectively. For the nine months ended September 30, 2020, the Corporation paid Network Plus, LLC (owner is the spouse of an employee) approximately $19,000 for IT assistance and computer setups. The spouse became an employee of the Corporation in July 2020, and there was no further activity with this vendor. For the nine months ended September 30, 2021 and 2020, the Corporation made lease payments to Dakota Ag Properties of approximately $301,000 (for each period). Dakota Ag Investments (part of Dakota Ag Properties) is a shareholder and owner of the Corporation. For the nine months ended September 30, 2021 and 2020, the Corporation made lease payments and lab supply payments to Sanford Health (which is a shareholder of the Corporation) totaling approximately $589,000 and $435,000, respectively. For the nine months ended September 30, 2020, the Corporation made payments of approximately $1.4 million to Christiansen Land and Cattle, Ltd. (“CLC”), who are owners, members of the board of directors, and employees of the Corporation, in accordance with the loan agreement the Corporation had entered into with CLC. In July 2020, the note payable was paid in full.

19000 19000

19000

301000

589000

435000

1400000

(14) Commitments and Contingencies The Corporation is not involved in any legal proceedings, investigations and claims which are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In April 2021, the Corporation entered into agreements that included other commitments of $4.5 million. A description of the joint development agreement that the Corporation entered into in June 2019 is disclosed in the audited consolidated financial statements as of, and for the years ended, December 31, 2020 and 2019, included in the proxy statement/prospectus filed with the SEC on September 24, 2021. As of September 30, 2021, as a result of the Corporation’s work around SARS-2 and the JPEO contract (please refer to Note 5, Revenue, for additional information), this project remains on hold.

4500000

(15) Subsequent Events In the preparation of the Corporation’s condensed consolidated financial statements, the Corporation completed an evaluation of the impact of subsequent events through December 3, 2021, which represents the date these condensed consolidated financial statements were available for issuance. On October 22, 2021 (the “Closing Date”), the Corporation consummated the Business Combination, pursuant to the terms of the agreement and plan of merger, dated as of June 21, 2021 and as amended on August 12, 2021 by the first amendment to the Business Combination Agreement with BCYP and Merger Sub. Pursuant to the Business Combination Agreement, on the Closing Date, (i) Merger Sub merged with and into the Corporation, with the Corporation as the surviving company in the Merger, and, after giving effect to such Merger, the Corporation was renamed SAB Sciences, Inc. and became a wholly-owned subsidiary of BCYP and (ii) BCYP changed its name to “SAB Biotherapeutics, Inc.” (“New SAB”). In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), (i) each share of the Corporation’s Common Stock and the Corporation’s Preferred Stock outstanding as of immediately prior to the Effective Time was exchanged for shares of common stock, par value $0.0001 per share, of New SAB based on the agreed upon Corporation’s equity value of $300 million (the “Equity Value”) and a conversion rate of $10.10; (ii) each outstanding vested and unvested option to purchase shares of the Corporation’s Common Stock was exchanged for a comparable option to purchase New SAB Common Stock, based on the Equity Value and a conversion rate of $10.10; and (iii) holders of vested options to purchase shares of the Corporation’s common stock received, in the aggregate, 1,507,124 restricted stock units (the “Earnout RSUs”) related to shares of New SAB Common Stock. Additionally, holders of the Corporation’s Common Stock and the Corporation’s Preferred Stock are entitled to receive their pro rata share of the shares of New SAB Common Stock that were issued into escrow at the Closing (the “Earnout Shares”) which will be released if certain conditions are met within the five-year period following the Closing (the “Earnout Period”). The total number of Earnout Shares and shares underlying the Earnout RSUs equaled 12,000,000 shares of New SAB Common Stock, in the aggregate. No fraction of a share of New SAB Common Stock was issued at the Closing, and each person who was otherwise entitled to a fraction of a share of New SAB Common Stock (after aggregating all fractional shares of New SAB Common Stock that otherwise would be received by such holder) received the number of shares of New SAB Common Stock rounded in the aggregate to the nearest whole share of New SAB Common Stock.

(i) each share of the Corporation’s Common Stock and the Corporation’s Preferred Stock outstanding as of immediately prior to the Effective Time was exchanged for shares of common stock, par value $0.0001 per share, of New SAB based on the agreed upon Corporation’s equity value of $300 million (the “Equity Value”) and a conversion rate of $10.10; (ii) each outstanding vested and unvested option to purchase shares of the Corporation’s Common Stock was exchanged for a comparable option to purchase New SAB Common Stock, based on the Equity Value and a conversion rate of $10.10; and (iii) holders of vested options to purchase shares of the Corporation’s common stock received, in the aggregate, 1,507,124 restricted stock units (the “Earnout RSUs”) related to shares of New SAB Common Stock

0.0001

300000000

10.10

1507124

12000000

12610383

6345969

20569497

2818735

1275134

124004

34455014

9288708

3053022

1861726

4184427

4349463

14845470

2503658

56537933

18003555

7382361

2170768

538731

28214

1364644

924265

371263

194717

182343

16778 6250

100000

1904878

494554

11061730

4618036

2372777

1519366

3923554

4118272

172037

53448

17530098

10309122

0.0001

3333333

9999999

0.0001

6615000 6615000

6615000

662

0.0001

2525800 2525800

2525800

4752040

253

0.0001

4039963 4039963

4039963

12119889

404

0.0001

3333333

9999999

333

0.0001

8571429 8571429

4090540

1236786

14316890

4328751

409

124

662

0.0001

110000000 110000000

35216000

3522

50986672

29791662

-11984420

-32102193

39007835

-2305566

56537933

18003555

55237759

3441807

55237759

3441807

27908659

8019705

6772303

4095642

34680962

12115347

20556797

-8673540

3996

2594

469151

428476

26131

113133

20117773

-8986289

0.37

-0.26

0.35

-0.26

35216000

58051614

35216000

3333333

9999999

6615000

662

2525800

253

4039963

404

35216000

3522

25115498

-23115904

2004435

23852

1236786

124

4304776

4304900

371388

-8986289

3333333

9999999

6615000

662

2525800

253

4039963

404

1236786

124

35216000

3522

29791662

-32102193

-2305566

87949

2853754

285

9899921

9900206

285

9899921

9900206

1295423

-3333333

-9999999

3333333

333

9999666

9999999

20117773

6615000

662

2525800

253

4039963

404

3333333

333

4090540

409

35216000

3522

50986672

-11984420

39007835

20117773

-8986289

383142

197210

165036 126197

1295423

371388

2252

-421

17750762

2562909

1151130

45512

-215122 10848

-100000

10528

-6353

5211593

1555046

3580

1410324 143628

10004795

-9214440

9000

12731702

608748

-12722702

-608748

9900206

4304900

661612

1364644

405112

32506 74876

182347

143284

8982321

3681628

6264414

-6141560

6345969

12487529

12610383

6345969

469151

428476

1773135

1979801

198512

(1) Nature of Business Nature of Business and Basis of Presentation SAB Biotherapeutics, Inc. (“SAB” or the “Corporation”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb™ platform enables the production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The COVID-19 pandemic continues to evolve, and the extent to which it may impact the Corporation’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The Corporation is following, and will continue to follow, recommendations from the United States Centers for Disease Control and Prevention, as well as federal, state, and local governments. To date, the Corporation has not experienced material business disruptions, but it cannot be certain of the future impact of the COVID-19 pandemic on its business and consolidated financial statements.

(2) Summary of Significant Accounting Policies A summary of the significant accounting policies applied in preparation of the accompanying consolidated financial statements is set forth below. Basis of presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Corporation’s financial position for the years presented. Principles of consolidation The accompanying consolidated financial statements include the results of the Corporation and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation. Significant risks and uncertainties The Corporation’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Corporation’s product candidates, the Corporation’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Corporation’s ability to raise capital. The Corporation currently has no commercially approved products and there can be no assurance that the Corporation’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Corporation operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements <div style="margin: 0pt auto; font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </div></div> Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as we move forward to with our efforts to develop a commercially approved product. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Corporation has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Corporation’s common stock, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Corporation’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates. Cash and cash equivalents Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less. Accounts receivable Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Corporation estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The allowance for doubtful accounts was $0 as of December 31, 2020 and 2019. Concentration of credit risk The Corporation maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. The Corporation received approximately 96% and 85% of its total revenue through grants from government organizations during the years ended December 31, 2020 and 2019, respectively, and <span id="xdx_904_ecustom--RevenuePercentage_pid_dp_uPure_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_zMw6QfMVi8Pk">4% and <span id="xdx_903_ecustom--RevenuePercentage_pid_dp_uPure_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_zR4LUEVNAKTj">12% of its total revenue through a grant from a non-government organization during the years ended December 31, 2020 and 2019, respectively. Lease liabilities and right-of-use assets The Corporation is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Corporation has, as of January 1, 2018 (the date of adoption), recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Corporation utilized the practical expedient regarding lease and non-lease components and has combined such items into a single combined component. The Corporation’s IBR was used in the calculation of its right of use assets and lease liabilities. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements Research and development expenses Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Corporation’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Corporation, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions. During 2020 and 2019, the Corporation had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB-185, the CRO has been contracted and paid by the US government. For SAB-176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately <span id="xdx_90C_ecustom--ResearchAndDevelopmentGoodsStandingPercentage_pid_dp_c20200101__20201231__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_z2jrSQpyQ5ga" title="Goods standing percentage">90% of the contract has been paid through June 17, 2021. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB-176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 35% of the contract has been paid through June 17, 2021. Equipment The Corporation records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Schedule of Estimated Useful Lives <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%">Animal facility equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 50%"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zP0TrwUqldje" title="Equipment useful life">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Laboratory equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Leasehold improvements</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentDepreciationMethods_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6QqxdqUYjt4" title="Equipment description">Shorter of asset life or lease term</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Office furniture & equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Vehicles</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> </table> Repairs and maintenance expenses are expensed as incurred. <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z6bxMkODO4G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Impairment of long-lived assets The Corporation reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Corporation compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Corporation believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the years ended December 31, 2020 and 2019. Stock-based compensation FASB ASC Topic 718, Compensation—Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Corporation recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Corporation determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. For awards with performance-based vesting criteria, the Corporation estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur. Income taxes Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Corporation’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements The Corporation uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Corporation has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes. Revenue recognition The Corporation’s revenue is primarily generated through grants from government and other (non-government) organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Corporation concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers, as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code. Comprehensive income (loss) The Corporation had no items of comprehensive income (loss) other than its net income (loss). Litigation From time to time, the Corporation is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Corporation accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred. Earnings per share In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options. In 2019, the Corporation issued shares of preferred stock, which it determined qualified as participating securities, as defined in ASC 260. Under ASC 260, securities are considered participating securities if the securities may participate in undistributed earnings with common stock, whether that participation is conditioned upon the occurrence of a specified event or not. In accordance with ASC 260, a company is required to use the two-class method when computing net income (loss) per share when a company has securities that qualify as participating securities. The two-class method is an earnings allocation formula that determines net income (loss) per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. Participating securities are included in the computation of basic net income (loss) per share using the two-class method. Under the two-class method, basic net income (loss) per share is computed by dividing net income (loss) attributable to the shareholders of the Corporation attributable to common stockholders by the weighted-average common shares outstanding during the period. Diluted net income (loss) per share for the Corporation’s common stock is computed using the more dilutive of the two-class method or the if-converted method. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements Segment reporting In accordance with ASC 280, Segment Reporting, the Corporation’s business activities are organized into one reportable segment, as only the Corporation’s operating results in their entirety are regularly reviewed by the Corporation’s chief operating decision maker to make decisions about resources to be allocated and to assess performance. Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques that would be used to measure fair value into one of three levels: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. As of December 31, 2020 and 2019, the Corporation does not have any assets and liabilities that are recorded at fair value on a recurring basis. The Corporation believes that the carrying amounts of its cash and cash equivalents, accounts receivable, and debt approximate their fair values due to their near-term maturities. Common stock valuations The Corporation is required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation expert when issuing stock options and computing its estimated stock-based compensation expense. The assumptions underlying these valuations represented management’s best estimates, which involved inherent uncertainties and the application of significant levels of management judgment. In order to determine the fair value of its common stock, the Corporation considered, among other items, previous transactions involving the sale of the Corporation’s securities, the Corporation’s business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of the Corporation’s common stock. Reclassification The prior period amount of $3.4 million related to grant revenue was reclassified from other income to grant revenue on the consolidated statements of operations, as the services performed under the grants were consistent with the Corporation’s ongoing major or central operations during the year ended December 31, 2020, and the reclassification conforms the prior period presentation to the current period presentation. The reclassification had no effect on the prior period net loss or total stockholder’s deficit. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

Basis of presentation The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Corporation’s financial position for the years presented.

Principles of consolidation The accompanying consolidated financial statements include the results of the Corporation and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation.

Significant risks and uncertainties The Corporation’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Corporation’s product candidates, the Corporation’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Corporation’s ability to raise capital. The Corporation currently has no commercially approved products and there can be no assurance that the Corporation’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Corporation operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements <div style="margin: 0pt auto; font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </div></div> Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as we move forward to with our efforts to develop a commercially approved product.

Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Corporation has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Corporation’s common stock, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Corporation’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates.

Cash and cash equivalents Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less.

Accounts receivable Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Corporation estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The allowance for doubtful accounts was $0 as of December 31, 2020 and 2019.

Concentration of credit risk The Corporation maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. The Corporation received approximately 96% and 85% of its total revenue through grants from government organizations during the years ended December 31, 2020 and 2019, respectively, and <span id="xdx_904_ecustom--RevenuePercentage_pid_dp_uPure_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_zMw6QfMVi8Pk">4% and <span id="xdx_903_ecustom--RevenuePercentage_pid_dp_uPure_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis__custom--NonGovernmentMember_zR4LUEVNAKTj">12% of its total revenue through a grant from a non-government organization during the years ended December 31, 2020 and 2019, respectively.

0.96 0.85 0.04 0.12

Lease liabilities and right-of-use assets The Corporation is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Corporation has, as of January 1, 2018 (the date of adoption), recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Corporation utilized the practical expedient regarding lease and non-lease components and has combined such items into a single combined component. The Corporation’s IBR was used in the calculation of its right of use assets and lease liabilities. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

Research and development expenses Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Corporation’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Corporation, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions. During 2020 and 2019, the Corporation had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB-185, the CRO has been contracted and paid by the US government. For SAB-176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately <span id="xdx_90C_ecustom--ResearchAndDevelopmentGoodsStandingPercentage_pid_dp_c20200101__20201231__dei--LegalEntityAxis__custom--ContractResearchOrganizationsMember_z2jrSQpyQ5ga" title="Goods standing percentage">90% of the contract has been paid through June 17, 2021. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB-176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 35% of the contract has been paid through June 17, 2021.

0.90 0.35

Equipment The Corporation records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Schedule of Estimated Useful Lives <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%">Animal facility equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 50%"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zP0TrwUqldje" title="Equipment useful life">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Laboratory equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Leasehold improvements</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentDepreciationMethods_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6QqxdqUYjt4" title="Equipment description">Shorter of asset life or lease term</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Office furniture & equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Vehicles</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> </table> Repairs and maintenance expenses are expensed as incurred.

The Corporation records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Schedule of Estimated Useful Lives <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%">Animal facility equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 50%"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zP0TrwUqldje" title="Equipment useful life">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Laboratory equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Leasehold improvements</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentDepreciationMethods_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6QqxdqUYjt4" title="Equipment description">Shorter of asset life or lease term</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Office furniture & equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">Vehicles</td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">5 years</td></tr> </table>

P7Y

Shorter of asset life or lease term

P5Y

<p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z6bxMkODO4G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Impairment of long-lived assets The Corporation reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Corporation compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Corporation believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the years ended December 31, 2020 and 2019.

Stock-based compensation FASB ASC Topic 718, Compensation—Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Corporation recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Corporation determines the fair value of stock-based awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The method incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. For awards with performance-based vesting criteria, the Corporation estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur.

Income taxes Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Corporation’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements The Corporation uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Corporation has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes.

Revenue recognition The Corporation’s revenue is primarily generated through grants from government and other (non-government) organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Corporation concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers, as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code.

Comprehensive income (loss) The Corporation had no items of comprehensive income (loss) other than its net income (loss). Litigation From time to time, the Corporation is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Corporation accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred.

Earnings per share In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options. In 2019, the Corporation issued shares of preferred stock, which it determined qualified as participating securities, as defined in ASC 260. Under ASC 260, securities are considered participating securities if the securities may participate in undistributed earnings with common stock, whether that participation is conditioned upon the occurrence of a specified event or not. In accordance with ASC 260, a company is required to use the two-class method when computing net income (loss) per share when a company has securities that qualify as participating securities. The two-class method is an earnings allocation formula that determines net income (loss) per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. Participating securities are included in the computation of basic net income (loss) per share using the two-class method. Under the two-class method, basic net income (loss) per share is computed by dividing net income (loss) attributable to the shareholders of the Corporation attributable to common stockholders by the weighted-average common shares outstanding during the period. Diluted net income (loss) per share for the Corporation’s common stock is computed using the more dilutive of the two-class method or the if-converted method. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

Segment reporting In accordance with ASC 280, Segment Reporting, the Corporation’s business activities are organized into one reportable segment, as only the Corporation’s operating results in their entirety are regularly reviewed by the Corporation’s chief operating decision maker to make decisions about resources to be allocated and to assess performance.

Fair value measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques that would be used to measure fair value into one of three levels: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. As of December 31, 2020 and 2019, the Corporation does not have any assets and liabilities that are recorded at fair value on a recurring basis. The Corporation believes that the carrying amounts of its cash and cash equivalents, accounts receivable, and debt approximate their fair values due to their near-term maturities.

Common stock valuations The Corporation is required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation expert when issuing stock options and computing its estimated stock-based compensation expense. The assumptions underlying these valuations represented management’s best estimates, which involved inherent uncertainties and the application of significant levels of management judgment. In order to determine the fair value of its common stock, the Corporation considered, among other items, previous transactions involving the sale of the Corporation’s securities, the Corporation’s business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of the Corporation’s common stock. Reclassification The prior period amount of $3.4 million related to grant revenue was reclassified from other income to grant revenue on the consolidated statements of operations, as the services performed under the grants were consistent with the Corporation’s ongoing major or central operations during the year ended December 31, 2020, and the reclassification conforms the prior period presentation to the current period presentation. The reclassification had no effect on the prior period net loss or total stockholder’s deficit. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

3400000

(3) New accounting standards Recently-adopted standards In July 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-07, Codification Updates to SEC Sections—Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization, and Miscellaneous Updates (SEC Update), which clarifies or improves a variety of ASC disclosure and presentation requirements by aligning them with the regulations of the United States Securities and Exchange Commission (“SEC”), thereby eliminating redundancies and making the codification easier to apply. The guidance was effective upon issuance. The adoption did not have a material impact on the Corporation’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. The guidance was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption was permitted. The Corporation adopted the guidance as of January 1, 2020. The adoption did not have a material impact on the Corporation’s consolidated financial statements. In June 2018, the FASB issued ASU 2018-08, Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made, which clarifies and improves the scope and the accounting guidance for contributions received and contributions made. The guidance should assist entities in: (1) evaluating whether transactions should be accounted for as contributions (nonreciprocal transactions) within the scope of ASC 958 or as exchange (reciprocal) transactions subject to other guidance; and (2) determining whether a contribution is conditional. Distinguishing between contributions and exchange transactions determines which guidance is applied. For resource recipients, ASU 2018-08 was effective for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. Early adoption was permitted. The Corporation adopted the guidance as of January 1, 2019. The adoption did not have a material impact on the Corporation’s consolidated financial statements. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption was permitted. The Corporation adopted the guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on the Corporation’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost and replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes may result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance, including ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (‘‘ASU 2019-05’’). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost. For public entities that are SEC filers, excluding entities eligible to be smaller reporting companies, ASU 2016-13 was effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted. The Corporation adopted the guidance as of January 1, 2020. The adoption did not have a material impact on the Corporation’s consolidated financial statements. Standards issued not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models required under current GAAP. The guidance removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for such exception and simplifies the diluted earnings per share calculation in certain areas. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted in annual reporting periods ending after December 15, 2020. The Corporation is currently evaluating its adoption of the guidance and the impact that the guidance may have on its consolidated financial statements. The Corporation believes that the adoption of the guidance will not have a material impact on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. The Corporation is currently evaluating its adoption of the guidance and the impact that the guidance may have on its consolidated financial statements. The Corporation believes that the adoption of the guidance will not have a material impact on its consolidated financial statements.

(4) Revenue During the years ended December 31, 2020 and 2019, the Corporation worked on the following grants: SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements Government grants The total revenue for government grants was approximately $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zZvRRVyEfcQk" title="Revenue">52,800,000 and $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_z5paljMOjxEf" title="Revenue">2,900,000 respectively, for the years ended December 31, 2020 and 2019. National Institute of Health – National Institute of Allergy and Infectious Disease (“NIH-NIAID”) (Federal Award #1R44AI117976-01A1) – this grant was for $<span id="xdx_90F_eus-gaap--CostOfRevenue_pn5n6_c20190901__20210831__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zDymO8Kjft1f" title="Grant">1.4 million and started in September 2019 through August 2021. For 2020 and 2019, there was approximately $<span id="xdx_90F_eus-gaap--NonoperatingIncomeExpense_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zmc9Rzfrbrc5" title="Grant income">228,000 and $<span id="xdx_902_eus-gaap--NonoperatingIncomeExpense_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zFvkRabEzqE1">343,000, respectively, in grant income recognized from this grant. Approximately $<span id="xdx_90C_ecustom--RemainingGrantFunding_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--NationalInstituteofHealthMember_zDOQm2Lrufu1" title="Remaining grant">850,000 in funding remains for this grant for 2021. NIH-NIAID (Federal Award #1R41AI131823-02) – this grant was for approximately $1.5 million and started in April 2019 through March 2021. For 2020 and 2019, approximately $99,000 and $97,000 respectively, in grant income was recognized from this grant. Approximately $1.1 million in funding remains for this grant for 2021. NIH-NIAID through Geneva Foundation (Federal Award #1R01AI132313-01, Subaward #S-10511-01) – this grant was for approximately $<span id="xdx_90B_eus-gaap--CostOfRevenue_pn5n6_c20170801__20210731__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zrUKZ2xEbGOc">2.7 million and started in August 2017 through July 2021. For 2020 and 2019, there was approximately $<span id="xdx_90D_eus-gaap--NonoperatingIncomeExpense_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zx81g420wE4h">351,000 and $<span id="xdx_90B_eus-gaap--NonoperatingIncomeExpense_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zx55VJic2MDb">261,000, respectively, in grant income recognized from this grant. Approximately $<span id="xdx_90E_ecustom--RemainingGrantFunding_pn5n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--GenevaFoundationMember_zFo8V8z7SFAg">1.6 million in funding remains for this grant for 2021. Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies (“JPEO”) through Advanced Technology International – this grant was for a potential of $<span id="xdx_907_eus-gaap--CostOfRevenue_pn6n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_z9cOFYqpRCRb">25 million, awarded in stages starting in August 2019 and with potential stages running through February 2023. Additional contract modifications were added to this contract in 2020 for work on a COVID therapeutic, bringing the contract total to $<span id="xdx_901_ecustom--Contract_pn6n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zZAZaYFNaiSb" title="Contract cost">143 million. For 2020 and 2019, approximately $<span id="xdx_904_eus-gaap--NonoperatingIncomeExpense_pn5n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zqjUUQCYn8ih">52.1 million and $<span id="xdx_908_eus-gaap--NonoperatingIncomeExpense_pn5n6_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zUIf5ozyG2fk">2.2 million, respectively, in grant income recognized from this grant. Approximately $<span id="xdx_903_ecustom--RemainingGrantFunding_pn5n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember__srt--ProductOrServiceAxis__custom--AdvancedTechnologyInternationalMember_zqW1R86dYB9g">88.8 million in funding remains for this grant for 2021. The grants for the JPEO contract are cost reimbursement agreements, with reimbursement of our direct research and development expense (labor and consumables) with an overhead charge (based on actual, reviewed quarterly) and a fixed fee (<span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_c20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zs1BwqI7b6Dc" title="Revenue remaining percentage">9%). However, a portion of the funding ($<span id="xdx_90B_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn6n6_c20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_ziwcQePy3ec8" title="Revenue remaining obligation">12 million in 2020) from this contract was for capacity building, including funding for equipment and facilities. A majority of this was for a 200L purification suite and two production barns, which are in locations that are currently leased by the corporation. While the government and SAB have agreed to negotiate in good faith to afford government access to this equipment, the corporation is allowed to use this equipment for any project. As a majority of the value is in leasehold improvements (and therefore cannot be returned to the government), the corporation is treating the assets as company owned, and recognized the proceeds from the reimbursement as revenue. Therefore, revenue significantly exceeded research and development, as there is <span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_do_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__us-gaap--GovernmentMember_zA5rNAbvbekh" title="Research and development cost">no research and development cost to offset this $12 million in revenue. Other grants (non-government) The total revenue for other grants (non-government) was approximately $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn5n6_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zRrAlicJ0zAj">2.4 million and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190101__20191231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zpJESzUzbRw">500,000 respectively, for the years ended December 31, 2020 and 2019. CSL Behring – <span id="xdx_90B_eus-gaap--DepositContractsDescriptionOfLiabilityContracts_c20200101__20201231__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zhKFBExAZdw8" title="Contracts description">there were three contracts for a combined $2.4 million that were started and completed in 2020. These contracts were related to research and development for a COVID-19 therapeutic ($2 million) and two other targets ($400,000). Battelle Memorial Institute – this contract was for approximately $<span id="xdx_909_ecustom--RevenueGrants_pn5n6_c20180401__20190131__dei--LegalEntityAxis__custom--BattelleMemorialInstituteMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zYFAkj4hJAta" title="Grant revenue">2.0 million, starting in April 2018 through January 2019. For 2019, there was $<span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__dei--LegalEntityAxis__custom--BattelleMemorialInstituteMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_z7ef4mUjPoSj" title="Income from contract">400,000 in income recognized from this contract, and the work for this contract was completed as of December 31, 2019. Henry Jackson Foundation – this contract was for $<span id="xdx_904_ecustom--RevenueGrants_c20180901__20190531__dei--LegalEntityAxis__custom--HenryJacksonFoundationMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zna3idXc2ls2">250,000, starting in September 2018 through May 31, 2019. For 2019, there was $<span id="xdx_908_eus-gaap--Revenues_c20190101__20191231__dei--LegalEntityAxis__custom--HenryJacksonFoundationMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis__custom--NonGovernmentMember_zDC3Cg5K5M8d">51,000 in income recognized from this contract, and the work for this contract was completed as of December 31, 2019. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

52800000

2900000

1400000

228000

343000

850000

1500000

99000

97000

1100000

2700000

351000

261000

1600000

25000000

143000000

52100000

2200000

88800000

0.09

12000000

2400000

500000

there were three contracts for a combined $2.4 million that were started and completed in 2020.

These contracts were related to research and development for a COVID-19 therapeutic ($2 million) and two other targets ($400,000). 2000000.0

400000

250000

51000

(5) Earnings per share Earnings (loss) per share The following table sets forth the allocation of net income attributable to the Corporation’s shareholders for the year ended December 31, 2020 under the two-class method: Schedule of Earnings per Share Allocation of Net Income <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231_z7HmWBjOAXa7" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net income attributable to the Corporation’s shareholders applicable to preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreferredStocksMember_z5EWt3Z8Laok" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">7,134,840</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStocksMember_zt6uqBcGzk0e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">12,982,933</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The following table reconciles the weighted-average common shares outstanding used in the calculation of basic earnings per share (“EPS”) to the weighted-average common shares outstanding used in the calculation of diluted EPS for the year ended December 31, 2020: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Determination of shares:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_497_20200101__20201231_zTS3ni0mvdVa" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zn7JU5Wa51qd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Weighted-average common shares outstanding - basic</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pid_zTgVbjvm4CRa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Assumed conversion of preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">19,353,143</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--IncrementalCommonSharesAttributabletoDilutiveEffectofEquityAwards_pid_z30eJYAisROa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Dilutive effect of equity awards</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">3,482,471</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zF939Hq4rESh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">58,051,614</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The following table presents the calculation of basic and diluted EPS for the Corporation’s common stock for the year ended December 31, 2020: Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Calculation of basic EPS attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20200101__20201231_zuITV2neoKm3" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_hus-gaap--StatementEquityComponentsAxis__custom--CommonStocksMember_zJgzUMdpS4g6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">12,982,933</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z8Ox017em5pk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding – basic</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_pid_z6UnkaTJCadc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Basic EPS</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.37</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Calculation of diluted EPS attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_497_20200101__20201231_zD4o66IXxRx1" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_znGz1kqzcJ7g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zFlj89141N9d" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">58,051,614</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_zRSL20u8QDC4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Diluted EPS</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.35</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> Since the Corporation reported a net loss for 2019, it was required by ASC 260 to use basic weighted-average common shares outstanding when calculating diluted net loss per share for the year ended December 31, 2019, as the potential common shares are antidilutive. In addition, since the Corporation reported a loss from operations for the year ended December 31, 2019, the shares of preferred stock were not deemed to be participating securities for the year ended December 31, 2019, pursuant to ASC 260. The Corporation’s participating securities contractually entitle the holders of such shares to participate in dividends but do not contractually require the holders of such shares to participate in losses of the Corporation. In 2019, the Corporation issued shares of preferred stock, which it determined qualified as participating securities, as defined in ASC 260. Under ASC 260, securities are considered participating securities if the securities may participate in undistributed earnings with common stock, whether that participation is conditioned upon the occurrence of a specified event or not. In accordance with ASC 260, a company is required to use the two-class method when computing net income (loss) per share when a company has securities that qualify as participating securities. The two-class method is an earnings allocation formula that determines net income (loss) per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. Participating securities are included in the computation of basic net income (loss) per share using the two-class method. Under the two-class method, basic net income (loss) per share is computed by dividing net income (loss) attributable to the shareholders of the Corporation attributable to common stockholders by the weighted-average common shares outstanding during the period. Diluted net income (loss) per share for the Corporation’s common stock is computed using the more dilutive of the two-class method or the if-converted method. Options to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z995B5QRRz1c" title="Share outstanding">6,748,250 shares and 17,750,882 shares of preferred stock were outstanding during the year ended December 31, 2019 but were not included in the computation of diluted net loss per share because their impact was antidilutive. Schedule of Computation Of Diluted Net loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20190101__20191231_zsD96BGmpH5j" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_di_zZpm9EzXIGv1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net loss attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">8,986,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zorDSsOuclb6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - basic and diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_zVBQCjnjKMn9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Loss per common share - basic and diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(0.26</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

The following table sets forth the allocation of net income attributable to the Corporation’s shareholders for the year ended December 31, 2020 under the two-class method: Schedule of Earnings per Share Allocation of Net Income <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231_z7HmWBjOAXa7" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net income attributable to the Corporation’s shareholders applicable to preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreferredStocksMember_z5EWt3Z8Laok" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">7,134,840</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStocksMember_zt6uqBcGzk0e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Net income attributable to the Corporation's shareholders applicable to common stock">12,982,933</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

20117773

7134840

12982933

The following table reconciles the weighted-average common shares outstanding used in the calculation of basic earnings per share (“EPS”) to the weighted-average common shares outstanding used in the calculation of diluted EPS for the year ended December 31, 2020: Schedule of reconciliation compute basic and diluted net income (loss) per share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Determination of shares:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_497_20200101__20201231_zTS3ni0mvdVa" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zn7JU5Wa51qd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Weighted-average common shares outstanding - basic</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_pid_zTgVbjvm4CRa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Assumed conversion of preferred stock</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">19,353,143</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--IncrementalCommonSharesAttributabletoDilutiveEffectofEquityAwards_pid_z30eJYAisROa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Dilutive effect of equity awards</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">3,482,471</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zF939Hq4rESh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">58,051,614</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

35216000

19353143

3482471

58051614

The following table presents the calculation of basic and diluted EPS for the Corporation’s common stock for the year ended December 31, 2020: Schedule of Earnings per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Calculation of basic EPS attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20200101__20201231_zuITV2neoKm3" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLoss_hus-gaap--StatementEquityComponentsAxis__custom--CommonStocksMember_zJgzUMdpS4g6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders applicable to common stock</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">12,982,933</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z8Ox017em5pk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding – basic</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_pid_z6UnkaTJCadc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Basic EPS</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.37</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Calculation of diluted EPS attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_497_20200101__20201231_zD4o66IXxRx1" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_znGz1kqzcJ7g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net income attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zFlj89141N9d" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">58,051,614</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_zRSL20u8QDC4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Diluted EPS</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">0.35</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

12982933

35216000

0.37

20117773

58051614

0.35

6748250

17750882

Schedule of Computation Of Diluted Net loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20190101__20191231_zsD96BGmpH5j" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iN_di_zZpm9EzXIGv1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%; text-align: left">Net loss attributable to the Corporation’s shareholders</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right">8,986,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zorDSsOuclb6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average common shares outstanding - basic and diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">35,216,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_zVBQCjnjKMn9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Loss per common share - basic and diluted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(0.26</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> </table>

-8986289

35216000

-0.26

(6) Equipment As of December 31, 2020 and 2019, the Corporation’s equipment was as follows: Schedule of Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20201231_zcreiosAmuTb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20191231_zAdZ7PGjoikb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Laboratory equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zz211V1DJr31" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Property, plant and equipment, gross">5,205,346</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zG450KIZflS3" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">1,740,088</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Animal facility</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zkDf97AOwJm9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">3,371,125</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zzEqW5c5EATb" style="font-family: Times New Roman, Times, Serif; text-align: right">1,459,459</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Animal facility equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zuBvMntkEn6i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">1,003,629</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zU48aZwgYoWk" style="font-family: Times New Roman, Times, Serif; text-align: right">540,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Construction-in-progress</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">6,729,673</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zC6nBaESzcxe" style="font-family: Times New Roman, Times, Serif; text-align: right">83,966</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSEzUzVXOel2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">185,971</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zubnreFK7zBj" style="font-family: Times New Roman, Times, Serif; text-align: right">34,285</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Vehicles</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z2BOjmVvb9Oh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">96,693</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zn8er4aPCaT" style="font-family: Times New Roman, Times, Serif; text-align: right">22,710</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zmohUJUWE6d2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">20,219</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcXJrRBUG8jc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">11,347</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzxbc_z5s4h7UBpCZb" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Property, plant and equipment, gross</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">16,612,656</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3,891,855</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_msPPAENzxbc_zrKMzV9tn4ol" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: accumulated depreciation and amortization</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,767,186</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,388,197</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_mtPPAENzxbc_z6HQVYGVcwx" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Property, plant and equipment net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">14,845,470</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,503,658</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> Depreciation and amortization expense for the years ended December 31, 2020 and 2019 was $383,142 and $197,210, respectively. All tangible personal property with a useful life of at least three years and a unit acquisition cost of $5,000 or more will be capitalized and depreciated over its useful life using the straight-line method of depreciation. The Corporation will expense the full acquisition cost of tangible personal property below these thresholds in the year of purchase. The basis of accounting for depreciable fixed assets is acquisition cost and any additional expenditures required to make the asset ready for use. The carrying amount at the balance sheet date of long-lived assets under construction-in-progress includes assets purchased, constructed, or being developed internally that are not yet in service. Depreciation commences when the assets are placed in service. <p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zUnIzLjS1e0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has several ongoing construction projects related to the expansion of its operating capacity. As of December 31, 2020 and December 31, 2019, the Corporation’s construction-in-progress was as follows: Schedule of Construction-in-Progress <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">200L commercial facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zBMbhWEPpSk2" style="width: 16%; text-align: right" title="Total construction-in-progress">4,148,113</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zaIg28NEWZ4a" style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">200L commercial facility equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zITcEQCTNLD2" style="text-align: right" title="Total construction-in-progress">486,381</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zNP7SOHIP5Ui" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New animal barn (#6)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalBarnMember_zQOl8cKpcvKa" style="text-align: right" title="Total construction-in-progress">1,551,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalBarnMember_zOeuK1It5rAf" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New office space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_zS8oTEbgiulk" style="text-align: right" title="Total construction-in-progress">477,907</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_z5HIorghxTYc" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zj2ZNd0gSbOj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total construction-in-progress">66,105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zxbKA0dQkF38" style="border-bottom: Black 1.5pt solid; text-align: right">83,966</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total construction-in-progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231_zcimuubhf782" style="border-bottom: Black 2.5pt double; text-align: right" title="Total construction-in-progress">6,729,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231_z0h8gs9tPIH3" style="border-bottom: Black 2.5pt double; text-align: right">83,966</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The 200L commercial facility and 200L commercial facility equipment are expected to be complete by the end of the third quarter of 2021. Construction of the new animal barn (#6) is expected to be completed in July 2021. Construction of the new office space (at Headquarters) is expected to be complete by the end of August 2021.

As of December 31, 2020 and 2019, the Corporation’s equipment was as follows: Schedule of Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20201231_zcreiosAmuTb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20191231_zAdZ7PGjoikb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Laboratory equipment</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zz211V1DJr31" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Property, plant and equipment, gross">5,205,346</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zG450KIZflS3" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">1,740,088</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Animal facility</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zkDf97AOwJm9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">3,371,125</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BreedingAndProductionAnimalsMember_zzEqW5c5EATb" style="font-family: Times New Roman, Times, Serif; text-align: right">1,459,459</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Animal facility equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zuBvMntkEn6i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">1,003,629</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFacilityEquipmentMember_zU48aZwgYoWk" style="font-family: Times New Roman, Times, Serif; text-align: right">540,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Construction-in-progress</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_pp0p0" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">6,729,673</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zC6nBaESzcxe" style="font-family: Times New Roman, Times, Serif; text-align: right">83,966</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zSEzUzVXOel2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">185,971</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zubnreFK7zBj" style="font-family: Times New Roman, Times, Serif; text-align: right">34,285</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Vehicles</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_z2BOjmVvb9Oh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">96,693</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zn8er4aPCaT" style="font-family: Times New Roman, Times, Serif; text-align: right">22,710</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zmohUJUWE6d2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Property, plant and equipment, gross">20,219</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcXJrRBUG8jc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">11,347</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzxbc_z5s4h7UBpCZb" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Property, plant and equipment, gross</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">16,612,656</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3,891,855</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pp0p0_msPPAENzxbc_zrKMzV9tn4ol" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: accumulated depreciation and amortization</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,767,186</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,388,197</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_mtPPAENzxbc_z6HQVYGVcwx" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> Property, plant and equipment net</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">14,845,470</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">2,503,658</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

5205346

1740088

3371125

1459459

1003629

540000

6729673

83966

185971

34285

96693

22710

20219

11347

16612656

3891855

1767186

1388197

14845470

2503658

383142

197210

P3Y

5000

<p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zUnIzLjS1e0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has several ongoing construction projects related to the expansion of its operating capacity. As of December 31, 2020 and December 31, 2019, the Corporation’s construction-in-progress was as follows: Schedule of Construction-in-Progress <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">200L commercial facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zBMbhWEPpSk2" style="width: 16%; text-align: right" title="Total construction-in-progress">4,148,113</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityMember_zaIg28NEWZ4a" style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">200L commercial facility equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zITcEQCTNLD2" style="text-align: right" title="Total construction-in-progress">486,381</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--TwoHunderdLCommercialFacilityEquipmentMember_zNP7SOHIP5Ui" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New animal barn (#6)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalBarnMember_zQOl8cKpcvKa" style="text-align: right" title="Total construction-in-progress">1,551,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalBarnMember_zOeuK1It5rAf" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">New office space (at Headquarters)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_zS8oTEbgiulk" style="text-align: right" title="Total construction-in-progress">477,907</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__custom--NewOfficeSpaceMember_z5HIorghxTYc" style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zj2ZNd0gSbOj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total construction-in-progress">66,105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zxbKA0dQkF38" style="border-bottom: Black 1.5pt solid; text-align: right">83,966</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total construction-in-progress</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20201231_zcimuubhf782" style="border-bottom: Black 2.5pt double; text-align: right" title="Total construction-in-progress">6,729,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ConstructionInProgressGross_iI_pp0p0_c20191231_z0h8gs9tPIH3" style="border-bottom: Black 2.5pt double; text-align: right">83,966</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4148113

486381

1551167

477907

66105

83966

6729673

83966

(7) Leases The Corporation has an operating lease for lab space from Sanford Health (a related party), under a lease that started in June 2014 and ran through June 2019, at which time the lease was amended to run through August 2024.<span id="xdx_906_eus-gaap--LesseeOperatingLeaseOptionToTerminate_c20200101__20201231__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--LabSpaceMember_zc0vealTui31" title="Lease termination description"> This lease can be terminated with 30 days advance written notice. The lease is for $58,496 per month. The operating lease does not include an option to extend beyond the life of the current term. The lease does not provide an implicit rate, and, therefore, the Corporation used an IBR of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20201231__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--LabSpaceMember_zr8Rt2JhccJ4" title="Operating lease liablity discount rate">4.77% as the discount rate when measuring the operating lease liability. The Corporation estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Corporation. The Corporation entered into a lease for office, laboratory, and warehouse space in November 2020. This lease has a 3-year term, with options to extend for 3 additional periods of 3 years each. The options were not included in the right of use calculation as it is unclear as to whether or not the location will meet the Corporation’s requirements beyond the next three years. The lease cost is $28,716 per month. The Corporation used an IBR of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20201231__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__srt--WarehouseMember_zPMxLYPR9ARd" title="Operating lease liablity discount rate">4.69% as the discount rate when measuring the operating lease liability. The Corporation estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Corporation. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements The Corporation entered into a lease for barn space for the housing of goats in April 2020. This lease has a <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--BarnSpaceMember_zl7nT0HFMkz8" title="Operating lease term">2-year term, with automatic renewals for a one-year period after the initial term expires until either party terminates. The options were not included in the right of use calculation, as the goat project is mostly funded by government grants, and those grants do not currently extend beyond the initial lease term. The lease cost is $665 per month for the first year, then $678 per month for the second year. The Corporation used an IBR of <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20201231__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--BarnSpaceMember_zzuia5RtqIk8" title="Operating lease liablity discount rate">4.08% as the discount rate when measuring the operating lease liability. The Corporation estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Corporation. The Corporation has the following finance leases: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2018, the Corporation entered into a finance lease with Dakota Ag Properties for a new animal facility which includes the surrounding land. The facility and the land have been accounted for as separate lease components. The lease is based upon payback of $4,000,000 in construction costs, with a 20-year term at an interest rate of 8%. The monthly payment for this lease is $33,458. The Corporation has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2018, the Corporation entered into an equipment lease for a 12,000-gallon propane tank that is located on the Corporation’s animal facility. The lease is for five years with an annual payment of $8,199. The Corporation has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In July 2018, the Corporation entered into a lease agreement with a bank, for a ruby cell analyzer. The lease agreement is for a five-year term. The monthly payment for this lease is $807. The Corporation has the option to purchase the asset at the end of the lease for $1.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In March 2019, the Corporation entered into two lease agreements for laboratory equipment. The leases are each for a 3-year term and a combined monthly payment of $5,956. Both leases have a $1 purchase option at the end of the lease term.</td></tr> </table> The lease agreements do not require material variable lease payments, residual value guarantees or restrictive covenants. The amortizable lives of the operating lease assets are limited by their expected lease terms. The amortizable lives of the finance lease assets are limited by their expected lives, as the Corporation intends to exercise the purchase options at the end of the leases. The following is the estimated useful lives of the finance lease assets: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: justify">Animal Facility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: justify"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AnimalFaciltyMember_zuSGQ8tYirIe" title="Estimated useful lives of the finance lease assets">40 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Equipment</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z6qrpCfiJnT9" title="Estimated useful lives of the finance lease assets">3 – 7 years</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Land</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_z6mEuJZy7et6" title="Estimated useful lives of the finance lease assets">Indefinite</td></tr> </table> The Corporation’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of December 31, 2020 are: Schedule of Operating and Finance Leases Discount Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Operating</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Finance</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.43 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17.61 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Weighted-average discount rate</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">4.75</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">7.96</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> </table> The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2020: Schedule of Undiscounted Future Minimum Lease Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Operating</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Finance </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">2021</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20201231_z9Q1YJhNWNYg" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Operating Lease 2021">1,053,891</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20201231_zNnuL0tE5A6f" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Finance Lease 2021">490,848</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20201231_zaNi9w0EnMq7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2022">1,048,573</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20201231_zc8iophLqT6d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2022">444,928</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2023</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20201231_zjQGwnK1bSZ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2023">989,107</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20201231_zEK3BqB5zfle" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2023">406,339</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2024</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20201231_zixZ49MSnKv8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2024">467,968</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20201231_zrZ9w0hPpzv" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2024">401,496</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2025</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20201231_zTv2Cl5eLCZ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2025">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_c20201231_zPS5fiTurTv2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2025">401,496</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Thereafter</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20201231_zrlBtjWiFBk2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Thereafter">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_c20201231_zRCtX8jzTqHl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Thereafter">5,185,990</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Undiscounted future minimum lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20201231_zb5hHWWQegp" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Undiscounted future minimum lease payments">3,559,539</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pp0p0_c20201231_zccJ8bjOabJk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance lease Undiscounted future minimum lease payments">7,331,097</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: Amount representing interest</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20201231_znjKfWsTbJ8j" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less:Operating Lease Amount representing interest payments">(262,497</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20201231_zefyLsEn0wV7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less: Finance lease Amount representing interest payments">(3,212,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iI_c20201231_zBSPNNdbWUO5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total Operating Lease liabilities">3,297,042</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_pp0p0_c20201231_z3q4SlllyVGg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total finance lease liabilities">4,118,271</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less current portion</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20201231_zsbP4PO1Rq48" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less current portion of Operating Lease">(924,265</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pp0p0_di_c20201231_z9jNQKjezPdg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less current portion of finance Lease">(194,717</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20201231_zKEzbIIaVNUa" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Noncurrent Operating lease liabilities">2,372,777</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pp0p0_c20201231_zifW0bwAS2rj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Noncurrent finance lease liabilities">3,923,554</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements Operating lease expense was approximately $710,000 and $373,000, respectively, for the years ended December 31, 2020 and 2019. Operating lease costs are included within research and development expenses on the consolidated statements of operations. Finance lease costs for the years ended December 31, 2020 and 2019 included approximately $163,000 and $140,000, respectively, in right-of-use asset amortization and approximately $445,000 and $316,000, respectively, of interest expense. Finance lease costs are included within research and development expenses on the consolidated statements of operations. Cash payments under operating and finance leases were approximately $564,000 and $491,000, respectively, for the year ended December 31, 2020. Cash payments under operating and finance leases were approximately $327,000 and $491,000, respectively, for the year ended December 31, 2019.

This lease can be terminated with 30 days advance written notice.

58496

0.0477

P3Y

28716

0.0469

P2Y

665

678

0.0408

4000000

P20Y

0.08

33458

P5Y

8199

five-year

807

P3Y

5956

40 years

3 – 7 years

Indefinite

The Corporation’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of December 31, 2020 are: Schedule of Operating and Finance Leases Discount Rate <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Operating</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Finance</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Weighted-average remaining lease term</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">3.43 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">17.61 years</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Weighted-average discount rate</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">4.75</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">7.96</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> </table>

P3Y5M4D

P17Y7M9D

0.0475

0.0796

The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2020: Schedule of Undiscounted Future Minimum Lease Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Operating</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">Finance </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">2021</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20201231_z9Q1YJhNWNYg" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Operating Lease 2021">1,053,891</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20201231_zNnuL0tE5A6f" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Finance Lease 2021">490,848</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20201231_zaNi9w0EnMq7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2022">1,048,573</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20201231_zc8iophLqT6d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2022">444,928</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2023</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20201231_zjQGwnK1bSZ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2023">989,107</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_c20201231_zEK3BqB5zfle" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2023">406,339</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2024</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20201231_zixZ49MSnKv8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2024">467,968</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_c20201231_zrZ9w0hPpzv" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2024">401,496</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2025</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20201231_zTv2Cl5eLCZ8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease 2025">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_c20201231_zPS5fiTurTv2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease 2025">401,496</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Thereafter</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20201231_zrlBtjWiFBk2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Thereafter">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_c20201231_zRCtX8jzTqHl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Thereafter">5,185,990</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Undiscounted future minimum lease payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20201231_zb5hHWWQegp" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Undiscounted future minimum lease payments">3,559,539</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pp0p0_c20201231_zccJ8bjOabJk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance lease Undiscounted future minimum lease payments">7,331,097</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less: Amount representing interest</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">payments</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20201231_znjKfWsTbJ8j" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less:Operating Lease Amount representing interest payments">(262,497</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20201231_zefyLsEn0wV7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less: Finance lease Amount representing interest payments">(3,212,826</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_iI_c20201231_zBSPNNdbWUO5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total Operating Lease liabilities">3,297,042</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_pp0p0_c20201231_z3q4SlllyVGg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total finance lease liabilities">4,118,271</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less current portion</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20201231_zsbP4PO1Rq48" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less current portion of Operating Lease">(924,265</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pp0p0_di_c20201231_z9jNQKjezPdg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Less current portion of finance Lease">(194,717</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Noncurrent lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20201231_zKEzbIIaVNUa" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Noncurrent Operating lease liabilities">2,372,777</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pp0p0_c20201231_zifW0bwAS2rj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Noncurrent finance lease liabilities">3,923,554</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

1053891

490848

1048573

444928

989107

406339

467968

401496

5185990

3559539

7331097

262497

3212826

3297042

4118271

924265

194717

2372777

3923554

710000

373000

163000

140000

445000

316000

564000

491000

327000

491000

(8) Accrued Expenses and Other Current Liabilities As of December 31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49C_20201231_zYPPOYFpIqF2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20191231_zyVU3dDMIyl2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_zZvK6KoQWKS2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Accrued vacation</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">438,936</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">248,722</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_z9NFPYTmiQT3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued payroll</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">314,451</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">143,210</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccruedConstructioninProgressCurrent_iI_zitwLSO2ZQTb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued construction-in-progress</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">637,776</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedSuppliesCurrent_iI_zGNBGSHSucBe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued lab supplies</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">301,989</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">18,837</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_zBNS4KkuJsm2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued project consulting</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">120,744</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5,352</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_zUnrV9SpmHs1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Other accrued expenses</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">90,982</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">78,433</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_zkTwLcgRvXE5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,904,878</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">494,554</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

As of December 31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49C_20201231_zYPPOYFpIqF2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49D_20191231_zyVU3dDMIyl2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedVacationCurrent_iI_zZvK6KoQWKS2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Accrued vacation</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">438,936</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">248,722</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_z9NFPYTmiQT3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued payroll</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">314,451</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">143,210</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccruedConstructioninProgressCurrent_iI_zitwLSO2ZQTb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued construction-in-progress</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">637,776</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedSuppliesCurrent_iI_zGNBGSHSucBe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued lab supplies</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">301,989</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">18,837</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_zBNS4KkuJsm2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Accrued project consulting</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">120,744</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">5,352</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_zUnrV9SpmHs1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Other accrued expenses</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">90,982</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">78,433</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_zkTwLcgRvXE5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,904,878</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">494,554</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

438936

248722

314451

143210

637776 301989 18837

120744

5352

90982

78433

1904878

494554

(9) Debt Note payable, related party On February 24, 2016, the Corporation entered into a loan agreement with Christiansen Land and Cattle, Ltd. (“CLC”), a related party, for a $<span id="xdx_908_eus-gaap--LineOfCredit_iI_pn6n6_c20160224__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristiansenLandandCattleLtdMember_z0nnHaVAN6vc" title="Line of credit">3.0 million revolving line of credit secured by a blanket security interest in the assets of the Corporation. The Corporation borrowed $2.5 million from the line of credit in 2016, and $350,000 in 2017. The line of credit bears a fixed rate per annum of 6% compounded annually. The initial agreement was based upon repayment following a significant capital event – closing of equity or debt financing with total proceeds to the Corporation of $15 million or more or one year from the agreement date, whichever occurred first. The agreement was amended in August 2018 to extend the repayment timeframe to August 31, 2019. The first payment to repay this loan was made on August 31, 2018 ($1.0 million payment). Additional voluntary payments were being made at the rate of $30,000 per month. In August 2019, the agreement was amended to extend the maturity date to the earlier of August 31, 2020 or the occurrence of a significant capital event, as defined above. The note payable balance as of December 31, 2019 was $1,364,644, which included accrued interest of $3,580. In July 2020, the note payable was paid in full. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements Notes payable On November 15, 2017, the Corporation entered into a loan agreement with a bank, for the financing of an ultrasound machine for $18,997. The agreement was for a four-year term, with monthly payments of $440. The note payable had a balance as of December 31, 2019 of $9,203 and was paid off in full in September 2020. In December 2017, the Corporation entered into two loan agreements with a financial institution. One agreement was for the purchase of a tractor for $116,661 at a 3.6% interest rate, and a second agreement for the purchase of a trailer, truck, scale, and chute for $47,721 at a <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20171231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrailerTruckScaleAndChuteMember_zfADidRvh4Z" title="Interest rate">5.9% interest rate. The loan for the tractor included annual payments of $25,913 for the next five years starting in December 2018. The loan for the trailer, truck, scale, and chute included monthly payments of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20170101__20171231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrailerTruckScaleAndChuteMember_zb2zW8sVRg9j" title="Monthly payment of loan">920 for five years starting in January 2018 through December 2022. During 2019, the trailer, truck, scale, and chute loan was paid in full. The tractor loan balance as of December 31, 2020 and 2019 was $49,156 and $72,459, respectively. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). In April 2020, the Corporation entered into a loan agreement (the “PPP Loan”) with First Premier Bank under the Paycheck Protection Program (the “PPP”), which is part of the CARES Act administered by the United States Small Business Administration (“SBA”). As part of the application for these funds, the Corporation, in good faith, certified that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Corporation. The certification further requires the Corporation to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. Under the PPP, the Corporation received proceeds of approximately $661,612. In accordance with the requirements of the PPP, the Corporation utilized the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan has a 1.00% interest rate per annum, matures in April 2022 and is subject to the terms and conditions applicable to loans administered by the SBA under the PPP. Under the terms of PPP, all or certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses, as described in the CARES Act. The Corporation recorded the entire amount of the PPP Loan as debt. Under the terms of the PPP Loan, monthly payments of principal and interest were due to commence November 1, 2020, however, the SBA is deferring loan payments for borrowers who apply for loan forgiveness until the SBA remits the borrower’s loan forgiveness amount to the lender. No payments were made in 2020., and an application for forgiveness of the loan was completed. The future loan payments are as follows: Schedule of Future Loan Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20201231__us-gaap--LongtermDebtTypeAxis__us-gaap--LoansPayableMember_znGSSR8FGXDb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Note Payable</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDzQ6M_zXLfgCW9iuJl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 72%; text-align: left">2021</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: right">538,731</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDzQ6M_z4NSkOtCCfV4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">172,037</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iI_mtLTDzQ6M_zQAqCaJOJmh3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">710,768</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> Please refer to Note 17, Subsequent Events, for additional information.

3000000.0

2500000

350000

0.06

15000000

1000000.0

30000

1364644

3580

18997

440

9203

116661

0.036

47721

0.059

25913

920

49156

72459

661612

0.01

The future loan payments are as follows: Schedule of Future Loan Payments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20201231__us-gaap--LongtermDebtTypeAxis__us-gaap--LoansPayableMember_znGSSR8FGXDb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Note Payable</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDzQ6M_zXLfgCW9iuJl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 72%; text-align: left">2021</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: right">538,731</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDzQ6M_z4NSkOtCCfV4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">172,037</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iI_mtLTDzQ6M_zQAqCaJOJmh3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">710,768</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

538731

172037

710768

(10) Preferred Stock In August 2019, the Corporation’s Certificate of Incorporation was amended to authorize the Corporation to issue 50,000,000 shares of preferred stock, of which 6,615,000 shares are designated as Series A preferred stock, 2,525,800 shares are designated as series A-1 preferred stock, 4,039,963 shares are designated as series A-2 preferred stock, 3,333,333 shares are designated as series A-2A preferred stock, and 8,571,429 shares are designated as series B preferred stock. The carrying value of Series A preferred stock is $1 per share, Series A-1 $1.88 per share, Series A-2 & A-2A $3.00 per share, and Series B $3.50 per share. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements The preferred stock is entitled to receive noncumulative dividends in preference to any dividend on the common stock when, as, and if declared by the Corporation’s board of directors. The holders of the preferred stock also are entitled to participate pro rata in any dividends paid on the common stock on an as-if-converted basis. Each holder of preferred stock is entitled to the number of votes equal to the number of shares of common stock that it could be converted into. As long as there are 8,000,000 shares of preferred stock outstanding, the vote or written consent of the holder of the majority of the outstanding preferred stock (all series voting as a single class) is required to approve any amendment of the certificate of incorporation that changes voting, preferences or privileges or restrictions of the preferred stock. In the event of liquidation or winding up of the Corporation, the preferred stockholders also are entitled to receive in preference to the holders of the common stock the greater of: a) a per share amount equal to their respective original purchase price plus any declared but unpaid dividends (the “Liquidation Preference”); or b) the amount to be paid on the common stock on an as-if-converted basis. The remaining assets would be distributed to the common stockholders. The holders of preferred stock have the right to convert the preferred stock into common stock, at any time, utilizing the then- effective conversion rate. The effective conversion rate as of December 31, 2020 and 2019 was 1:1. All preferred shares are automatically converted into common shares utilizing the then effective preferred conversion rate upon: a) the closing of the Corporation’s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, covering the sale of the Corporation’s common stock if gross proceeds are at least $20,000,000 and the Corporation’s shares have been listed on a stock exchange, as defined; or b) the election of the holders of a majority of the outstanding shares of preferred stock. With any change of control of the Corporation or financing, the preferred stockholders must approve through majority vote any such change in control or financing event approved by the board of directors or the majority of the common stockholders. The preferred stock contains certain anti-dilution provisions, as defined. In addition to the rights described above, series A-2A preferred stock was redeemable at a price equal to $5 per preferred share at the option of the investor at any time during the redemption period, which was scheduled to commence in August 2022 and end in August 2023. As a result of the redemption feature, the Corporation classified the series A-2A preferred stock as mezzanine equity as of December 31, 2019. However, the redemption feature was terminated during 2020, and the series A-2A preferred stock was reclassified from mezzanine equity to permanent equity. In 2019, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBOv53pc82Kd" title="Units issued during the period, shares">1,236,786 shares of series B preferred stock were sold in a private offering with gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20190101__20191231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDA34pJ9HD66" title="Gross proceeds from IPO">4,328,752. In 2020, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX6LxFWpu7Za" title="Units issued during the period, shares">2,853,754 shares of series B preferred stock were sold in a private offering with gross proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0p0_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zg49ZdF4pDF4" title="Gross proceeds from IPO">9,988,155. The debt issuance costs associated with the offering of the preferred stock were $87,949 in 2020 and $23,852 in 2019. The series B preferred stock bears all of the same rights described above, with the exception of the additional rights for the series A-2A preferred stock.

50000000

6615000

2525800

4039963

3333333

8571429

1.88

3.00

3.50

8000000

The effective conversion rate as of December 31, 2020 and 2019 was 1:1.

20000000

1236786

4328752

2853754

9988155

87949

23852

(11) Stock Option Plan On August 5, 2014, the Corporation approved a stock option grant plan (the “Plan”) for employees, directors, and non-employee consultants, which provides for the issuance of options to purchase common stock. The total shares authorized under the plan was originally 8,000,000; however, during 2019, the Plan was amended to increase the total shares authorized under the plan to 16,000,000. Vesting of the stock options is based upon years of service (employment). As of December 31, 2020 and 2019, <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20200101__20201231_zKRvprx0Crs1" title="Number of Non-vested Stock Options Outstanding, Vested">6,882,575 and <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20190101__20191231_z1v6KxelWmU6" title="Number of Non-vested Stock Options Outstanding, Vested">6,021,528 stock options, respectively, were vested and exercisable. None of the vested stock options were exercised as of December 31, 2020 and 2019. As of December 31, 2020, the aggregate intrinsic value of stock options outstanding was $11,256,034, of which $1,315,588 was unvested and $9,940,446 was vested and exercisable. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements The Corporation uses the Black Scholes model to estimate the fair value of the stock options granted. For stock options granted during the years ended December 31, 2020 and 2019, the Corporation utilized the following weighted-average assumptions: A risk free interest rate of 0.13% and 1.58%, respectively; expected term of 6.25 years (both years); expected dividend yield of 0% (both years); and a volatility factor of 106.1% and 102.9%, respectively. There were no forfeitures or expirations during the years ended December 31, 2020 and 2019. The expected term of the stock options was estimated using the “simplified” method, as defined by the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Corporation does not have sufficient trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Corporation’s history and expectation of dividend payouts. The Corporation has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Therefore, the Corporation has assumed no dividend yield for purposes of estimating the fair value of the options. Stock option activity for employees and non-employees under the Plan for the years ended December 31, 2020 and 2019 was as follows: Summary of stock options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Options</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Fair Value</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%">Balance, December 31, 2018</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20180101__20181231_zEelQKUC9wtj" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">6,516,250</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20180101__20181231_zAwn5tk3P6zd" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.35</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20190101__20191231_zik7lZ6gqPH4" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.38</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231_zzJh5DzRFy64" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted">232,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20180101__20181231_zux0Co6ilP0e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">1.01</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231_zqWTej6a37Q9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.04</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2019</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20190101__20191231_zlpHMWIQD871" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">6,748,250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20190101__20191231_zStYkygqMnh3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.38</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zeAv3KV0lfy3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.41</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231_zUDA9Gg539G6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted">2,067,742</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pid_c20190101__20191231_zva1HEMc7eof" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">1.60</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zsTeuQjLLuY" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.25</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20200101__20201231_zeZ1RjrsaMa8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">8,815,992</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231_z1VYadUF0ts4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Ending of Period">0.62</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20201231_z39vyjSBKyDd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">0.60</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Unvested at December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20201231_zYsBccUo3Nc8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Non-vested Stock Options">1,933,417</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateUnvested_pid_c20200101__20201231_z91n7efVGGSe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value, Unvested">1.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageUnvested_pid_c20200101__20201231_zfOEUt3jXFp3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Unvested">1.20</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vested and exercisable at December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231_zbkRqtccZnL2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">6,882,575</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateVestedandExercisable_pid_c20200101__20201231_zBC2rkIz46Y5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value, Vested">0.39</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageVestedandExercisable_pid_c20200101__20201231_za1P7s7OVMwj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Vested">0.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> Total unrecognized compensation cost related to non-vested stock options as of December 31, 2020 was approximately $2,592,025 and is expected to be recognized within future operating results over a weighted-average period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zLryQ0gahEO8" title="Weighted average period">2.37 years. As of December 31, 2020, the weighted-average contractual term of the options outstanding was approximately <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zHlFpfWZJLri" title="Stock option outstanding">5.94 years. As of December 31, 2020, the weighted-average contractual term of the vested options was approximately <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_ze71QWMl0ZA" title="Stock option vested">4.99 years. During the years ended December 31, 2020 and 2019, 861,047 shares and 636,530 shares, respectively, vested. Stock-based compensation expense for the years ended December 31, 2020 and 2019 was as follows: Schedule of stock based compensation expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_493_20200101__20201231_z3BEG7bEzNFd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_49B_20190101__20191231_ztNMXMw1ajGe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTgBWL5SwR37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">635,824</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">150,773</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLiYxbYRmYd9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">659,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">220,615</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_zOOYtm1bPOki" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,295,423</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">371,388</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements

8000000

16000000

6882575

6021528

11256034

1315588

9940446

0.0013

0.0158

P6Y3M

1.061

1.029

Stock option activity for employees and non-employees under the Plan for the years ended December 31, 2020 and 2019 was as follows: Summary of stock options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Weighted Average</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Options</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Fair Value</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Exercise Price</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%">Balance, December 31, 2018</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20180101__20181231_zEelQKUC9wtj" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">6,516,250</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20180101__20181231_zAwn5tk3P6zd" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.35</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20190101__20191231_zik7lZ6gqPH4" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.38</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231_zzJh5DzRFy64" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted">232,000</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20180101__20181231_zux0Co6ilP0e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">1.01</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231_zqWTej6a37Q9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.04</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2019</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20190101__20191231_zlpHMWIQD871" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Outstanding at Beginning of Period">6,748,250</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20190101__20191231_zStYkygqMnh3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Beginning of Period">0.38</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zeAv3KV0lfy3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding at Beginning of Period">0.41</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Granted</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231_zUDA9Gg539G6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Granted">2,067,742</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pid_c20190101__20191231_zva1HEMc7eof" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair Value Price Per Share, Granted">1.60</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zsTeuQjLLuY" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Granted">1.25</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Balance, December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20200101__20201231_zeZ1RjrsaMa8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Stock Options Outstanding, Outstanding at End of Period">8,815,992</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20200101__20201231_z1VYadUF0ts4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value Price Per Share, Outstanding at Ending of Period">0.62</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20200101__20201231_z39vyjSBKyDd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at End of Period">0.60</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif">Unvested at December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20201231_zYsBccUo3Nc8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Non-vested Stock Options">1,933,417</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateUnvested_pid_c20200101__20201231_z91n7efVGGSe" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value, Unvested">1.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageUnvested_pid_c20200101__20201231_zfOEUt3jXFp3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Unvested">1.20</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vested and exercisable at December 31, 2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231_zbkRqtccZnL2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Non-vested Stock Options Outstanding, Vested">6,882,575</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateVestedandExercisable_pid_c20200101__20201231_zBC2rkIz46Y5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Fair value, Vested">0.39</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageVestedandExercisable_pid_c20200101__20201231_za1P7s7OVMwj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share, Vested">0.44</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

6516250

0.35

0.38

232000

1.01

1.04

6748250

0.38

0.41

2067742

1.60

1.25

8815992

0.62

0.60

1933417

1.44 1.20

6882575

0.39 0.44

2592025

P2Y4M13D

P5Y11M8D

P4Y11M26D

861047 636530

635824

150773

659599

220615

1295423

371388

(12) Income Taxes Net deferred tax assets as of December 31, 2020 and 2019 consisted of the following: Schedule of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20201231_zKnrgIeJOgW7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20191231_znFXnxIzNrlk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzVZO_zSA5K1RNcXed" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">2,659,082</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">6,438,409</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsStockBasedCompensation_iI_maDTAGzVZO_zWA2mSXYhcDi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">600,592</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">328,553</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsVacationAccrual_iI_maDTAGzVZO_zeSJgUWAO1zc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vacation accrual</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">84,553</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">45,128</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzVZO_zGds4EWejltc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Lease Liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">727,587</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">467,139</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzVZO_maDTANzDCW_zJUr8U93xvya" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">4,071,814</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">7,279,229</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzDCW_zmwa0A9fFIQh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(2,320,958</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,563,244</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzDCW_msDTLzGpI_zotB5igUhlt3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax assets after valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,750,856</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">715,985</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightUseAsset_iI_maDITLzkYG_zUspZFAB8bca" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Operating lease Right of Use Asset</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">641,135</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">390,962</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzkYG_zx7PtpWBUQr7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Depreciation and amortization</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,109,721</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">325,023</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzkYG_maDTLzGpI_zkr23hYPDr" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,750,856</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">715,985</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzGpI_zuihtVshbul1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net deferred tax asset/(liability)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The reconciliation between the Corporation’s effective tax rate and the statutory tax rate of 21% includes the following significant items: changes in the valuation allowance and permanent items including meals and entertainment. The rate reconciliation was as follows: Schedule Of Income Tax Rate Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Rate reconciliation:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left">Net income before tax</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right">(8,986,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Federal income tax at statutory rate</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4,224,732</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20200101__20201231_zhKieZxqfNP2" title="Effective income tax rate at federal statutory income tax rate">21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,887,121</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Permanent items</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">918</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-0.01</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,144</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-0.02</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20200101__20201231_zldm6lOMkLPf" title="Effective income tax rate reconciliation, Change in deferred tax assets Valuation allowance, amount">(4,225,651</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,884,977</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-20.98</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Other</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical losses and the uncertainty of future taxable income over the periods which the Corporation will realize the benefits of its net deferred tax assets, management believes it is more likely than not that the Corporation will not fully realize the benefits on the balance of its net deferred tax asset and, accordingly, the Corporation has established a valuation allowance on it net deferred tax assets. The valuation allowance decreased by approximately $4,226,000 and increased by $1,885,000, respectively, for the years ended December 31, 2020 and December 31, 2019. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements As of December 31, 2020, the Corporation had approximately $12,662,000 of federal net operating losses, which were generated after December 31, 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act and may generally be used to offset up to 80% of future taxable income. The Corporation has not completed a study to determine whether any ownership change per the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions, has occurred. Utilization of the Corporation’s net operating loss carryforwards may be subject to substantial annual limitation due to ownership changes that may have occurred or that could occur in the future. These ownership changes may limit the amount of the net operating loss carryover that can be utilized annually to offset future taxable income. In general, an “ownership change”, as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. U.S. GAAP provides that the tax effects from uncertain tax positions can be recognized in the consolidated financial statements only if the position is more likely than not of being sustained on audit, based on the technical merits of the position. As of December 31, 2020 and December 31, 2019, there were no uncertain tax provisions. There was no interest or penalties related to income taxes for the years ended December 31, 2020 and 2019, and there was no accrued interest or penalties associated with uncertain tax positions as of December 31, 2020 and December 31, 2019. The Corporation files tax returns as prescribed by the laws of the jurisdictions in which it operates. In the normal course of business, the Corporation is subject to examination by federal and state jurisdictions, where applicable. The Corporation’s tax years are still open under the statute from 2017 to present. However, to the extent allowed by law, the taxing authorities may have the right to examine the period from 2015 through 2020 where net operating losses were generated and carried forward and make adjustments to the amount of the net operating loss carryforward amount. The Corporation is not currently under examination by federal or state jurisdictions. As discussed in Note 9, Debt, on March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. It was determined the CARES Act did not materially impact the Corporation’s tax provision as of December 31, 2020.

Net deferred tax assets as of December 31, 2020 and 2019 consisted of the following: Schedule of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20201231_zKnrgIeJOgW7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20191231_znFXnxIzNrlk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzVZO_zSA5K1RNcXed" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">2,659,082</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right">6,438,409</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxAssetsStockBasedCompensation_iI_maDTAGzVZO_zWA2mSXYhcDi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Stock-based compensation</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">600,592</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">328,553</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsVacationAccrual_iI_maDTAGzVZO_zeSJgUWAO1zc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Vacation accrual</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">84,553</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">45,128</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsLeaseLiability_iI_maDTAGzVZO_zGds4EWejltc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Lease Liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">727,587</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">467,139</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzVZO_maDTANzDCW_zJUr8U93xvya" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">4,071,814</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">7,279,229</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzDCW_zmwa0A9fFIQh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Less valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(2,320,958</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(6,563,244</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzDCW_msDTLzGpI_zotB5igUhlt3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax assets after valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">1,750,856</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">715,985</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightUseAsset_iI_maDITLzkYG_zUspZFAB8bca" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Operating lease Right of Use Asset</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">641,135</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">390,962</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesDepreciationAndAmortization_iI_maDITLzkYG_zx7PtpWBUQr7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Depreciation and amortization</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,109,721</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">325,023</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzkYG_maDTLzGpI_zkr23hYPDr" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Total deferred tax liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1,750,856</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">715,985</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzGpI_zuihtVshbul1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Net deferred tax asset/(liability)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

2659082

6438409

600592 328553 84553 45128 727587 467139

4071814

7279229

2320958

6563244

1750856

715985

641135 390962 1109721 325023

1750856

715985

0.21

Schedule Of Income Tax Rate Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.25in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2019</td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Rate reconciliation:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left">Net income before tax</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right">20,117,773</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right">(8,986,289</td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif; width: 2%"> </td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Federal income tax at statutory rate</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">4,224,732</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20200101__20201231_zhKieZxqfNP2" title="Effective income tax rate at federal statutory income tax rate">21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">(1,887,121</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Permanent items</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">918</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-0.01</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">2,144</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-0.02</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20200101__20201231_zldm6lOMkLPf" title="Effective income tax rate reconciliation, Change in deferred tax assets Valuation allowance, amount">(4,225,651</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-21.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,884,977</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-20.98</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif">Other</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">1</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">0.00</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">%</td></tr> </table>

20117773

-8986289

4224732

0.2100

-1887121

0.2100

918

0.0001

2144

0.0002

-4225651

0.2100

1884977

0.2098

0.0000

-0

0.0000

-0

0.0000

-0

0.0000

4226000

1885000

12662000 0.80

(13) Related Party Transactions The Corporation paid consulting fees to a board member, Christine Hamilton, who is also an owner, of $25,000 and $33,527, respectively, for the years ended December 31, 2020 and 2019. As of December 31, 2020 and 2019, there was $6,250 (both years) in accrued board member fees for this related party. On an as needed basis, the Corporation engages Network Plus, LLC (owner is the spouse of an employee) for IT assistance and computer setups. There was approximately $20,000 and $40,000 in expenses, respectively, with this vendor in 2020 and 2019. The spouse became an employee of the Corporation in July 2020, so there will be no further activity with this vendor going forward. As discussed in Note 7, Leases, the Corporation has a finance lease for the animal facility with Dakota Ag Properties. Dakota Ag Investments (part of Dakota Ag Properties) is a shareholder and owner of the Corporation. As discussed in Note 7, Leases, the Corporation leases laboratory space from Sanford Health (which is a shareholder of the Corporation). Since the Corporation operates out of a building it shares with Sanford Health, the Corporation utilizes Sanford Health’s food services, medical services (shots and exams), and research services, as needed. Not including the lease payments, the combined expense of these services was approximately $152,000 and $190,000, respectively, for the years ended December 31, 2020 and 2019. The Corporation had approximately $10,000 in related party payables with Sanford Health as of December 31, 2020. There were <span id="xdx_903_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_do_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SanfordHealthCorporationMember_zEtnij7StiWb" title="Due from related party">no related party payables as of December 31, 2019. SAb Biotherapeutics, Inc. and subsidiaries Notes to consolidated financial statements TK Concept was engaged by the Corporation for business consulting in 2019. The owner is a member of the board of directors. There was approximately $42,500 in expense with this vendor in 2019. There were no consulting expenses in 2020. As discussed in Note 9, Debt, on February 24, 2016, the Corporation entered into a loan agreement with CLC for a $<span id="xdx_900_eus-gaap--LineOfCredit_iI_pn6n6_c20160224__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristiansenLandandCattleLtdMember_zLSTFw8mkD1l" title="Line of credit">3.0 million revolving line of credit secured by a blanket security interest in the assets of the Corporation. The principal owners of CLC are owners, members of the board of directors, and employees of the Corporation. In July 2020, the note payable was paid in full. Please refer to Note 9, Debt, for additional information.

25000 33527

6250

20000

40000

152000

190000

10000

42500

3000000.0

(14) Employee Benefit Plan The Corporation sponsors a defined contribution retirement plan. All the Corporation’s employees are eligible to be enrolled in the employer-sponsored contributory retirement savings plan, which include features under Section 401(k) of the Internal Revenue Code of 1986, as amended, and provides for Corporation matching contributions. The Corporation’s contributions to the plan are determined by its Board of Directors, subject to certain minimum requirements specified in the plan. For the years ended December 31, 2020 and December 31, 2019 the Corporation made matching contributions of 100% on 3% of the employee contributions, with an additional 50% match on the next 2% of employee contributions, resulting in approximately $188,000 and $139,000, respectively, of matching contributions paid by the Corporation.

0.03

0.50

0.02

188000

139000

(15) Commitments and Contingencies The Corporation is not involved in any legal proceedings, investigations and claims which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

(16) Joint Development Agreement In June 2019, the Corporation entered into a joint development agreement with the University of South Dakota Research Park, Inc. (“USDRP”) for the construction of a multi-tenant office building and a manufacturing building. Pursuant to the agreement, the Corporation also entered into a lease agreement for <span id="xdx_905_ecustom--NumberOfLeaseAgreementSquareFeet_iI_pid_uSqft_c20190630__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zAk0LHqWJmPi" title="Number of lease agreement square feet">41,195 square feet of leasable area located in the building. The lease will commence upon completion of the building for an initial term of <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20190630__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zO4a3gwcfDPc" title="Lease completion of building initial term">12 years at a monthly payment of approximately $118,000. Aurochs, LLC, a wholly owned subsidiary, was founded to manage the construction funds for this project. All pre-construction costs up to a budgeted $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentInProcess_pn5n6_c20190601__20190630__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember__srt--RangeAxis__srt--MaximumMember_zQIVTIN9NJHh" title="Pre construction costs">2.7 million were paid directly by the Corporation and reimbursed by USDRP. As of December 31, 2019, the Corporation had approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentInProcess_pn4n6_c20191201__20191231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zgiRh6MEnuLb" title="Pre construction costs">1.14 million in pre-construction costs recorded as a receivable from USDRP, with approximately $<span id="xdx_90C_eus-gaap--OtherRestructuringCosts_pn4n6_c20190101__20191231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zaaxK7MPdeBl" title="Pre construction costs related payables">1.14 million in related payables for these pre-construction costs. As of December 31, 2020, USDRP has spent approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost_pn4n6_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zUx9ysiDGXGj" title="Design costs">2.12 million in design costs for this facility, with approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zN8ekkCnXjeb" title="Design costs expense">580,000 of the $<span id="xdx_908_ecustom--ResearchAndDevelopmentExpenseBudgetRemaining_pn4n6_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zRSakskVZavj" title="Budget remaining">2.7 million budget remaining. There were <span id="xdx_902_eus-gaap--PaymentsToAcquireReceivables_do_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zTlM2Fv4mdwk" title="Receivables project"><span id="xdx_902_eus-gaap--PaymentsToAcquireProjects_do_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--UniversityOfSouthDakotaResearchParkIncMember_zT2NGQDsURQa" title="Payables project">no receivables or payables for this project as of December 31, 2020. USDRP and the Corporation intend to secure outside funding for all expenses incurred after the pre-construction phase. If funding cannot be secured to finance the construction of this facility, the Corporation will not be required to refund any of the design costs incurred to date. Due to the work around SARS-2 and the JPEO contract (please refer to Note 4, Revenue, for additional information), this project is on hold until 2021. 41195

P12Y

118000

2700000

1140000

2120000

580000

2700000

(17) Subsequent Events In the preparation of the Corporation’s consolidated financial statements, the Corporation completed an evaluation of the impact of subsequent events through June 17, 2021, which represents the date these consolidated financial statements were available for issuance. In February 2021, the Corporation submitted a forgiveness application related to its PPP Loan. In March 2021, the SBA approved the forgiveness of the PPP Loan, plus accrued interest. In April 2021, the Corporation entered into agreements that included other commitments of $4.5 million.

4500000

Includes up to 343,125 founder shares subject to forfeiture by the Sponsor and up to 31,875 representative shares held by Ladenburg and certain of its employees subject to forfeiture if over-allotment option was not exercised in full or in part by the underwriters (see Note 5 and Note 8). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). Excludes up to 343,125 founder shares subject to forfeiture by the Sponsor and up to 31,875 representative shares held by Ladenburg and certain of its employees subject to forfeiture if over-allotment option was not exercised in full or in part by the underwriters (see Note 5 and Note 8). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). Includes up to 343,125 founder shares subject to forfeiture by the Sponsor and up to 31,875 representative shares held by Ladenburg and certain of its employees subject to forfeiture if over-allotment option was not exercised in full or in part by the underwriters (see Note 5 and Note 8). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8).